



PHARMACOEPI.ORG

29th International Conference on
**PHARMACOEPIDEMIOLOGY AND
THERAPEUTIC RISK MANAGEMENT**



International des Feux Loto-Québec, Montréal International Fireworks Competition | Credit: ©Tourisme Montréal, Stephan Poulin

August 25-28, 2013 | Montréal Convention Center | Montréal, Canada

Final Program

ACCESS ICPE ABSTRACTS ON YOUR MOBILE DEVICE



www.abstracts2view.com/ispe

–Online only Abstract Supplement
–Free WiFi is provided for you to access this tool

BOARD OF DIRECTORS & VOLUNTEER LEADERS



PHARMACOEPI.ORG

29th International Conference on PHARMACOEPIDEMIOLOGY AND THERAPEUTIC RISK MANAGEMENT

ISPE BOARD OF DIRECTORS

Officers

Stella Blackburn, FISPE, *President*
 Til Stürmer, FISPE, *President-Elect*
 Nancy C Santanello, FISPE, *Immediate Past President*
 Kate Lapane, FISPE, *Vice President Finance*
 Mark H Epstein, *Executive Secretary*

Directors

Morten Andersen	Kiyoshi Kubota, FISPE
Ariel E Arias	Marie Lindquist
Alison Bourke	John D Seeger
Nancy A Dreyer, FISPE	Scott R Smith
Edeltraut Garbe	Sabine Straus
Tobias Gerhard, FISPE	Suzanne L West, FISPE
Richard Hill	Wei Zhou
Wan-Ting Huang	Stanley A Edlavitch, <i>Lifetime Emeritus</i>

2013 SCIENTIFIC PROGRAM COMMITTEE

Yola Moride, FISPE, *Chair*

Core Program Committee

Morten Andersen	Yea-Huei Kao Yang, FISPE
Frank Andersohn	Olaf Klungel
Stella Blackburn, FISPE	Kate Lapane, FISPE
Gillian Caughey	Jacques LeLorier, FISPE
Corinne de Vries, FISPE	Lisa Pont
Mark H Epstein	Robert Reynolds, FISPE
Stephen JW Evans, FISPE	Mary Beth Ritchey
Edeltraut Garbe	Patricia Saddier
Tobias Gerhard, FISPE	Nancy C Santanello, FISPE
Andrew Gilbert	John D Seeger
Gillian Hall, FISPE	Soko Setoguchi-Iwata, FISPE
Andrew Jerdonek	Til Stürmer, FISPE
Janet Hardy	

CHAIRS/CO-CHAIRS

Committees

Archivist..... Hugh Tilson, FISPE
Bylaws & Policies..... Michael Lewis, FISPE
 John D Seeger
Development Susan Oliveria, FISPE
 Syd Philips
Education Frank Andersohn
 Tobias Gerhard, FISPE
Fellowship & Awards..... Nancy C Santanello, FISPE
Finance Kate Lapane, FISPE
Global Development Kiyoshi Kubota, FISPE
 K. Arnold Chan, FISPE
Management Oversight..... Nancy C Santanello, FISPE
Membership Michael Taylor
 Vincent Lo Re, FISPE
Nominating Nancy C Santanello, FISPE
Public Policy & Ethics..... Jesper Hallas, FISPE
 Yola Moride, FISPE
Publications..... Jennifer Christian
Scholarship..... Frank May, FISPE
Scientific Program..... Yola Moride, FISPE
Strategic Planning..... Til Stürmer, FISPE

Councils

Academic Jodi B Segal
Government/Regulatory Gunilla Sjölin-Forsberg
 Sabine Straus
Industry/Service Providers..... Susan Oliveria, FISPE
Student Caitlin Knox
 Linda Wijlaars

Special Interest Groups

Adherence Robert Gross
**Asian Pharmacoepidemiology
 Network (AsPEN)** Kiyoshi Kubota, FISPE
 Yea-Huei Kao Yang, FISPE
**Benefit Risk Assessment,
 Communication &
 Evaluation (BRACE)** Ken Hornbuckle
 Paul Coplan
 Peter Mol
Biologics..... Veronique Kugener
 Jane Porter
**Comparative Effectiveness
 Research (CER)** Nicole Gatto
Databases Helga Gardarsdottir
 David Miller
Drug Utilization Research Morten Andersen
 Bjorn Wettermark

Medical Device Danica Marinac-Dabic

Medicines In Pregnancy Elena Rivero, FISPE
Jennita Reefhuis

**Molecular Epi/Biomarkers/
Pharmacogenetics**..... Bruce Carleton
Wei Zhou
Geoff Liu

Pediatrics Tamar Lasky
Rachel Sobel

Regional Chapters

Gulf Region..... Hisham Aljadhey

Latin America Carlos E Duran
Marcela Jirón
Veronika Wirtz

**FarmacoEpiEnRed-
Spanish Chapter** Ana Afonso
Sandra Lopez Leon
Elisa Martin-Merino

LOCAL HOST COMMITTEE

Yola Moride, FISPE, <i>Chair</i>	Jacques LeLorier, FISPE
Ariel E Arias	Adrian Levy
Alexandria Aubourg	Geoffrey Liu
Sarah-Gabrielle Béland	Colleen Metge
Sarah Frise	Maria Perrotta
Jason Guertin	Michel Rossignol
Jean Lachaine	Brian White-Guay

DEVELOPMENT COMMITTEE

Susan Oliveria, FISPE, <i>Chair</i>	Andrew Jerdonek
Dimitri Bennett	Kirk Midkiff
Rhonda Bohn, FISPE	JJ Nelson
Andrzej Czarnecki, FISPE	Cynthia O'Malley
Mark Cziraky	Syd Phillips
Mark H Epstein	Marianne Ulcickas Yood, FISPE
Nick Everage	Jasmanda Hsiao-Hui Wu

Nikkie Aarts
G Caleb Alexander
Jon Andersen
Heather Anderson
Karolina Andersson Sundell
Ariel E Arias
LaVette Arms
Darren Ashcroft
Elodie Aubrun
Shahram Bahmanyar
Nicole Baker
Ümniye Balaban
Anjan Banerjee
Fabio Barbone
Kristen Bibeau
Michael Blum
William Blumentals
Rhonda L Bohn, FISPE
Emily Brouwer
Jeffrey Brown
Andrea Burden
Suzanne Cadarette
Gloria Caldwell
Manuela Casula
Rachel Charlton
Brian Cleary
Alexander Cole
Preciosa Coloma
Lyn Colvin
Florence Coste
Ineke Crijns
Suellen Curkendall
Sandra de Bie
Marieke De Bruin
Petra Denig
Jane Der
Paul Dolin
Yaa-Hui Dong
Ruben Duijnhoven
Stacie Dusetzina
Stanley Edlavitch,
Conference Chair Emeritus
Tewodros Eguale
Habab El Kheir
Marjolein Engelkes
Richard Epstein
Katherine Etter
Efe Eworuke
Kristian Filion
Jean-Pascal Fournier
Kari Furu
Joshua Gagne
David Gagnon
Shujun Gao
Helga Gardarsdottir
Stewart Geary
Tobias Gerhard, FISPE
Andrew Gilbert
Cynthia Girman
Amanda Golembesky
Luke Grzeskowiak
Line Guenette
Jason Guertin
Staffan Hägg
Joanna F Haas, FISPE
Penina Haber

Gillian Hall, FISPE
Christian Hamp
Joseph Hanlon
Abraham Hartzema, FISPE
Jari Haukka
Eibert Heerdink
Sonia Hernández-Diaz, FISPE
Richard Hill
Michie Hisada
Jason C. Hsu
Yu-wen Ruby Huang
Wan-Ting Huang
Krista Huybrechts
Luisa Ibanez
John Iskander
Anna Jönsson
Maria-Isabel Jimenez-Serrania
Aaron Katz
Santosh KC
Helle Kieler
Elaine Kingwell
Natalia Kutishenko
Chao-Lun Lai
Stephan Lanes
Kate Lapane, FISPE
Francesco Lapi
Tamar Lasky
J Bradley Layton
Deborah Layton
Hoa Le
Hristina Lebanova
Michael Lewis, FISPE
Lin Li
Wei Liu
Zhiwen Liu
Xinyue Liu
Sandra Lopez Leon
Jeanne Loughlin
Andrea Margulis
Megan McAuliffe
Robert McConeghy
Sharon Meropol
Allen Mitchell, FISPE
Jon Morris
Erwan Muros le Rouzic
Jessica Myers
Kazeem Oshikoya
Eva Ostenfeld
Rae Woong Park
Michael Peng
Carlo Piccinni
Ratnakar Pingili
Simone Pinheiro
Federica Pisa
Hanne Plet
Elena Prokofyeva
Dima Qato
Hong Qiu
Marsha Raebel
Sudha Raman
Jeremy Rassen
Gema Requena
Elena Rivero, FISPE
Melissa Roberts
Elizabeth Roughead
Susan Sacks, FISPE

ABSTRACT REVIEWERS (cont.)

Maribel Salas
Leah Sansbury
Surasak Saokaew
Vernon Schabert
Amand Floriaan Schmidt
Fred Schneiweiss
Martijn Schuemie
John D Seeger
Harry Seifert
Jason Simeone
Leah Sirkus McGrath
Janet Sluggett

Espen Jimenez Solem
Pakawadee Sriphirinya
Danijela Stojanovic
Parimalakrishnan Sundararajan
Sonja Swanson
Mina Tadrous
Amir Abbas Tahami Monfared
Derek Tang
Yuexin Tang
Bharat Thakrar
Paula Thompson
Veena Thyagarajan

Darren Toh
Pramote Tragulpiankit
Ilse Truter
Carla Van Bennekom
Niels Vermeer
Giacomo Veronese
Patrice Verpillat
Marco Villa
Loes Visser
Steven Vlad
Helle Wallach Kildemoes
Tongtong Wang

Shirley Wang
Alexandra Ward
Suzanne West FISPE
Linda Wijlaars
Veronika Wirtz
Jasminda Hsiao-Hui Wu
Wanning Xu
Anamaria Zaccolo
Yueqin Zhao
Che Suraya Zin

ISPE SUPPORTERS

ORGANIZATIONAL & INSTITUTIONAL MEMBERS

Pharmaceuticals

- ▶ F. Hoffmann-LaRoche AG
- ▶ GlaxoSmithKline
- ▶ Sanofi-Aventis

Service Providers

- ▶ RTI Health Solutions

Government/Regulatory Agencies

- ▶ Department of Health, Pharmaceutical Services, Hong Kong Special Administrative Region, People's Republic of China
- ▶ Drug Safety and Effectiveness Network, Canadian Institutes for Health Research

Academic Programs

- ▶ Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- ▶ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- ▶ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- ▶ Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School
- ▶ Division of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of Cincinnati
- ▶ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- ▶ Harvard School of Public Health
- ▶ London School of Hygiene and Tropical Medicine
- ▶ McGill Pharmacoepidemiology Research Unit, McGill University
- ▶ Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ▶ Regenstrief Institute
- ▶ Slone Epidemiology Center, Boston University

ANNUAL CAMPAIGN as of August 1, 2013

The Society expresses its sincere appreciation to the following supporters listed below for their contributions in honor of the 29th Annual Meeting (ICPE).

Yasser Albogami
Ulf Bergman, FISPE
Stella Blackburn, FISPE
Greta Bushnell
Wendy Carman
Nam-Kyong Choi
Lyn Colvin
Nasbarun Dasgupta
Yaa-Hui Dong
Montserrat Soriano
Gabarro
Joshua Gagne
Tobias Gerhard, FISPE
Gro Cecilie Havnen

Kevin Haynes
Klaas Heinemann
Deborah Hennessey
Sean Hennessey, FISPE
Judith Jones, FISPE
Natalia Kutishenko
Jin Won Kwon
Edward Chia-Cheng Lai
JoongYub Lee
James Lewis, FISPE
Jeanne Loughlin
Angela Lupattelli
Sergey Martsevich
Frank May, FISPE

Colleen Metge
Paul Niklewski
Olayinka Ogunleye
Emilie Peron
Paola Primatesta
Carolien Ruesen
Mary Skovron
Carla Van Bennekom
Patrice Verpillat
Douglas Watson, FISPE
Jing Xie
Huifeng Yun

In this program

29th ICPE Agenda

Saturday, August 24	9
Sunday, August 25	14
Monday, August 26	20
Tuesday, August 27	32
Wednesday, August 28	44

29th ICPE Posters

Poster Guidelines	52
Poster Session A	53
Poster Session B	61
Poster Session C	70

Indexes

Abstract Index.....	79
Advertisers Index.....	89

FUTURE MEETINGS

2013

8th Asian Conference on Pharmacoepidemiology

- October 25-27, 2013
Li Ka Shing Faculty of Medicine
The University of Hong Kong, Hong Kong

2014

ISPE Mid-Year Meeting

- April 6-8, 2014
Inntel Hotels Rotterdam Centre
Rotterdam, The Netherlands

30th Anniversary ICPE

- October 24-27, 2014
Taipei International Convention Center
Taipei, Taiwan

2015

ISPE Mid-Year Meeting

- April 2015
U.S. East Coast

31st ICPE

- August 23-26, 2015
Hynes Convention Center
Boston, Massachusetts



INTERNATIONAL CONFERENCE ON
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT

30 ICPE

OCT 24-27, 2014

TAIPEI INTERNATIONAL CONVENTION CENTER
TAIPEI, TAIWAN

MEETING AT-A-GLANCE

SATURDAY, AUGUST 24, 2013

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:45am - 6:00pm Registration Open Viger Hall												
7:45am - 5:00pm Speakers' Ready Room 522C												
8:00am - Noon Educational Sessions Pharmacogenetics 520C					Noon - 1:30pm Lunch on Your Own		1:15 - 5:00pm Educational Session Pharmacogenetics (Cont.) 520C				6:30pm - ? Students/Young Professionals Meet & Greet Les Soeurs Grises	
Intro. to Pharmacoepidemiology 520AD							1:30 - 6:00pm Educational Sessions Pharmacovigilance & Signal Detection 520AD					
							Medical Device Epidemiology 521C					
							Using Pharmacoepidemiology Database Resources 520BE					
							Student Skills Workshop 521AB					
9:00am - 5:00pm ISPE Board of Directors Meeting InterContinental Hotel												

SUNDAY, AUGUST 25, 2013

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:30am - 6:00pm Registration Open Viger Hall												
7:30am - 5:00pm Speakers' Ready Room 522C												
8:30am - Noon Educational Sessions					Noon - 1:30pm Lunch on Your Own		1:30 - 6:00pm Educational Sessions					
Registries/Prospective Cohort Studies 520C							Advanced Topics in Pharmacoepidemiology 519AB					
Propensity Scores 520F					Noon - 1:30pm New Members Luncheon-By Invitation 524		Introduction to Therapeutic Risk Management and Evaluation 520F				6:00 - 7:30pm Welcome Reception / Academic Showcase Marquee 720-725	
Comparative Effectiveness Research 520AD							Advanced Drug Utilization Research 525					
Intermediate Pharmacoepidemiology 519B							A State-of-the-Art Review of Benefit-Risk Assessment and Risk Comm. 520AD					
Regulatory Pharmacoepi./Health Care Decision-Making 519A												
Introduction to Drug Utilization Research 520BE												

MONDAY, AUGUST 26, 2013

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
7:00am - 6:00pm Registration Open Viger Hall			10:00-10:30am Break/Posters/Exhibits 220BC		12:45-1:30pm Poster Walks 220BC		3:00-3:30pm Break/Posters/Exhibits 220BC				7:30 - 8:30pm PDS Editorial Board (By invitation) 521B		
7:00am - 5:00pm Speakers' Ready Room 522C													
7:00-8:00am Poster Session A Set-Up 220BC		8:00am - 6:00pm Exhibitors/Posters 220BC		10:30am - Noon Concurrent Sessions		Noon - 1:30pm Lunch/Poster Session A/Exhibits/Roundtable Discussions 220BC		1:30 - 3:00pm Concurrent Sessions		3:30 - 5:00pm Plenary Session: Risk Assessment to Guide Treatment - The Case of Tysabri and PML 517D		5:00 - 6:30pm Symposia & Workshops	
		8:00 - 8:30am Bienvenue 517D		Back to the Future: Methods in Time (Methods I) 519AB		ISPE Committee/Council Meetings		Big Molecules, Big Problems? 524AB		BRACE 520BE		6:30 - 7:30pm ISPE Council Meetings	
		Yola Moride		Burden of Disease: Profiles and Prospects 524AB		Development 523		Gene Meets Drug 520CF		Design & Method Considerations 520CF		Academic 520CF	
		Mireille Mathieu		Opioids or NSAIDs 520CF		Fellowship & Awards 521A		Hot Topics in Diabetes 520BE		Drug Response 518AB		Government/Regulatory 520BE	
		Stella Blackburn		Part Man-Part Machine, A Device Potpourri 518AB		Finance 521B		Methods in CER 519AB		Harmonizing Methods and Data 517D		Industry/Service Providers 520AD	
7:00-7:45am History of Pharmacoepi. 520BE		8:30 - 10:00am Keynote Session 517D		Pregnancy Session 1 520AD		Public Policy 521C		Respiratory 518AB		Non-Database Pharmacoepi. 524AB		7:30pm - ??? Students/Young Professionals Night Out -SOLD OUT	
Chapter Meetings:		Thomas MacDonald Jacques LeLorier & Bernard Begaud		Use Your Heart 520BE		Student Council 516AB		Sounding All the Sources 520AD		Post-Marketing Database Studies 519AB			
Gulf Region 520AD										Comparative Effectiveness 520AD			
Latin America 521C													
FarmacoEpiEnRed 519AB													

MEETING AT-A-GLANCE

TUESDAY, AUGUST 27, 2013

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 6:00pm Registration Open Viger Hall												
7:00am - 5:00pm Speakers' Ready Room 522c												
7:00-8:00am Poster Session B Set-Up 220BC	8:00am - 6:00pm Exhibitors/Poster Session 220BC				12:15-1:00pm Poster Walks 220BC				4:00-4:30pm Break/Posters/Exhibits 220BC	4:30 - 6:00pm Symposia & Workshops Database Algorithm Development 517D Best Practices in Risk Communication 518AB Signal Detection Methods 524AB Comparative Effectiveness Research 520AD Adherence to Drug Treatment 520BE Selection Bias and Confounding 520CF Pregnancy Research 519AB	6:00 - 7:00pm SIGs Adherence 518AB AsPEN 524AB Biologics 518C BRACE 520AD Comparative Effective Research 520CF Databases 519AB Drug Utilization/HSR 517D Medical Devices 524C Meds in Pregnancy 520BE Molecular Epidemiology 525A Pediatrics 525B	7:30pm - 12:30am Social Event at Montréal Science Centre Bring your dancing shoes! Shuttle buses will be available.
	8:00 - 9:30am Concurrent Sessions CNS Drugs 520CF Money Matters 518AB Pediatrics 520AD PS, I Love You (Methods II) 519AB That's Interesting... 524AB Up and Down the GI Tract 520BE		9:30-10:00am Break/Posters/Exhibits 220BC	10:00 - 11:30am Concurrent Sessions Methods 3 519AB Cardiovascular Studies 520BE Pregnancy Potpourri 520CF Psychotropics on Your Mind 518AB Sweet Spot on CER 520AD Vaccines 524AB	11:30am- 1:00pm Lunch/Poster Session B/Exhibits/Roundtable Discussions 220BC ISPE Committee Meetings Bylaws and Policies 521C Education 523 Global Development 521B Membership 521A Publications 514C	1:00 - 2:30pm Plenary Session: The Patients Voice in Benefit & Risk 517D	2:30 - 4:00pm Annual Meeting of ISPE Members & Awards Ceremony 517D					

WEDNESDAY, AUGUST 28, 2013

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 4:30pm Registration Open Viger Hall												
7:00am - 3:30pm Speakers' Ready Room 522C												
7:00-8:00am Poster Session C Set-Up 220BC	8:00am - 1:45pm Exhibitors/Poster Session 220BC				12:45-1:30pm Poster Walk 220BC			3:00 - 4:30pm Hot Topics Session: Considering the Safety of Compounded Drugs 517D	4:30-5:00pm The Final Word: •Poster Awards •Future Meetings Adjournment 517D			
	7:15-8:15am 2014 ICPE Scientific Program Committee 516A	8:30 - 10:00am Concurrent Sessions Around the World in 90 Minutes 518AB Chicken and Egg: Common Drugs, Cancer Risk and Outcome 524AB Effective Choices (CER) 519AB Risky Business 520BE Sexy Hormones 520AD The Down Side of Pregnancy 520CF		10:00-10:30am Break/Posters/Exhibits 220BC	10:30am - Noon Symposia & Workshops ARITMO Final Results 520CF Drug-Induced Liver Injury 518AB Measurement Bias 517D IMI-PROTECT 520BE Regulatory Decision-Making 520AD Risk of Meds in Pregnancy 519AB Natural Language Processing 524AB	12:00 - 1:30pm Lunch/Poster Session C/Exhibits 220BC Noon - 1:30pm ISPE Board of Directors Luncheon 516A	1:30 - 3:00pm Concurrent Sessions Elderly 524AB Methods 4 519AB Pediatrics: Potpourri 520CF Self-Controlled Studies 520BE Sticky Treatments & Sticky Outcomes 520AD CNS Drugs & Diseases 518AB					

ICPE EXHIBITORS & SUPPORTERS

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped to enhance the scientific program content and increase attendance at the 2013 ICPE.

-Thank You-

EXHIBITORS

- ▶ Analysis Group
- ▶ Boehringer Ingelheim Int. GmbH
- ▶ Cerner Corporation
- ▶ CPRD, Clinical Practice Research Datalink
- ▶ Dacima Software Inc.
- ▶ Drug Safety and Effectiveness Network / Réseau sur l'innocuité et l'efficacité des médicaments
- ▶ Eu2P, Online Courses and Diplomas
- ▶ Evidera
- ▶ Genesis Research
- ▶ HealthCore, Inc.
- ▶ IMS Health
- ▶ Kantar Health
- ▶ LASER ANALYTICA
- ▶ Mapi
- ▶ MedMining
- ▶ Optum
- ▶ ParagonRX
- ▶ PHARMO Institute
- ▶ Quintiles Outcome
- ▶ RTI Health Solutions
- ▶ Springer
- ▶ Truven Health Analytics
- ▶ UBC
- ▶ Uppsala Monitoring Centre
- ▶ Wiley-Blackwell
- ▶ Xcenda

ACADEMIC SUPPORTERS

- ▶ Boston University Schools of Public Health and Medicine – Slone Epidemiology Center
- ▶ Brigham & Women's Hospital, Division of Pharmacoepidemiology
- ▶ Center for Drug Safety & Effectiveness, John Hopkins School of Public Health
- ▶ Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- ▶ DESS, Faculty of Pharmacy, Université de Montréal
- ▶ Drug Safety Research Unit
- ▶ Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ▶ The University of British Columbia | Child & Family Research Institute
- ▶ University of Rhode Island

ANNUAL MEETING SPONSORS

Platinum

- ▶ CPRD, Clinical Practice Research Datalink
- ▶ Wiley-Blackwell

Gold

- ▶ Amgen
- ▶ Analysis Group
- ▶ Boehringer Ingelheim Int. GmbH
- ▶ Celgene Corporation
- ▶ Eli Lilly & Company
- ▶ Evidera
- ▶ Genesis Research
- ▶ HealthCore, Inc.
- ▶ IMS Health
- ▶ LASER ANALYTICA
- ▶ MedMining
- ▶ Merck & Co., Inc.
- ▶ Optum
- ▶ ParagonRX
- ▶ Pfizer, Inc.
- ▶ Quintiles Outcome
- ▶ RTI Health Solutions
- ▶ UBC
- ▶ Xcenda

Silver

- ▶ Bayer Healthcare
- ▶ Biogen Idec
- ▶ Novartis
- ▶ PPD
- ▶ Purdue Pharma L.P.

Bronze

- ▶ Allergan, Inc.
- ▶ Boston Collaborative Drug Program, Boston University School of Medicine
- ▶ Cerner Corporation
- ▶ CSD Medical Research
- ▶ The Degge Group
- ▶ EpiSource
- ▶ Uppsala Monitoring Centre
- ▶ WHISCON

as of August 1, 2013

BADGES

All attendees at the 2013 ICPE must wear their badges to all events. A badge will be needed for admission to a conference-related function, such as the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social evening event. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., guests.

Badge Legend ■ Student ■ New Member ■ One-Day Admission

7:45am-6:00pm
Registration
 (Viger Hall)

7:45am-5:00pm
Speakers' Ready Room
 (522C)

9:00am-5:00pm
ISPE Board of Directors Meeting
 (InterContinental Hotel Montréal)

(Open to ISPE members; notify ISPE staff if you would like to attend.)

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

INCLUDES AN
 INTERACTIVE
 WORKSHOP &
 LUNCH

8:00am-5:00pm

Pharmacogenetics Epidemiology: A Basic and Advanced Course (520C)

Content

This highly interactive course is intended to involve participants in:

- A dynamic didactic experience of the foundational principles of pharmacogenomics
- An appreciation for the different methods used in pharmacogenomics research.
- Examination of real world examples of pharmacogenomic epidemiology.
- Application of methodology to designing pharmacogenomic epidemiology studies.
- Interpretation of the data found in the pharmacogenomic epidemiology literature, and understanding wider implications of the results.

Educational Objectives

- To understand the genetic and pharmacogenomic terminology and how cellular and molecular biology informs pharmacogenomic studies at the level of analysis.
- To better understand the study design and methodologic approaches, their strengths and weakness used in pharmacogenomic epidemiology.
- To understand the latest statistical approaches used in pharmacogenomics studies.
- To understand the role that pharmacogenomics can play in pharmacovigilance.
- To understand how pharmacogenomics relates to the current focus of Personalized Medicine
- To have an overview of clinical utility of pharmacogenomics and associated regulatory issues as well as policy-relevant research.

Workshop Topics

Roundtable 1: Clinical Utility and Clinical Adoption

Roundtable 2: Methods and Logistics

Roundtable 3: Basic Methods: Study Design Issues

Roundtable 4: Advanced Methods: Clinical Trials

Roundtable 5: Policy and Regulatory Issues

Roundtable 6: Databases, Biospecimens, and Analysis of Real Data

Course Faculty

Gillian Bartlett-Esquillant, Department of Family Medicine, McGill University

Paul Boutros, Ontario Institute for Cancer Research in Canada

Bruce Carleton, Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, & Canadian Pharmacogenomics Network for Drug Safety.

Andrew Freedman, Clinical and Translational Epidemiology Branch (CTEB), Epidemiology and Genomics Research Programs (EGRP)

Rayjean Hung, Mount Sinai Lunenfeld Research Institute

Amalia M. Issa, Department of Health Policy and Public Health, University of the Sciences in Philadelphia

Stephen Kimmel, FISPE, Center for Therapeutic Effectiveness Research, University of Pennsylvania

Geoffrey Liu, Molecular Genomics, University of Toronto

Anke Hilde Maitland-van der Zee, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University

Greg Pond, Departments of Oncology, and Clinical Epidemiology and Biostatistics, McMaster University

David Pulford, GlaxoSmithKline

Leah Sansbury, GlaxoSmithKline

8:00am-Noon

Introduction to Pharmacoepidemiology (520AD)

*Included as part of the full meeting registration; registration required.

Course Faculty/Presentations

Almut Winterstein, FISPE, University of Florida, *Cohort Studies*

Sonia Hernández-Díaz, FISPE, Harvard School of Public Health, *Case-Control Studies*

Soko Setoguchi-Iwata, FIPSE, Duke University School of Medicine, *Bias & Confounding*

Noon-1:30pm

Lunch On Your Own

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

1:30-6:00pm

Pharmacovigilance & Signal Detection (520AD)

This half-day course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including the EU-ADR project and the US FDA's Mini-Sentinel program, aimed at using routinely collected electronic healthcare data to conduct signal detection and prospective medical product safety monitoring.

Educational Objectives

- Explain the need for pharmacovigilance and its component activities with a focus on safety surveillance
- Describe the potential data sources (e.g., spontaneous reports, claims, electronic medical records, etc.) for safety surveillance in pharmacovigilance
- Understand the array of basic analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases
- Recognize the limitations of each data source and approach and how they complement each other

Target Audience

- ICPE attendees interested in gaining a basic understanding of the need for and approaches to classical pharmacovigilance using spontaneous adverse event reports and/or signal detection and active medical product safety monitoring using routinely collected electronic healthcare data
- Pharmacoepidemiologists from all perspectives (e.g., regulatory agencies, pharmaceutical companies, academia, etc.) and students interested in learning about opportunities in pharmacovigilance and signal detection
- No prior ISPE courses are required for this beginner-to-intermediate-level course

Course Faculty/Presentations

Andrew Bate, Worldwide Safety Strategy, Pfizer Ltd, UK, *Multiple Data Streams for Safety Surveillance: Leveraging Emerging Data Sources*


Gianluca Trifirò, Department of Medical Informatics, Erasmus University Medical Center, & Department of Clinical and Experimental Medicine, University of Messina, *Electronic Medical Records and Claims Data for Drug Safety Signal Detection: Lessons Learned from the EU-ADR Project*

Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Semi-Automated, Distributed, Prospective Medical Product Safety Monitoring*

Transforming the language of life into vital medicines

AMGEN

Pioneering science delivers vital medicines™



At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com

Amgen is a proud sponsor of the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Epidemiologic research at Amgen focuses on benefiting patients with grievous illnesses and advancing knowledge in our field.

©2013 Amgen Inc. All rights reserved.

Mapi™

Insight for solutions

Come see what's new at Mapi

And take a fresh look at the
breadth and depth of our services:

- **Late-Phase Studies and Real-World Evidence**
- **Risk-Management and Safety**
- **Epidemiology**
- **Market Access**
- **Evidence Synthesis**
- **Health Economics and Decision Modeling**
- **PROs and ClinROs**
- **Linguistic Validation**
- **Information Center and Databases**

Booth #38

www.mapigroup.com

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

1:30-6:00pm

Medical Device Epidemiology (521C)

Topics will cover the regulation of medical devices, international initiatives for evaluating post-market performance of medical devices, and methods for evidence synthesis. Special attention will be paid to the “how-to” aspects of conducting valid medical device safety and effectiveness research including considerations in identifying devices, selecting comparator groups, studying long-term outcomes, and using appropriate methodology.

Educational Objectives

- Define medical devices and their classification
- List different data sources appropriate for studying different types of medical devices and their strengths and limitations
- Describe regulatory environment for medical devices and how it differs from medications
- Name and explain international collaborative initiatives for improving the safety of medical devices using registries from different countries
- Describe methods for combining multiple sources of quantitative evidence to understand the safety and effectiveness profile of medical devices
- Enumerate considerations for evaluating long-term safety and effectiveness of medical devices
- Describe biases that may be introduced in a study depending on how devices and comparator groups are selected and identified
- Describe special considerations which must be taken into account when conducting medical device epidemiologic research
- Recount real-world examples of medical device epidemiology, in the context of comparative effectiveness research

Target Audience

- Members of the Medical Device Special Interest Group (SIG)
- ISPE members with an interest in medical device epidemiology
- Scientists interested in learning how to conduct medical device epidemiology in real-world settings
- Scientists interested in learning more about medical device epidemiology and about the intersection and differences between medical device epidemiology and pharmacoepidemiology
- Students and scientists interested in learning about how medical devices are regulated, how medical devices are evaluated in clinical trials, available data sources for the conduct of observational research in medical device epidemiology and special considerations/challenges when conducting medical device epidemiologic research

Course Faculty/Presentations

- Jessica Jalbert**, LA-SER Group & Weill Cornell Medical College, *Considering Provider Effects in Medical Device Epidemiology*
- Kristian Filion**, McGill University, *Medical Device Epidemiology: An Introduction*
- Danica Marinac-Dabic**, Center for Devices and Radiological Health, Food and Drug Administration, *International Infrastructure for Medical Device Epidemiology: A Glimpse into the future*
- Veronica Sansing**, Center for Devices and Radiological Health Food and Drug Administration, *Differences Between Medical Device and Drug Regulation in the US*
- Ted Lystig**, Medtronic, *Making Sense of the Evidence: Bayesian Methods for Evidence Synthesis in Medical Device Epidemiology*
- Mary Beth Ritchey**, Merck Research Laboratories, *Evaluating Use of Drugs and Devices in Studies with Long-Term Outcomes*
- Soko Setoguchi-Iwata, FISPE**, Duke Clinical Research Institute & Tokyo University, *Identifying Devices and Comparator Group: Considering Biases*
- Michele Jonsson-Funk**, University of North Carolina at Chapel Hill, *Evaluating the Comparative Safety and Effectiveness of Mesh for Pelvic Organ Prolapse: Methodological Considerations*
- Paul Niklewski**, Johnson and Johnson, *Methodological Considerations when Evaluating the Safety of a Computer-Assisted Personalized Sedation System in the Real-World*

1:30-6:00pm

Using Pharmacoepidemiology Database Resources to Address Drug Safety Research (520BE)

Content

- Examine the use of database resources in pharmacoepidemiology research;
- Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource;
- Review the details of data resources available within Canada;
- Identify the elements to properly select a study population and;
- Explore a method to harmonize data from multiple resources.

Educational Objectives

- To review the Guidelines for Good Database Selection and Use in Pharmacoepidemiology Research
- To gain an understanding of available Pharmacoepidemiology resources.
- To develop the skills to select an appropriate resource to conduct pharmacoepidemiology research.
- To learn techniques to identify a study population and validate outcome measures.
- To examine methods for defining exposure.

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

Target Audience:

- Intermediate level of epidemiology background preferred
- Members of the Database SIG
- Those interested in exploring pharmacoepidemiology resources
- Those working in harmonizing data resources
- Those working in creating analytic datasets
- Clinical pharmacoepidemiologists
- Clinical guideline developers
- Those interested in validating outcomes in secondary databases
- Health practitioners

Course Faculty/Presentations

- Gillian Hall, FISPE**, *Overview of Database Use in Pharmacoepidemiology*
- Matthew Reynolds**, *Selection of Databases for Pharmacoepidemiology Research*
- Yola Moride, FISPE**, *Canadian Data Resources*
- Kevin Haynes**, *Database Selection Workshop Activity Distributed Data Resources*
- Vincent Lo Re, FISPE**, *Validation of Outcomes*

1:30-6:00pm

Student Skills Workshop (521AB)

—Organized by ISPE Student Council

** STUDENTS ONLY **

Included as part of the full meeting registration; registration required.

Introduction to Systematic Review And Meta-Analysis

Tamar Lasky, MIE Resources, *Systematic Literature and Meta-Analysis in Pharmacoepidemiology*

Tarek Hammad, FISPE, Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, *Role of Meta-analysis in Drug Safety: Basic Concepts*

Careers in Pharmacoepidemiology

- Sonia Hernández-Díaz, FISPE**, Harvard School of Public Health, *Academia*
- Michael Taylor**, Genentech, *Industry*
- Solomon Iyasu**, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, *Government*
- Susana Perez-Gutthann, FISPE**, RTI Health Solutions, *Consultant*

6:15-?

Meet and Greet (Les Soeurs Grises)

Open to all Students and Young Professionals

Meet at the ICPE Registration Desk, then walk to Les Soeurs Grises.

Raising the standard in pharmacoepidemiology

For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop compelling results for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Peri-approval safety studies for IND and NDA submissions and post-approval commitment
 - Observational pharmacoepidemiology studies (claims analysis + chart review, EMR data analysis)
 - Prospective drug safety surveillance
 - Drug safety monitoring boards
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analysis and meta-analysis for drug safety endpoints
- Patient registries
- Strategic responses to drug safety concerns raised by the U.S. and ex-U.S. regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Advanced methods in causal inference (ex, marginal structural models, mediation analysis, high-dimensional propensity score matching)
- Comparative effectiveness research
- Quality of life instrument development and validation
- Mass tort pharmaceutical liability litigation



ANALYSIS GROUP
ECONOMIC, FINANCIAL and STRATEGY CONSULTANTS

For more information, contact Mei Sheng Duh, Sc.D., M.P.H., at 617 425 8131, mduh@analysisgroup.com, or visit our website at www.analysisgroup.com



PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

7:30am-6:00pm
Registration
 (Vlger Hall)

7:00am-5:00pm
Speakers' Ready Room
 (522C)

8:30am-Noon
Registries/Prospective Cohort Studies (520C)

Content

- Registries using prospective observational cohort designs as alternatives to randomized controlled trials (RCTs)
- The scope and purpose of different types of registries and how they are being used today in pharmacoepidemiology and risk management
- Considerations of registry development in terms of design and data sources; how they are operationalized and applications for research

Educational Objectives

- To describe the evidence hierarchy and differentiate between the important features of various types of “registries” (or “registers”) and review the traditional terms used to describe timing (retrospective and prospective)
- To review the opportunities and developments of “registries” as tools to support pharmacoepidemiology, pharmacovigilance and risk management.
- To critically explore the challenges in the design, establishment and conduct of prospective observational cohort studies, with a focus on minimizing the influence of bias and confounding.

Target Audience

- Those interested in designing prospective observational cohort studies, including registries and registers

- Those interested in conducting prospective studies of comparative effectiveness and safety
- People wishing to learn how prospective studies, including registries, can be used to support risk management and pharmacovigilance
- Anyone interested in knowing how prospective studies, including registries, are used to support pharmacovigilance
- A modest understanding of epidemiologic methods is assumed.

Course Faculty/Presentations

Nancy Dreyer, FISPE, Quintiles Outcome, *Registries for Safety and Effectiveness: Designing Practical Studies Fit for Purpose*

Deborah Layton, Drug Safety Research Unit, Portsmouth University, *Interactive Group Session-Considerations for Registry Study Design*

Saad Shakir, FISPE, Drug Safety Research Unit, Portsmouth University, *Special Challenges of Registries for Risk Management Plans*

Sonia Hernández-Díaz, FISPE, Pharmacoepidemiology Program, Department of Epidemiology, Harvard School of Public Health, *Pregnancy Registries: Methodological Points and Real Examples*

8:30am-Noon
Propensity Scores (520F)

Course Faculty/Presentations

John Seeger, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Introduction and Overview of Propensity Scores in Pharmacoepidemiology*

Jeremy Rassen, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, *Implications of Propensity Score –Based Analyses*

8:30am-Noon
Comparative Effectiveness Research: Methodologic Challenges of Newly Marketed Medical Products (520AD)

This course explains the methodologic challenges of comparing the effectiveness of newly marketed medical products. The speakers will discuss different study designs and types of data for comparative effectiveness research: a prospective surgical registry, systematic reviews of trials, retrospective cohort studies and prospective database studies. To illustrate the methodologic challenges, the speakers will present case studies from their past and ongoing CER studies. The course covers advanced solutions, such as propensity score-matched sequential monitoring designs, for addressing the challenges of comparing newly marketed medical products.

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

Educational Objectives

- Recognize the limitations of indirect treatment comparisons across studies in systematic reviews.
- Understand how the patient, provider and healthcare setting can confound comparative effectiveness estimates for newly marketed medications.
- Recognize the unique challenges of studying products that diffuse slowly into the market.
- Appreciate the advantages of sequential monitoring strategies using healthcare databases or registries.

Target Audience

The course is designed for those who conduct comparative effectiveness research and assumes knowledge of introductory pharmacoepidemiologic methods.

Faculty

Jodi B Segal, Johns Hopkins University School of Medicine and Bloomberg School of Public Health

Joshua J Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School

Eric S Johnson, Kaiser Permanente's Center for Effectiveness and Safety Research

Sebastian Schneeweiss, FISPE, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School

8:30am-Noon

Intermediate Pharmacoepidemiology - Dealing with Unmeasured Confounders (519B)

The possibility of unmeasured determinants of disease and exposure poses the most difficult critique of observational research. Intermediate Pharmacoepidemiology will examine the range of techniques for dealing with unmeasured confounders, including randomization, self-matching, proxies, instruments and the identification of populations in which unmeasured confounding is unlikely to be a concern.

Faculty

Alexander Walker, FISPE, WHISCON



**OUR WORK IS SOMEONE'S HOPE.
JOIN US.**

Merck, established in 1891, is a global research-driven pharmaceutical company dedicated to putting patients first. This philosophy was first articulated by George Merck and still guides us today. Join us and experience our culture first-hand – one of strong ethics & integrity, diversified experiences and a resounding passion for improving human health. As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.

MRL Epidemiology, founded by Dr. Harry Guess in 1985 – Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate benefits and the risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, develop and validate patient reported outcomes, link biomarkers to outcomes and help understand the safety of our products pre- and post-launch. Our team is an active member of clinical development and outcomes research teams. MRL Epidemiology includes the Pharmacoepidemiology and Database Research Unit (PEDRU) which concentrates Merck's efforts to lead in the application and development of pharmacoepidemiologic methods, and to further the appropriate use of large automated databases to address drug safety and risk/benefit issues across the full spectrum of Merck's portfolio. MRL Epidemiology also includes European Research Units and an Asia Pacific Unit based in China.

Join us and participate in our investigative design and interpretation that enables us to bring life-enhancing products to market.

Visit www.merck.com/careers to find out how.



PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

8:30am-Noon

Regulatory Pharmacoepidemiology/Health Care Decision Making (519A)

Educational Objectives

- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Gain an overview of worldwide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

Course Faculty/Presentations

- Gerald Dal Pan**, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, *Challenges in Regulatory Epidemiology*
- June Raine**, Vigilance and Risk Management of Medicines Division, Medicines and Healthcare Regulatory Products Agency, *Challenges in Regulatory Epidemiology*

8:30am-Noon

Introduction to Drug Utilization Research (520BE)

Included as part of the full meeting registration; registration required.

Content

- The educational session consists of presentations providing an overview of drug utilization research and presenting essential methods
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples
- Interpretation of study results taking into account limitations of data sources and methods will be addressed
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions
- Interaction with participants will be encouraged, e.g. by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations

Educational Objectives

- To provide an overview of Drug Utilization Research within the context of Pharmacoepidemiology, Health Services Research and Public Health
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges
- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms of volume, expenditures and quality of drug use, facilitating international cross-national comparisons
- To explain the process of developing and validating prescribing quality indicator
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research (time series analysis)

Target Audience

- New members of the DUR/HSR SIG
- Those interested in drug utilization research who need an overview of the area
- Those interested in monitoring medicine use and quality assurance aspects
- Those working in health care organizations involved in payment and reimbursement of medicines
- Those working in medicines policy areas
- Health service planners

Course Faculty/Presentations

- Lisa Pont**, Sydney Nursing School, University of Sydney, *Methodological Framework and Skills Needs in Drug Utilization Research*
- Hanne Strom**, WHO Collaborating Centre for Drug Statistics, *The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose Methodology: Classifying & Quantifying Drug Use*
- Morten Andersen**, Centre for Pharmacoepidemiology, Karolinska Institute, *Drug Utilization Research and Monitoring in Individual Based Registers – Study Design & Epidemiological Measures of Drug Use*
- Julie Zito, FISPE**, School of Pharmacy, University of Maryland, *Overview of Drug Utilization Research in the United States*

Noon-1:30pm

Lunch On Your Own

Noon-1:30pm

New Member Luncheon (524)

(By Invitation)



CPRD

More Dimensions to Data

Quality • NHS Clinical • Linkage • Real world • Randomised • PROs • Population 52M+

To the pharmacoepi community
**we thank you
for being
part of our
success**

www.cprd.com

Visit us at
Booth 24-26
for your personal
thank you

Medicines and Healthcare
Products Regulatory Agency

NHS
National Institute for
Health Research



PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

1:30-6:00pm

Advanced Topics in Pharmacoepi (519AB)

Faculty/Presentations

Irene Petersen, Department of Primary Care and Population Health, University College, London, *Multiple Imputation of Missing Data in Longitudinal Electronic Health Records.*

Jessica Myers Franklin, Division of Pharmacoepidemiology and Pharmacoeconomics, Department

of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Simulation as a Tool for Understanding Pharmacoepidemiology.*

Rayjean J. Hung, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, *Bayesian Methods for Hierarchical Modeling of High Dimensionality Data.*

Linda Lévesque, Department of Community Health and Epidemiology, Queens University, Ontario, *Immortal Time Bias: Beyond the Basics.*

1:30-6:00pm

Introduction to Therapeutic Risk Management & Evaluation (520F)

Educational Objectives

- To provide basic overview/framework for biopharmaceutical risk management including:
- To describe the current requirements for evaluation studies and types of results that have been seen in the past few years
- To illustrate key concepts of evaluation research with examples of RMP/REMS assessment studies
- To provide an opportunity for interactive session in developing and evaluating a Risk Mgmt. Plan

Course Faculty/Presentations

Elizabeth Andrews, FISPE, RTI Health Solutions, *Overview of Risk Management and the Role of Evaluation*

Stella Blackburn, FISPE, European Medicines Agency Risk Management Development and Scientific Lead, *Requirements and Lessons Learned from Evaluating Risk Management Programs in the EU*

Gerald Dal Pan, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, *Requirements and Lessons Learned from Evaluating Risk Management Programs in the US*

Carla Van Bennekom, Slone Epidemiology Center, Boston University, *Examples of RMPs and Evaluations*

Judith Jones, FISPE, The Degge Group, Ltd., *Workshop for Participants to Develop a Risk Management Plan, Including an Assessment Approach*

LASER
ANALYTICA
 population health intelligence

Come visit us at our *Booth #27-28*
 to discuss our latest experiences in

Comparative effectiveness and continuous benefit risk assessment
Relative risk and crisis management studies
Outcomes research on disease burden and impact on health care

www.la-ser.com

PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

1:30-6:00pm

Advanced Drug Utilization Research (525)

Course Faculty/Presentations

- Douglas Steinke**, Manchester Pharmacy School, University of Manchester, *Chair*
- Libby Roughead**, School of Pharmacy & Medical Services, University of South Australia, *Methods for Identifying & Managing Problems with Medicine Use in Practice*
- Petra Denig**, University of Groningen, *Developing Valid Prescribing Quality Indicators*

- Colin Dormuth**, Pharmacology & Therapeutics, University of British Columbia, *Evaluating Interventions on Drug Utilization: Analysis Methods*
- Jerry Avorn, FISPE**, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, *Evaluating Practice or Policy*

1:30-6:00pm

A State-of-the-Art Review of Benefit-Risk Assessment and Risk Communication Practices (520AD)

—Sponsored by the Benefit-Risk Assessment, Communication and Evaluation (BRACE) SIG

Background:

The priority placed on benefit-risk assessment and risk communication in the recent PDUFA reauthorization and update of the EU pharmacovigilance legislation, in addition to other ongoing regulatory, industry, and public-private partner initiatives, highlights the rising global prominence of an emerging, interdisciplinary field of benefit-risk assessment (B-RA), communication (C) and evaluation of risk minimisation (E). In addition to exploring new requirements, challenges and opportunities in BRACE, this session will focus on state of the art methodologies and tools to assess and communicate the benefit-risk profile of pharmaceutical products.

Educational Objectives

- Develop an understanding of new B-RA and RC initiatives and requirements
- Share new tools and methodologies for B-RA and RC
- Demonstrate the application of these tools and methods via a case study

Target Audiences

- ICPE attendees with an interest in pharmacoepidemiologic methods, regulatory affairs, benefit-risk assessment, risk management and risk communication

Course Faculty/Presentations

- Becky Noel**, Eli Lilly & Company, *Regulatory and Industry B-RA and RC Initiatives*

- Priya Bahri**, European Medicines Agency, Risk Communication in a Global Environment; EMA and DHPCs, *Collaboration Between Regulator and Industry*
- Juhaeri Juhaeri**, Sanofi-Aventis, Application and Case Study: *Use of the PROACT-URL or BRAT Framework to Structure a B-R Assessment*
- Gerald Dal Pan**, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, *FDA Current Risk Communication Strategies*
- Elaine Morrato**, University of Colorado at Denver, *Developing Effective Risk Communication Strategies*
- Peter Mol**, University Medical Center Groningen, *Impact of Risk Communication*
- Meredith Smith**, Abbott Laboratories, *Presenting Risk Information to Healthcare Professionals and Patients*

6:00-7:30pm

Welcome Reception/Academic Showcase (Marquee 720-725)

—Admission by badge or ticket. Cash Bar.

- Yola Moride, ISPE**, Chair, 2013 Scientific Program Committee
- Stella Blackburn, FISPE**, ISPE President

Academic Showcase Participants (as of August 1, 2013)

- Boston University Schools of Public Health and Medicine – Slone Epidemiology Center
- Brigham & Women's Hospital, Division of Pharmacoepidemiology
- Center for Drug Safety & Effectiveness, John Hopkins School of Public Health
- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- DESS, Faculty of Pharmacy, Université de Montréal
- Drug Safety Research Unit
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- The University of British Columbia | Child & Family Research Institute
- University of Rhode Island



PHARMACOEPI.ORG

29th International Conference on
**PHARMACOEPIDEMOLOGY AND
 THERAPEUTIC RISK MANAGEMENT**

7:00am-6:00pm

Registration (Viger Hall)

7:00am-5:00pm

Speakers' Ready Room (522C)

7:00-8:00am

Poster Session A Set-up
(220BC)

7:00-7:45am

History of Pharmacoepidemiology
(520BE)

- ▶ David Lilienfeld, FISPE, Coordinator
–An open organizational meeting.

7:00-7:45am

Chapter Meetings (Open to all interested)

- ▶ Gulf Region (520AD)
- ▶ Latin America (521C)
- ▶ FarmacoEpiEnRed (519AB)

8:00am-6:00pm

Exhibits/Posters
(220BC)

8:00-8:30am

BIENVENUE (517D)

- ▶ Yola Moride, FISPE, Chair,
2013 Scientific Program Committee
- ▶ Mireille Mathieu, Vice-President, Scientific
Production, Institut National D'Excellence
en Santé et en Services Sociaux
- ▶ Stella Blackburn, FISPE
ISPE President

8:30-10:00am

KEYNOTE SESSION (517D)**Two Solitudes: Are We Talking to Each
Other?**

Host:

- ▶ Thomas M. MacDonald, FISPE

Presenters:

- ▶ Jacques LeLorier, FISPE, *Pharmacology: The
Neglected Half of Pharmacoepidemiology*
- ▶ Bernard Begaud, *Epidemiology: The Neglected
Half of Pharmacoepidemiology*

10:00-10:30am

Break/Posters/Exhibits
(220BC)10:30am-noon **CONCURRENT SESSIONS: CONTRIBUTED PAPERS****Back to the Future: Methods in Time (Methods 1)** (519AB)

Moderators: Soko Setoguchi-Iwata, FISPE, & Sonia Hernandez-Diaz, FISPE

10:30am

- ▶ Flexible Marginal Structural Cox Models for Estimating Cumulative Effect of
Time-Dependent Treatment on the Hazard [1]
Yongling Xiao, Michal Abrahamowicz, Erica EM Moodie, Rainer Weber, Jim
Young. (Canada)

10:45am

- ▶ De-Constructing a Marginal Structural Model: Effects of Follow-Up Duration
on Stabilized Weights and Findings in a Study of Myocardial Infarction Risk
in Hemodialysis Patients [2]
Alan R Ellis, Chin-Hua Wang, Janet K Freburger, Abhijit V Kshirsagar,
Wolfgang C Winkelmayr, M Alan Brookhart. (United States)

11:00am

- ▶ Evaluating Newly-Marketed Medications with a High-Dimensional Disease
Risk Score Estimated in a Historical Cohort [3]
Jeremy A Rassen, Joshua Gagne, Robert J Glynn, Jessica M Franklin,
Sebastian Schneeweiss. (United States)

11:15am

- ▶ Using Predicted Probabilities of Exposure and Outcome to Assess Con-
founding [4]
Joshua J Gagne, Katsiaryna Bykov, Sebastian Schneeweiss. (United States)

11:30am

- ▶ Relative Performance of Approaches Handling Immortal Person-Time in
Comparative Effectiveness Research: A Simulation Study [5]
Xiaojuan Mi, Bradley G Hammill, Lesley H Curtis, Soko Setoguchi.
(United States)

11:45am

- ▶ Misclassification in Assessment of Diabetogenic Risk Using Laboratory-
Enhanced Claims Data [6]
Steven T Bird, Joseph AC Delaney, Rhonda M Cooper-DeHoff, Gregory A
Nichols, Almut G Winterstein. (United States)

Burden of Disease: Profiles and Prospects (524AB)

Moderators: Marieka De Bruin & Vicki Osborne

10:30am

- ▶ Risk of Hemorrhagic Stroke and Seizure Are Increased in Patients with
Alzheimer's Disease [7]
Michael N Cook, Stephan Lanes, Charles Wentworth III, Michael Arrighi,
Nicole Baker, Roger A Bullock. (United States)

10:45am

- ▶ Incidences of Herpes Zoster, Its Manifestations and Complications for 2005
– 2009 in Germany- A Retrospective Cohort Study [8]
Kathrin Hillebrand, Lena Kemper, Renate Schulze-Rath, Tania Schink,
Edeltraut Garbe. (Germany)

11:00am

- ▶ Dyslipidemia, Inflammation and Cardiovascular Risk in Patients with
Rheumatoid Arthritis [9]
DA Pappas, A John, J Kremer, G Reed, J Greenberg, A Shewade, DH
Solomon, JR Curtis. (United States)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

11:15am

▶ **Incidence of Venous Thromboembolic Events among ALS Patients in a U.S. Health Insurance Claims Database [10]**

James R Williams, Douglas A Kerr, Wildom R Farwell. (United States)

11:30am

▶ **Predictors of Clinical Metastases and Survival among Non-Metastatic Prostate Cancer (PC) Patients (pts) Treated with Androgen-Deprivation Therapy (ADT) in Sweden [11]**

Rohini K Hernandez, Johan Mesterton, Jonas Banefelt, Jan Stålhammar, Patrik Sobocki, Bo-Eric Persson, Alexander Liede. (United States)

11:45am

▶ **Rising Trends in the Incidence of Nonmelanoma Skin Cancer in the United States: Findings from an Administrative Database [12]**

Kunal K Gandhi, Seongjung Joo, Jeanette A Preston, Andres Gomez. (United States)

Opioids or NSAIDs: A Painful Choice (520CF)

Moderators: Dave Dore & Kristian Filion

10:30am

▶ **Ambulatory Diagnosis and Treatment of Non-Malignant Pain in the United States, 2000-2010 [13]**

Matthew Daubresse, Hsien-Yen Chang, Yu Yuping, Shilpa Viswanathan, Nilay Shah, Randall Stafford, Stefan Kruszewski, G Caleb Alexander. (United States)

10:45 am

▶ **Patient Requests for Specific Narcotics Influence Physician Prescribing [14]**

Michael A Fischer, Jeffrey N Katz, Lisa D Marceau, Felicia L Trachtenberg, Jing Yu, John B McKinlay. (United States)

11:00am

▶ **Changes in Rates of Doctor Shopping after Introduction of a Reformulated ER Oxycodone Product [15]**

Howard Chilcoat, Paul Coplan, Brian Schulz, Nelson Sessler, Yingli Yuan. (United States)

11:15am

▶ **Use of Opioids and Risk of Dementia in Older Adults [16]**

Sascha Dublin, Rod L Walker, Shelly L Gray, Rebecca Hubbard, Melissa L Anderson, Onchee Yu, Paul K Crane, Eric B Larson. (United States)



MEDMINING
Our data is different.*

Discover what makes our
EHR data extracts different.

View our bibliography at medmining.com

Stop by booth 3 for a chance to win an iPad mini!

Inpatient, Outpatient, Primary, Specialty Care settings. Multiple Payers (Medicare, Medicaid, Commercial, Self-Pay)
Actual Costs, 1,100+ Lab Results (HbA1C, Lipids, CBC, etc.), BMI, Blood Pressures, Tobacco Status, Employment, Mortality,
Medications, 8,000+ Flowsheet Measures, Tumor Stage/Size/Histology, Chemo Tx Plans, Ejection Fraction, NYHA,
PFT Values, DXA, FRAX®, EEGs, MMSE, Operating Room Data, Mother-Child Link, IIQ, SHIM, etc.
Plus Claims Data, Clinician Consultation, and Patient/Provider Surveying

www.medmining.com

A Geisinger Health System Business



CONCURRENT SESSIONS: CONTRIBUTED PAPERS

11:30am

▶ **Comparative Safety of Nonsteroidal Anti-Inflammatory Drugs Commonly Used in Asia—Preliminary Findings from Asian Pharmacoepidemiology Network (AsPEN) Association Study [17]**
Edward Chia-Cheng Lai, Ju-Young Shin, Nobuhiro Ooba, Nicole Pratt, Yea-Huei Kao Yang, Byung Joo Park, Kiyoshi Kubota, Libby Roughead, Soko Setoguchi. (Taiwan)

11:45am

▶ **Use of Over-the-Counter Non-Steroidal Anti-Inflammatory Drugs in the General Population and in Patients with a High Risk of Adverse Drug Events [18]**
Aafke R Koffeman, Vera E Valkhoff, Sevde Çelik, Geert W 't Jong, Miriam CJM Sturkenboom, Patrick JE Bindels, Johan Van der Lei, Pim AJ Luijsterburg, Sita MA Bierma-Zeinstra. (Netherlands)

Part Man - Part Machine, A Device Potpourri (518AB)

Moderators: Kristina Bardenheuer & Ted Lystig

10:30am

▶ **Outcomes after Carotid Artery Stenting (CAS) in Real-World vs. Trial Settings [19]**
Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, Andrew T Rothman, Hiraku Kumamaru, Lauren A Williams, Chih-Ying Chen, Jun Liu, John D Seeger, Soko Setoguchi. (United States)

10:45am

▶ **Transatlantic Active Surveillance of Cardiovascular Safety (TASC) of an Etonogestrel/Ethinylestradiol-Containing Vaginal Ring [20]**
Sabine Moehner, Juergen Dinger, Klaas Heinemann. (Germany)

11:00am

▶ **Comparison of Early Mortality after Aortic Valve Replacement with Biological Versus Mechanical Prosthetic Valve among Medicare Beneficiaries [21]**
Dongyi (Tony) Du, Stephen McKean, Jeffrey Kelman, John Laschinger, Chris Johnson, Rob Warnock, Chris Worrall, Thomas E MaCurdy, Hector Izurieta. (United States)

11:15am

▶ **Breastfeeding as a Risk Factor for Uterine Perforation during IUD Insertion: Interim Results from the EURAS-IUD Study [22]**
Klaas Heinemann, Suzanne Reed, Sabine Moehner. (Germany)

The catalyst for
successful decision
making in the life
sciences industry



Kantar Health provides a broad range of epidemiology information and custom analysis.

Our multi-client epidemiology offers span multiple geographies for a wide variety of indications.

CancerMPact® Patient Metrics: 30+ tumors across 7 countries

Epi Database: up to 190 indications across 13 countries

National Health and Wellness Survey: 165 indications across 10 countries



ZEG Berlin (Center for Epidemiology and Health Research), a Kantar Health company, provides expertise in pharmacoepidemiology with a focus on drug safety and risk management and minimization. The company specializes in large multinational observational/active surveillance studies.

If you would like us to act as catalysts for you,
contact us at www.kantarhealth.com/contactus.

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

11:30am

- ▶ **Long-Term Outcomes of Vaginal Mesh Versus Native Tissue Repair for Anterior Vaginal Wall Prolapse [23]**

Michele Jonsson Funk, Antony G Visco, Alison C Weidner, Virginia Pate, Jennifer M Wu. (United States)

11:45am

- ▶ **Acute Kidney Injury after Routine Colonoscopy: A Comparative Safety Study of Sodium Phosphate and Polyethylene Glycol [24]**

J Bradley Layton, Abhijit V Kshirsagar, Andrew S Bombback, Philip J Klemmer. (United States)

Pregnancy Session 1 (520AD)

Moderators: Deborah Covington & Allen Mitchell, FISPE

10:30am

- ▶ **Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study [25]**

Jon T Andersen, Espen Jimenez-Solem, Nadia L Andersen, Henrik E Poulsen. (Denmark)

10:45am

- ▶ **Ondansetron Use in Pregnancy and Risk of Adverse Fetal Outcomes [26]**

Björn Pasternak, Henrik Svanström, Anders Hviid. (Denmark)

11:00 am

- ▶ **Risks and Safety of Pandemic H1N1 Vaccine in Pregnancy: Birth Defects, Spontaneous Abortion, Preterm Birth, and Small for Gestational Age Infants [27]**

Christina D Chambers, Diana L Johnson, Ronghui Xu, Yunjun Luo, Carol Louik, Allen A Mitchell, Michael Schatz, Kenneth L Jones. (United States)

11:15am

- ▶ **The Influence of Vaccination Against Influenza A (H1N1) during Pregnancy on Pregnancy Outcomes in the Netherlands; a Cross Sectional Linkage Study [28]**

Nicoline AT van der Maas, Joyce Dijs-Elsinga, Miriam J Knol, Jeanet M Kemmeren, Alies van Lier, Hester E de Melker. (Netherlands)



Celgene Corporation is proud to sponsor the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Celgene shares ISPE's dedication to enhancing public health through the creation of critical and innovative safety and risk management programs in areas of great medical need

www.celgene.com



CONCURRENT SESSIONS: CONTRIBUTED PAPERS

11:30am

▶ **Use of Fluconazole during Pregnancy and the Risk of Major Birth Defects [29]**

Ditte Mølgaard-Nielsen, Björn Pasternak, Anders Hviid. (Denmark)

11:45am

▶ **A Methodological Comparison of Antiepileptic Drug Pregnancy Registries and Implications on Estimated Birth Defect Rates [30]**

Amanda Golembesky, Deborah Covington, Jessica Albano, Linda Kalilani. (United States)

Use Your Heart (520BE)

Moderators: Annlouise Assaf, FISPE, & K. Arnold Chan, FISPE

10:30am

▶ **Warfarin Safety in a Residential Aged Care Setting [31]**

Lisa G Pont, Alice Cheng, Gerard Stevens, Andrew J McLachlan. (Australia)

10:45am

▶ **Drug Use Pattern of Rivaroxaban in the UK [32]**

Carlos Martinez, Stephan Rietbrock, Kiliana Suzart-Woischnik, Mari-Ann Wallander. (Germany)

11:00am

▶ **Adherence to the JNC 7 Treatment Guideline and Impact on Patient Outcomes [33]**

Christopher G Rowan, Ankit J Shah, Jeffrey A Spaeder. (United States)

11:15am

▶ **National Trends in the Treatment of Hypertension in the United States, 1997-2012 [34]**

Meijia Zhou, G Caleb Alexander. (United States)



Proven epidemiology expertise to meet your comprehensive drug safety research needs

Rooted in scientific rigor, our methodologically innovative pharmacoepidemiology experts can assist you through customized services tailored to any scope or specialty, including:

- Retrospective and prospective studies
- Medical record confirmation of exposures/outcomes
- Validation of algorithms
- Safety signal detection and refinement
- Risk management — study design, execution of risk management programs and safety assessments
- Regulatory/safety consulting
- Natural history of disease
- Provider/patient surveys
- Publication and presentation

Visit Optum at our booth during the 29th ICPE to learn more about how we can support your drug safety research.

For additional information, contact Jessica Fachini today at +1 952.917.7085 or jessica.fachini@optum.com.
optum.com/life-sciences-solutions

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

11:30am

▶ **Increasing Age Is Associated with Underuse of Evidence-Based Treatment for Heart Failure [35]**

Catherine Girouard, Jeanne-Françoise Kay-ibanda, Jean-Pierre Grégoire, Paul Poirier, Éric Demers, Jocelyne Moisan. (Canada)

11:45am

▶ **Persistence with Statin Therapy: Does Family History of Cardiovascular Events Influence Medication-Taking Behaviour? [36]**

Anna Citarella, Helle Kieler, Anders Sundström, Marie Linder, Björn Wettermark, Ingegärd Anveden Berglind, Morten Andersen. (Sweden)

Noon -1:30pm

Lunch/Poster Session A/Exhibits (220BC)**Roundtable Discussions** (Reserved tables in 220BC)

To foster the ability of the more junior ISPE members to network and new ISPE members to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Monday and Tuesday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

- **Jean-Pierre Grégoire, FISPE**, Challenges in Medication Adherence Research
- **Alicia Gilseman**, Linkage with Cancer Registry Data in the US
- **Brian Strom, FISPE**, Developing a Career in Pharmacoepidemiology

ISPE Committee/Council Meetings

Open to all participants.

- **Development Committee** (523)
- **Fellowship & Awards Committee** (521A)
- **Finance Committee** (521B)
- **Public Policy Committee** (521C)
- **Student Council** (516AB)

12:45-1:30pm

Poster Walks (220BC)

- **Adherence SIG**
- **CER (Comparative Effectiveness Research) SIG**
- **Medications in Pregnancy SIG**

Successful Journeys Start with Great Maps

UBC continues to power global patient access and product safety strategies with real-world evidence gathering and analysis

Value Demonstration
Risk Management
Database Analytics Automation



Visit us at
Booth #4



Learn More with
your smartphone
2013 UBC
ICPE Abstracts

INFORMED DECISIONS • OPTIMIZED CARE

ubc.com

©2013 Express Scripts Holding Company All Rights Reserved

1:30-3:00pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

Big Molecules, Big Problems? (524AB)

Moderators: Jeanne Loughlin & David Miller

1:30pm

► **Risk of Venous Thromboembolism and Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis [37]**

Seoyoung C Kim, Daniel H Solomon, Jun Liu, Robert J Glynn, Sebastian Schneeweiss. (United States)

1:45pm

► **Hyperimmune Globulins (HIGs) and Same-Day Thrombotic Adverse Events (TEs) in a Large Health-Care Database [38]**

Mikhail Menis, Gayathri Sridhar, Nandini Selvam, Mikhail V Ovanesov, Hozefa A Divan, Yideng Liang, Dorothy Scott, Basil Golding, Richard Forshee, Robert Ball, Steven A Anderson, Hector S Izurieta. (United States)

2:00pm

► **Comparative Safety of Biological Agents among Medicare Rheumatoid Arthritis Patients [39]**

Huifeng Yun, Fenglong Xie, Elizabeth S Delzell, Lang Chen, Emily Levitan, James Lewis, Kenneth G Saag, Timothy Beukelman, Kevin Winthrop, William J Baddley, Paul Muntner, Jeffrey R Curtis. (United States)

2:15pm

► **Women with Autoimmune Disease Who Receive the Influenza Vaccine During Pregnancy Have Rates of Influenza-Like Illness Similar to Healthy Women Who Are Vaccinated during Pregnancy [40]**

Yunjun Luo, Diana L Johnson, Ronghui Xu, Christina D Chambers. (United States)

2:30pm

► **Cancer Risk Following beta-Interferon Treatment for Multiple Sclerosis: Findings from the Malignancy in MS [MaMS] Study [41]**

Elaine Kingwell, Charity Evans, Feng Zhu, Stanley Hashimoto, Joel Oger, Helen Tremlett. (Canada)

2:45pm

► **Persistence with Biologics for Rheumatoid Arthritis Associated with Concomitant Methotrexate Use [42]**

Jie Zhang, Fenglong Xie, Elizabeth S Delzell, James D Lewis, Lang Chen, Jeffrey R Curtis. (United States)

Gene Meets Drug (520CF)

Moderators: Stephen Kimmel, FISPE, & David Pulford

1:30pm

► **Germline Polymorphisms and Response to Cetuximab in Colorectal Cancer: A Meta-Analysis of Published Studies [43]**

Eric K Morgen, Derek J Jonker, Chris J O'Callaghan, Geoffrey Liu. (Canada)

1:45pm

► **Polymorphisms in microRNA (miRNA) Pathways as Predictors of Survival and Response to Cisplatin in Esophageal Cancer (EC) Patients [44]**

Lawson Eng, Abul K Azad, Xin Qiu, Dangxiao Cheng, Daniel J Renouf, Lorin Dodbiba, Sharon Marsh, Sevta Savas, Jennifer J Knox, Gail E Darling, Rebecca KS Wong, Wei Xu, Olusola O Faluyi, Geoffrey Liu. (Canada)

2:00pm

► **Genetic Variation in the PPARA Gene Is Associated with Simvastatin-Mediated Cholesterol Reduction in the Rotterdam Study [45]**

Catherine E de Keyser, Matthijs L Becker, André G Uitterlinden, Albert Hofman, Jan J Lous, Laure Elens, Ron HN van Schaik, Bruno H Stricker. (Netherlands)

2:15pm

► **Risks of Venous Thromboembolism in Women Using Combined Hormonal Contraception and Carrying Genetic Hemostatic Variations [46]**

Helle Kieler, Ingemar Persson, Jacob Odeberg, Anders Sundström, Annica Bergendal. (Sweden)

2:30pm

► **ST13 Polymorphisms Increase the Risk of Exacerbations in Steroid-Treated Asthmatic Children and Young Adults [47]**

Susanne JH Vijverberg, Ellen S Koster, Roger Tavendale, Maarten Leusink, Leo Koenderman, Jan am Raaijmakers, Dirkje S Postma, Gerard H Koppelman, Steve W Turner, Somnath Mukhopadhyay, Sze Man Tse, Kelan G Tantisira, Colin NA Palmer, Anke-Hilse Maitland-van der Zee. (Netherlands)

2:45pm

► **Plasma Fibrinogen Predicts Mortality in Patients with COPD [48]**

Jason C Simeone, Stephan Lanes, Kyle Fahrbach, David M Mannino, Bruce E Miller, amber Martin, David A Lomas, Jørgen Vestbo, Graham Barr, Anna Maeser, Mitchell Goldman, Ubaldo Martin, Ruth Tal-Singer, Stephen Rennard, Debora D Merrill. (United States)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Hot Topics in Diabetes: Pancreatitis and Cancer (520BE)

Moderators: **Kim Brodovicz & Marloes Bazelier**

1:30pm

▶ **Adherence to Oral Diabetes Medications and Glycemic Control During and Following Breast Cancer Treatment [49]**
 Gregory S Calip, Denise M Boudreau. (United States)

1:45pm

▶ **Glucagon-Like Peptide-1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes: Population Based Matched Case-Control Study [50]**
 Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan M Weiner, Jeanne M Clark, Jodi B Segal. (United States)

2:00pm

▶ **Incretin-Based Drugs and Comparative Pancreatic Cancer Risk among Older Adults [51]**
 Mugdha Gokhale, Til Sturmer, Virginia Pate, Alison Marquis, Christine Gray, John Buse. (United States)
Student Award Recipient–Best Methods Abstract Submitted by a Student/Post-Doc

2:15pm

▶ **Duration of Metformin Use and Risk of Colon Cancer in Patients with Diabetes [52]**

Laurel A Habel, Lori C Sakoda, Ninah S Achacoso, Charles P Quesenberry, Christine Iodice, Tiffany Peng, Samantha Erlich, Assiamira Ferrara. (United States)

2:30pm

▶ **Mortality after Cancer in People with and without Pre-Existing Diabetes: Diabetes Duration and Treatment Effect [53]**
 Kristina Ranc, Marit E Jorgensen, Bendix Carstensen. (Denmark)

2:45pm

▶ **Trends in First Anti-Diabetes Drug Initiated among Adults with Incident Diabetes in SUPREME-DM [54]**
 Marsha A Raebel, Glenn K Goodrich, H Lester Kirchner, Patrick J O'Connor, Julie A Schmittiel, Emily B Schroeder, Stanley Xu, Melissa G Butler, Jean M Lawrence, Katherine M Newton, Gregory A Nichols, Ram D Pathak. (United States)

GENESIS RESEARCH

Promised · Delivered

Genesis Research provides authoritative Data Analytics and Statistical Services to the BioPharmaceutical Industry.

Epidemiologic studies

Biostatistics

Analysis of Large Claims Data Sources, EMRs and Population-based Data

Health-Outcomes Research

Multi-Level Modeling

GENESIS RESEARCH

50 Harrison St, Hoboken, New Jersey 07030
 1-888-503-2680



ANALYSIS
 STATISTICS TEST SEARCH DATA DEVELOPMENT

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Methods in CER (519AB)

Moderators: **Mary Beth Ritchey, & Sebastian Schneeweis, FISPE**

1:30pm

- ▶ **Comparing Effectiveness Estimates from Randomized and Nonrandomized Studies, Using Subgroup Analyses and Individual Patient Data [55]**

Amand F Schmidt, Rolf HH Groenwold, Stuart Pocock, Francois Gueyffier, Arno W Hoes, Anthonius de Boer, Mirjam Nielen, Olaf H Klungel. (Netherlands)

1:45pm

- ▶ **Information Gained by Linking Administrative Claims to Structured Electronic Health Record Data in a Statin Comparative Effectiveness Study [56]**

Peter M Wahl, Jeremy A Rassen, Marc B Rosenman, Daniel Mines, Robert J Glynn, Sebastian Schneeweiss. (United States)

2:00pm

- ▶ **Imaging and Electronic Health Record (EHR) Data for Comparative Effectiveness Research (CER): Experience from a Tertiary Care Hospital [57]**

Jessica J Jalbert, Marie D Gerhard-Herman, Andrew T Rothman, Lauren A Williams, Chih-Ying Chen, Jun Liu, John D Seeger, Louis L Nguyen, Soko Setoguchi. (United States)

2:15pm

- ▶ **Preference-Based Instrumental Variable Methods in the Comparative Effectiveness of Osteoporosis (OP) Medications in Women with Postmenopausal Osteoporosis (PMO) [58]**
- Jane S Der, Cathy Critchlow, Fei Xue. (United States)

2:30pm

- ▶ **Comparing Propensity Score Estimation Using Logistic Regression and Generalized Boosted Regression in a Real-World Comparative Effectiveness Study of Glaucoma Therapies (RiGOR) [59]**

Jaclyn LF Bosco, Kristina Franke, Anne L Coleman, Flora C Lum, Richard Gliklich, Zhaohui Su, Priscilla Valentgas. (United States)

2:45pm

- ▶ **Identifying Appropriate Comparisons for Comparative Effectiveness Research (CER) [60]**
- Patrick B Ryan, Alec Walker, Paul E Stang, Martijn J Schuemie, David Madigan, Marc A Suchard, Marc J Overhage, Jesse Berlin. (United States)

Respiratory (518AB)

Moderators: **Kiyoshi Kubota, FISPE, & Kourtney J. Davis**

1:30pm

- ▶ **Application of Instrumental Variables Method in Pharmacoepidemiology: An Example of Beta2-Agonist Use and Myocardial Infarction [61]**

M Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)

1:45pm

- ▶ **Factors Associated with Time to Triple Therapy in Newly Diagnosed COPD Patients in the UK General Practice Research Database [62]**

Keele E Wurst, Greta Bushnell, amit Shukla, Hana Muellerova, Kourtney J Davis. (United States)

2:00pm

- ▶ **Role of Tiotropium in Reducing Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients When Added to Long-Acting 2-Agonists (LABA) and Inhaled Corticosteroids (ICS) [63]**

Valeria Belleudi, Eliana Ferroni, Nera Agabiti, Mirko Di Martino, Ursula Kirchmayer, Silvia Cascini, Lisa Bauleo, Luigi Pinnarelli, Elisabetta Patorno, Riccardo Pistelli, Giulio Formoso, Danilo Fusco, Marina Davoli. (Italy)

2:15 pm

- ▶ **Feasibility of Ruling out Small Treatment-Associated Increase in Asthma Mortality Risk [64]**

Patricia Tennis, Catherine Johannes, CA Camargo, Jr., Til Stürmer, Stephan Lanes, Jeff Brown, Elizabeth Andrews, Kourtney Davis, Michael Schatz. (United States)

2:30pm

- ▶ **Profile of Asthma Exacerbation Patients in a US Administrative Claims Database [65]**

Maria Gerhardsson de Verdier, David M Kern, Siting Zhou, Ozgur Tunceli, Judith Hackett, Giuseppe Ciaramella, Scott L Butler. (Sweden)

2:45pm

- ▶ **Type of Stress Ulcer Prophylaxis and the Risk of Nosocomial Pneumonia in Cardiac Surgical Patients [66]**

Brian T Bateman, Katsiaryna Bykov, Sebastian Schneeweiss, Joshua Gagne, Jennifer M Polinski, Jessica M Franklin, Michael A Fischer, Niteesh K Choudhry, Jeremy A Rassen. (United States)

Sounding All the Sources (520AD)

Moderators: **Niels Vermeer & Andrzej Czarnecki, FISPE**

1:30pm

- ▶ **TNF Inhibitors Exposure and Cancer? Data of Case/Non Case Study in French Pharmacovigilance Database [67]**

Layla Saliba, Malak Aboutaam, Vanessa Rousseau, Leila Chebane, Nadine Petitpain, Bernadette Baldin, Pierre Gillet, Jean-Louis Montastruc, Haleh Bagheri. (France)

1:45pm

- ▶ **Designing a Fit-for-Purpose Data Extraction Tool for Australian General Practice Electronic Health Records [68]**

Nancy PT Huang, Siaw-Teng Liaw, Jane Taggart, Hiarong Yu. (Australia)

2:00pm

- ▶ **Evaluating an ICD-10 Algorithm To Detect ONJ among Cancer Patients in Denmark [69]**

John Acquavella, Henrik Gammelager, Claus Sværke, Morton Schiødt, Sven Erik Nørholt, Henrik Toft Sørensen, Vera Ehrenstein. (United States)

2:15pm

▶ **Pharmacosurveillance Using Real-Time Electronic Medical Records [70]**

Tewodros Eguale, Robyn Tamblin, James A Hanley. (Canada)

2:30pm

▶ **Active Surveillance of Adverse Events Following Immunization with Meningococcal A Conjugate Vaccine MenAfriVac™ in Mali [71]**

Kirsten S Vannice, Modibo Keita, Samba Sow, Fabien Diomandé, Anna Durbin, Lawrence Moulton, Saad Omer, Massambou Sacko, Téné Yaméogo, Patrick Zuber, Neal Halsey. (United States)

2:45pm

▶ **Comparison of Disproportionality Measures in EudraVigilance [72]**

Jim Slattery, Gianmario Candore, Phil Tregunno, Jenny Wong, Suzie Seabroke, Kristina Juhlin, Niklas Noren, Naashika Quarcoo, Katrin Manlik, Antoni Wisniewski, Ramin Arani, Marietta Rottenkolber, Bharat Thakrar. (United Kingdom)

3:00-3:30pm

Break/Posters/Exhibits (220BC)3:30-5:00pm **PLENARY SESSION (517D)****Risk Assessment to Guide Treatment - The Case of Natalizumab (Tysabri) and Progressive Multifocal Leukoencephalopathy (PML)**

Educational Objectives. The aim of the session is to outline a case study (PML with Tysabri) that illuminates challenges faced by pharmacoepidemiology in addressing a serious but rare adverse effect of an effective treatment.

Following attendance at this session, attendees will:

- Describe the clinical course of multiple sclerosis and how Tysabri is used
- Describe the pathogenesis/epidemiology of PML as a risk of Tysabri treatment
- Describe risk stratification of PML as a guide to Tysabri treatment
- Describe the patient/regulatory considerations around Tysabri and PML

Target Audiences.

- ICPE attendees with an interest in using risk assessment to guide drug therapy and regulatory and patient considerations

Moderators

John Seeger
Patricia Saddier

Presenters

Gary Bloomgren, *PML and Tysabri - Industry Perspective*
Stella Blackburn, *FISPE, PML and Medications - Regulatory Perspective*
Ryan Kaplan, *MS Patient to Provide Patient Perspective*
Deborah Ashby, *Benefit-Risk Considerations (Protect)*

Big Data.

**Large populations or clinical detail?
With deep data, you don't have to choose.**

**Automated data for tens of millions of patients
across the spectrum of care, with access to
medical charts, physicians, and patients.**

Safety & Epidemiology

Registries

HEOR

Comparative Effectiveness

Visit us at ICPE booth #36 or www.HealthCore.comMichael Chance: 484.301.3090; mchance@healthcore.com

HealthCore[®]
real-world insight



5:00-6:30pm

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

Benefit-Risk Assessment, Communication and Evaluation (BRACE): Embrace the Challenges and Opportunities [73] (520BE)

- Rebecca Noel, Paola Primatesta, Gerald Dal Pan, Michael Wolf, Meredith Smith, Priya Bahri, Elaine Morrato, Debashish Dey. (United States)

SPONSORED BY THE BRACE SIG

Design and Methodological Considerations in Conducting Relative Effectiveness Studies of Newly Launched Products [74] (520CF)

- Raphaelle Beau-Lejdstrom, Jessica J Jalbert, Xavier Kurz, Tjeerd van Staa, Michel Rossignol. (United Kingdom)

Drug Response in Diverse Populations: Role of Ethnicity [75] (518AB)

- David J Pulford, Geoffrey Liu, Annette S Gross, Bruce Carleton. (United Kingdom)

SPONSORED BY THE MOLECULAR EPI, BIOMARKERS/PHARMACOGENETICS SIG

Harmonizing Methods and Data Across Multiple Databases: Beautiful Music or Cacophony? [76] (517D)

- Xiaofeng Zhou, Miriam Sturkenboom, Kevin Haynes, Patrick B Ryan, Alison D Bourke, Andrew Bate. (United States)

SPONSORED BY THE DATABASE SIG

Non-Database Pharmacoepidemiology in Low Resource Settings: Current Status and Unique Opportunities To Advance Methods [77] (524AB)

- Veronika Wirtz, Soko Setoguchi, Frank May, Marcela Jirón, Parthasarathi Gurumurthy, Hisham Aljadhey, Penkarn Kanjanarat, Alec Walker. (United States)

Post-Marketing Pharmacoepidemiologic (PE) Database Studies to Assess Drug Safety [78] (519AB)

- Cathy Critchlow, Jeffrey Curtis, David Dore, Kenneth Rothman, Lars Pedersen, Michael Sprafka, Judy Staffa, Miriam Sturkenboom, Fei Xue. (United States)

Strategies To Enhance Validity in the Design of Comparative Effectiveness Studies [79] (520AD)

- Robert J Glynn, Til Sturmer, Jeremy A Rassen, Alan Brookhart, Sebastian Schneeweiss. (United States)

6:30-7:30pm

ISPE Council Meetings

Open to all interested participants

- Academic Council (520CF)
- Government/Regulatory Council (520BE)
- Industry/Service Providers Council (520AD)

7:30-8:30pm

PDS Editorial Board (521B) - By Invitation

7:30pm

Students/Young Professionals Night Out at Sur Bleury - Sold Out

7:30pm

FarmacoEpiEnRed-Spanish Chapter Dinner (TBA)

SAVE THE DATES...

ROTTERDAM, THE NETHERLANDS

◆ SUNDAY, APRIL 6 - TUESDAY, APRIL 8 ◆



ISPE 2014 MID-YEAR MEETING



Health
Economics

Outcomes
Research

Market
Access

Data
Analytics

Epidemiology

We partner with life sciences organizations worldwide to optimize the market access and commercial success of their products. Our scientists, researchers and consultants leverage deep knowledge of the global payer and regulatory landscape and offer expertise in developing, capturing and communicating the evidence required to demonstrate the value of treatment interventions.

Stop by booth #14 to learn more about our services
and our newly named company.

Our presentations include:

Workshop

- Using Pharmacoepidemiology Database Resources to Address Drug Safety Research – Selection of Databases for Pharmacoepidemiology Research
Matthew W. Reynolds, PhD

Oral Presentations

- Plasma Fibrinogen Predicts Mortality in Patients with COPD
Simeone JC, Lanes S, Fahrbach K, Mannino DM, Miller BE, Martin A, Lomas DA, Vestbo J, Barr G, Maeser A, Goldman M, Martin U, Tal-Singer R, Rennard S, Merrill DD
- Use of Common Data Model to Meaningfully Compare Patients Diagnosed and Treated for Depression Among Disparate Databases
Reisinger S, Powell G, Dreyfus B, Schneider G

Posters

- Estimation of the Incidence Rate of Very Rare Diseases – A Case Study of Multicentric Castleman’s Disease
- Leveraging Multiple EHR Databases in Parallel as an Innovative Means for Active Postmarketing Hepatotoxicity Monitoring in Oncology Patients
- Analyzing Database Studies with Many Outcomes or Co-morbidities: Using SAS® to Dynamically Generate Analytic Programs from Case Definitions Stored in Excel®
- Creating Treatment Episodes for Biologic Medications from Pharmacy and Medical Claims

info@evidera.com  www.evidera.com



7:00am-6:00pm

Registration
(Viger Hall)

7:00am-5:00pm

Speakers' Ready Room (522C)

7:00-8:00am

Poster Session B Set-up
(220BC)

8:00am-6:00pm

Exhibits/Posters
(220BC)

8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Brain, Skin and Bones in Relation to CNS Drugs (520 CF)

Moderators: **Bram Hartzemza, FISPE, & Patrice Verpillat**

8:00am

▶ **Use of Antiepileptic Drugs and the Risk of Severe Cutaneous Adverse Drug Reactions in Elderly Patients: A Nationwide Case-Control Study [349]**

Ji Young Kim, Young-Jin Ko, Ju-Young Shin, Joongyub Lee, Sun-Young Jung, Nam-Kyong Choi, Byung-Joo Park. (Republic of Korea)

8:15am

▶ **Comparative Risks of Severe Cutaneous Reactions Associated with Individual Antiepileptic Drugs Following FDA Black Box Warning [350]**

Alexis Parente, Ping Chen, Christie Teigland, Barton Jones, John Scoggins, Sandhya Mehta, Xiaoqin Yang, Zulkarnain Pulungan. (United States)

8:30am

▶ **Comparative Effectiveness of Antidepressants in Reducing Risk of Dementia in Older Adults with Depression [351]**

Sandhya Mehta, Rajender Aparasu, Hua Chen, Michael L Johnson, Holly Holmes, Anuja N Roy. (United States)

8:45am

▶ **Angiotensin II Receptor Blockers and the Risk of Dementia [352]**

Kah Lay Goh, Ian Douglas, Krishnan Bhaskaran, Stephen Evans, Liam Smeeth. (United Kingdom)

9:00am

▶ **Antidepressants and the Risk of Fractures [353]**

Tania Schink, Stefanie Höhne, Niklas Schmedt, Edeltraut Garbe. (Germany)

9:15am

▶ **A Case-Crossover Study of Age-, Gender-, and Dose-Specific Effects of Non-Benzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents [354]**

David D Dore, Sarah D Berry, Yoojin Lee, Vincent Mor. (United States)

Money Matters (518AB)

Moderators: **Jean Lachaine & Jason Guertin**

8:00am

▶ **Impact of the Type of Drug Insurance Plan on Adherence and Cost of Antihypertensive Agents [355]**

François Després, amélie Forget, Fatima-Zohra Kettani, Sylvie Perreault, Lucie Blais. (Canada)

8:15am

▶ **Cost-Utility Analysis of Various Chemotherapy Regimens among Elderly Ovarian Cancer Patients: A Longitudinal Cohort Study [356]**

Rohan C Parikh, David R Lairson, Janice N Cormier, Xianglin L Du. (United States)

8:30am

▶ **Mental Disorder Treatment, Healthcare Costs and Utilizations for US Veterans [357]**

Lin Xie, Juan Du, Furaha Kariburyo, Anne H Dysinger, Li Wang, Onur Baser. (United States)

8:45am

▶ **Final Results from the Multicenter COMPACT Study of Complications in Patients with Sickle Cell Disease (SCD) and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review [358]**

Lanetta B Jordan, Patricia Adams-Graves, Julie Kanter-Washko, Patricia Oneal, Francis Veke-man, Christine Bieri, Medha Sasane, Andrea Marcellari, Matthew Magestro, Zachary Gorn, Mei S Duh. (United States)

9:00am

▶ **Impact of the Maximum Quantity Policy on Dispensing Fee and Prescribed Drug Expenditures in the Ontario Public Drug Benefit Program [359]**

Kednapa Thavorn, Muhammad Mamdani, Tara Gomes, David Juurlink, Ximena Camacho, Zhan Yao, Michael Paterson. (Canada)

9:15am

▶ **High Resource Beneficiaries of the Ontario Drug Benefit (ODB) Formulary [360]**

Ximena Camacho, Tara Gomes, David Juurlink, Michael Paterson, Irfan Dhalla, Muhammad Mamdani. (Canada)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Pediatrics (520AD)

Moderators: Patrick Souverein & Gillian Hall, FISPE

8:00am

- ▶ **Risk of Suicide and Suicide Attempt Associated with Atomoxetine Compared to Central Nervous System Stimulant Treatment [361]**
Stephan Linden, Regina Bussing, Tobias Gerhard, Jonathan J Shuster, Almut G Winterstein. (United States)

Student Award Recipient—Second Best Abstract Submitted by a Student/Post-Doc

8:15am

- ▶ **Pediatric Sleep Disorders: Trends, Treatment and Association with Adolescent Depression [362]**
Linda pmM Wijlaars, Irwin Nazareth, Irene Petersen. (United Kingdom)

8:30am

- ▶ **Risk of Febrile Seizure Following Inactivated Influenza Vaccine and Concomitant Vaccines [363]**
Jonathan Duffy, Eric Weintraub, Claudia Vellozzi, Frank DeStefano. (United States)

8:45am

- ▶ **Antibiotics and Hepatotoxicity in Pediatric Primary Care: A Case-Control Study Using Electronic Healthcare Databases [364]**
Carmen Ferrajolo, Katia MC Verhamme, Gianluca Trifiró, Geert W 't Jong, Gino Picelli, Carlo Giaquinto, Giampiero Mazzaglia, Claudio Cricelli, Francesco Rossi, Annalisa Capuano, Miriam CJM Sturkenboom. (Netherlands)

9:00am

- ▶ **Growth Impairment and Risk of Cancer and Cardiovascular Disease in Children [365]**
Bharat T Thakrar, Xiuqing Kou, Alan Nevitt. (Switzerland)

9:15am

- ▶ **Effectiveness of Rotavirus Vaccines in Preventing Rotavirus Gastroenteritis Related Hospitalizations in Privately-Insured US Children, 2007-2010 [366]**
Catherine A Panozzo, Sylvia Becker-Dreps, Virginia Pate, Michele Jonsson Funk, Til Stürmer, David J Weber, M Alan Brookhart. (United States)

Pfizer

Working together for a healthier world™

Committed to improving health and well-being at every stage of life

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent

with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

We are proud to support the **29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management** and welcome the opportunity for the open exchange of scientific ideas and findings to advance the fields of pharmacoepidemiology and risk management.

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

PS, I Love You (Methods 2) (519AB)

Moderators: Olaf Klungel & John Seeger

8:00am

- ▶ **Poor Performance of High-Dimensional Propensity Score Matching in Primary Care Medical Records Data [367]**

Jaco Voorham, Petra Denig. (Netherlands)

8:15am

- ▶ **High-Dimensional Confounding Adjustment with Area-Based Socioeconomic Measures [368]**

Jennifer M Polinski, Jeremy A Rassen, Jessica M Franklin, Sebastian Schneeweiss. (United States)

8:30am

- ▶ **Propensity Score Matching with Multiple Treatment Comparisons: The Shifting Reference Group [369]**

J Bradley Layton, Michele Jonsson Funk, Til Stürmer, Richard Wyss, M Alan Brookhart. (United States)

8:45am

- ▶ **Validation of Propensity Score Calibration Method To Control for Unmeasured Confounding in Time-to-Event Analyses [370]**

Rebecca Burne, Michal Abrahamowicz. (Canada)

9:00am

- ▶ **Bias When Using Propensity Score Methods [371]**

John H Page, Victoria M Chia. (United States)

9:15am

- ▶ **Effects of Aggregation of Medical Codes on the Performance of the High-Dimensional Propensity Score (hd-PS) Algorithm [372]**

Hoa V Le, Charles Poole, Alan M Brookhart, Victor J Schoenbach, Kathleen J Beach, Til Stürmer. (United States)

Generate evidence to build successful real-world strategies with Xcenda.

- Natural history of disease
- Background rates to support emerging risk profile
- Safety/benefit of medicinal products
- Pharmacoepidemiology studies
 - Database studies and chart reviews
 - Prospective studies and post-approval registries
 - Methods development
 - Pregnancy studies, including registries

Turn to Xcenda for customized solutions and reliable studies that meet your needs. Start a conversation to find out how we can help you with the strategies and data you need to demonstrate your brand's value.



proving value. maximizing access.®



www.xcenda.com

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

That's Interesting... (524AB)

Moderators: Ron Herings, FISPE, & Kate Lapane, FISPE

8:00am

▶ **Rosiglitazone Versus Pioglitazone and Acute Myocardial Infarction: Systematic Review and Meta-Analysis of Observational Studies [373]**

Manel Pladevall, Cristina Varas Lorenzo, Andrea Margulis, Nuria Riera-Guardia, Brian Calingaert, Silvana Romio, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)

8:15am

▶ **International Pharmacovigilance: Modeling Exposure to Diabetic Drugs in Relationship to Cardiovascular Effects [374]**

Robyn Tamblyn, Michal Abrahamowicz, Marie-Eve Beauchamp, Nadyne Girard, William Dixon. (Canada)

8:30am

▶ **Diabetes Performance Measures: Potential Overtreatment and Undertreatment [375]**

Petra Denig, Flora M Haaijer-Ruskamp, Jaco Voorham. (Netherlands)

8:45am

▶ **Incident Type II Diabetes Mellitus among Patients Exposed to the Combination of Pravastatin and Paroxetine [376]**

Kristen B Bibeau, Kyna M Gooden, Jennifer Wood-Ives, Michael C Irizarry, Xianying Pan. (United States)

9:00am

▶ **Association between Active Vitamin D and the Risk of Infection-Related Hospitalizations in Patients Receiving Chronic Hemodialysis: A Nested Case-Control Study [377]**

Isabelle Normand, Naoual Elftouh, Jean-Philippe Lafrance. (Canada)

9:15am

▶ **Achieving Glycemic Control Differs between Patients with Type 2 Diabetes Mellitus Starting on Metformin and Sulfonylureas [378]**

Egbert JF Lamberts, Patrick C Souverein, Jacqueline G Hugtenburg, Giel Nijpels, Marcel L Bouvy. (Netherlands)

Up and Down the GI Tract (520BE)

Moderators: James Lewis, FISPE, & Cheryl Enger

8:00am

▶ **Suboptimal Prescribing of Proton Pump Inhibitors in Low-Dose Aspirin Users in General Practice: A Population-Based Cohort Study [379]**

Hilda J De Jong, Joke C Korevaar, Liset Van Dijk, Eef Voogd, Christel E Van Dijk, Martijn G Van Oijen. (Canada)

8:15am

▶ **Prevalence and Trend of Proton Pump Inhibitor Use among Current Users of Non-Steroidal Anti-Inflammatory Drugs and Risk Factors for Gastrointestinal Complications – A Population-Based Longitudinal Study in Sweden [380]**

Tobias Svensson, Fredrik Granath, Christian Jonasson, Jan G Hatlebakk, Lars Lundell, Morten Andersen. (Sweden)

8:30am

▶ **The Influence of Hospital Drug Policy on the Prescribing Patterns of Proton Pump Inhibitors in Primary Care [381]**

Michael Due Larsen, Jesper Hallas. (Denmark)

8:45am

▶ **Oral Bisphosphonates and Upper Gastrointestinal Toxicity: A Study of Cancer and Early Signals of Esophageal Injury [382]**

Nancy E Morden, Jeffrey C Munson, Jeremy Smith, Todd A Mackenzie, Stephen K Liu, Anna NA Tosteson. (United States)

9:00am

▶ **Peripheral and Total Parenteral Nutrition as Primary Risk Factors for Nosocomial Candidemia among Elderly Adult Patients [383]**

Fabio Barbone, Silvia Cavinato, Manuela Giangreco, Gianluca Granà, Sandro Centonze, Maria Luisa Deiana, Gianni Biolo, Roberto Luzzati. (Italy)

9:15am

▶ **Proton Pump Inhibitors and Clostridium Difficile-Associated Disease in Canadian and Australian Community Settings – A Prescription Sequence Symmetry Analysis [384]**

TongTong Wang, Nicole Pratt, Graeme Killer, Elizabeth E Roughead, Jenna Griffiths. (Canada)

9:30-10:00am**Break/Posters/Exhibits**

(220BC)



10:00-11:30am **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

Methods 3 (519AB)

Moderators: **Suellen Curkendall & Earl Goehring, Jr.**

10:00am

- ▶ **Reporting of Instrumental Variable Analyses in Comparative Effectiveness Research [385]**
 Sonja A Swanson, Miguel Hernan. (United States)

10:15am

- ▶ **Considerations for Creating a Calendar Time Instrumental Variable in Specific Settings of Nonexperimental Comparative Effectiveness Research [386]**
 Christina D Mack, M Alan Brookhart, Robert Glynn, Til Stürmer. (United States)

10:30am

- ▶ **Improvement of 1:M Matching Using an Adaptive Algorithm: Proof of Concept [387]**
 Til Stürmer, Richard Wyss, Virginia Pate, Kenneth J Rothman. (United States)

10:45am

- ▶ **Comparison among EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies for Data Extraction and Management [388]**
 Rosa Gini, Patrick B Ryan, Jeffrey S Brown, Edoardo Vacchi, Massimo Coppola, Walter Cazzola, Preciosa M Coloma, Roberto Berni, Gayo Diallo, Paul Avillach, Gianluca Trifirò, José L Oliveira, Peter R Rijnbeek, Johan van der Lei, Miriam CJM Sturkenboom, Martijn J Schuemie. (Italy)

11:00am

- ▶ **Comparing Disease Risk Scores with Propensity Scores for Confounding Control When Evaluating Newly Introduced Treatment Therapies [389]**
 Richard Wyss, M Alan Brookhart, Robert J Glynn, Virginia Pate, Til Stürmer. (United States)

11:15am

- ▶ **Evidence of Free Sample Use among New Users of Branded Statins [390]**
 Xiaojuan Li, M Alan Brookhart. (United States)



ParagonRx[®]

INVENTIV HEALTH

Using Systematic Methods to Guide Global Pharmaceutical Safe Use for Over a Decade

We would love to meet you!

Visit us at BOOTH #9 for a chance to win a Nike+ FUELBAND!

- » Email: info@paragonrx.com
- » Phone: +1 888.459.8080
- » Website: www.paragonrx.com



Use your smartphone to scan the QR code to visit our website and sign up for Safe Use updates

630 Churchmans Road, Suite 200, Newark, DE 19702, USA

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Potential Bias in Cardiovascular Studies (520BE)

Moderators: **Thomas M. MacDonald, FISPE, & Klaas Heinemann**

10:00am

▶ **Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone Versus amiodarone and Other Antiarrhythmics [391]**

Shujun Gao, Wanju Dai, Ling Zhang, Juhaeri Juhaeri, Patrick Caubel. (United States)

10:15am

▶ **Do Statins Reduce Short-Term Mortality among Patients Hospitalized with Perforated Peptic Ulcers? [392]**

Jennifer L Lund, Morten Schmidt, Til Stürmer, Anders H Riis, Lars Pedersen, Henrik Toft Sorensen. (Denmark)

10:30am

▶ **Comparative Safety of Cardiovascular Medication Use and Breast Cancer Outcomes [393]**

Denise M Boudreau, Onchee Yu, Jessica Chubak, Erin Bowles, Heidi S Wirtz, Monica Fujii, Diana SM Buist. (United States)

10:45am

▶ **Cardiac Mortality in Users of Olmesartan, Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors [394]**

Alec Walker, Caihua Liang, Robin Clifford, Crawford Parker, Allen Feldman. (United States)

11:00am

▶ **Adherence to Antihypertensive Agents and Risk Reduction of End-Stage Renal Disease [395]**

Louise Roy, Brian White-Guay, Marc Dorais, Alice Dragomir, Myriam Lessard, Sylvie Perreault. (Canada)

11:15am

▶ **Re-Assessing the Cardiovascular Risk of Abacavir in the Swiss HIV Cohort Study (SHCS) Using a Flexible Marginal Structural Model [396]**

Marina B Klein, Yongling Xiao, Michal Abrahamowicz, Erica Moodie, Rainer Weber, Jim Young. (Canada)

Value through Innovation



Even with more than 128 years of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 140 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more than 46,228 employees worldwide and a track record built up in more than 128 years, we are continuously dedicated to improving the outlook for a healthier life.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com



CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Pregnancy Potpourri (520CF)

Moderators: **Andrea Margulis & Judith Jones, FISPE**

10:00am

▶ **Positive Predictive Values of Algorithms for Ascertainment of Major Congenital Malformations in Administrative Databases [397]**

Nicholas J Everage, Daina B Esposito, Li Zhou, Gaurav Deshpande, Crystal N Holick, K Arnold Chan, Daniel Mines. (United States)

10:15am

▶ **Pitfalls of Evaluating Overall Relative Risk of Major Congenital Malformations (MCM) in Healthcare Databases [398]**

Patricia Tennis, Brian Calingaert, Elizabeth Andrews. (United States)

10:30am

▶ **Methylergonovine Maleate and the Risk of Myocardial Ischemia and Infarction [399]**

Brian T Bateman, Krista F Huybrechts, Sonia Hernandez-Diaz, Jun Liu, Jerry Avorn. (United States)

10:45am

▶ **Acid-Reducing Drugs in Pregnancy: Patterns of Use and Risk of Selected Birth Defects [400]**

Carla M Van Bennekom, Allen A Mitchell. (United States)

11:00am


▶ **Use of Macrolides During Pregnancy and the Risk of Birth Defects [401]**

Odile Sheehy, Fabiano Santos, Anick Berard. (Canada)

11:15am

▶ **SSRI and the Risk of Miscarriage – A Register Based Nation Wide Cohort Study [402]**

Jon T Andersen, Espen Jimenez-Solem, Nadia L Andersen, Jonas K Jensen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)



RTI HEALTH SOLUTIONS®



RISKS AND BENEFITS:

Define. Measure. Evaluate. Communicate.



We provide full-service solutions for your international epidemiological, safety, and risk management needs.

Visit our exhibit booth to learn how we can help you *define, measure, evaluate and communicate* the risks and benefits of your products.

www.rtihs.org

LEADING RESEARCH...
 MEASURES THAT COUNT

Research Triangle Park • Ann Arbor • Barcelona • Lund • Manchester • Sheffield • Waltham

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Psychotropics on Your Mind (518AB)

Moderators: Morten Andersen & Julie Zito, FISPE

10:00am

▶ **Technology Diffusion in the Antipsychotic Market: A Comparison of France and the USA between 1998 and 2008 [403]**

Adeline Gallini, Haiden A Huskamp, Julie M Donohue. (France)

10:15am

▶ **Geographic and Clinical Variation in Clozapine Use in the U.S. [404]**

Tobias Gerhard, T Scott Stroup, Stephen Crystal, Cecilia Huang, Mark Olfson. (United States)

10:30am

▶ **Prevalence and Trends of Antipsychotic Utilization in Long-Term Care in Saskatchewan, Canada [405]**

Nianping Hu, David Blackburn, Yvonne Sevchuck, Teare Gary, Lisa Lix, Verena Schneider-Lindner. (Germany)

10:45am

▶ **The Risk of Incident Rosacea Associated with Psychiatric Diseases and Psychotropic Drug Therapy [406]**

Julia Spöndlin, Fabian Bichsel, Johannes J Voegel, Susan S Jick, Christoph R Meier. (Switzerland)

11:00am

▶ **A Proxy of Cancer Progression in Dispensing Claims: Validation and Performance [450]**

Vikram Joshi, Barbara-Ann Adelstein, Andrea Schaffer, Preeyaporn Srasuebkul, EoCC Investigators, Timothy Dobbins, Sallie-Anne Pearson. (Australia)

11:15am

▶ **Reported Off-Label Use of Psychotropic Drugs in Rehabilitation Centers for Acquired Brain Injury: A Cross-Sectional Survey in Italy [408]**

Federica E Pisa, Giorgia Cosano, Tullio Giorgini, Emanuele Biasutti, Manuela Giangreco, Fabio Barbone. (Italy)



CA10033 0912 PRINTED IN USA ©2012, Lilly USA, LLC. ALL RIGHTS RESERVED.

*The best medical breakthrough:
 enjoying your grandkids.*

In 1900, the average life expectancy was 47 years. Today it's 77. There's no more dramatic example of the power of medical innovation. It's not only saving millions of lives, but it's completely changing life experiences.

Lilly is in the business of making medicines that help people live longer, healthier and more active lives. For more than 135 years, we've been a leader in medical innovation. From diabetes to mental health, we've seen what our dedicated scientists and researchers can do. Our industry's work means more fathers are seeing their daughters get married, and more grandmothers are watching their grandsons play baseball. And we're not done. Lilly is dedicated to being there for the next century of memories.

Learn more at lilly.com and lillypad.lilly.com

CMM The Campaign for
 Modern Medicines
modernmedicines.com

Lilly
 Answers That Matter.

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Sweet Spot on CER (520AD)

Moderators: Lisa Pont & Adrian Levy

10:00am

▶ **Comparative Effectiveness of Oral Diabetes Drugs in Observational Data: Closing Evidence Gaps [409]**

James H Flory, Dylan Small, Patricia Cassano, David Brillon, Sean Hennessy, Alvin Mushlin. (United States)

10:15am

▶ **Risk of Acute Myocardial Infarction in Patients with Diabetes Mellitus Type 2 Treated with Basal Insulin [410]**

Sigrid Behr, Bianca Kollhorst, Dirk Enders, Antje Timmer, Franz-Werner Dippel, Karlheinz Theobald, Edeltraut Garbe. (Germany)

10:30am

▶ **Comparative Effectiveness of Insulin Versus Combination Insulin and Sulfonylurea on Cardiovascular Outcomes [411]**

Christianne L Rومية, Robert A Greevy, Carlos G Grijalva, Adriana M Hung, Xulei Liu, Harvey J Murff, Tom A Elasy, Marie R Griffin. (United States)

10:45am

▶ **The Effect of Intravenous Iron Supplementation Practices on Infection Risk in Hemodialysis Patients [412]**

Maurice A Brookhart, Janet Freburger, Alan R Ellis, Lily Wang, Wolfgang C Winkelmayr, Abhi Kshirsagar. (United States)

11:00am

▶ **Comparative Safety of Corticosteroids on the Risk of Acute Myocardial Infarction: A Retrospective Cohort Study [413]**

Sun-Young Jung, Bong Gi Kim, Hyun-Joo Jung, Kyoung-eun Kwon, Byung-Joo Park. (Republic of Korea)

11:15am

▶ **Choice of Scale for Assessment of Comparative Treatment Effect Heterogeneity [414]**

Michele Jonsson Funk, Virginia Pate, Til Stürmer. (United States)

Vaccines: Benefits, Risks; Reducing the Unknowns (524AB)

Moderators: Joanna Haas, FISPE, & Ariel E. Arias

10:00am

▶ **Autoimmune Disorders and Quadrivalent Human Papillomavirus Vaccination of Young Females [415]**

Lamiae Grimaldi-Bensouda, Didier Guillemot, Bertrand Godeau, Alfred Mahr, Paul-Henri Lambert, Jacques Benichou, Christine Lebrun-Frenay, Caroline Papeix, Pierre Labauge, Patrick Berquin, Alfred Penfornis, Pierre-Yves Benhamou, Marc Nicolino, Albane Simon, Jean-Francois Viillard, Nathalie Costedoat-Chalumeau, Marie-France Courcoux, Corinne Pondarre, Pascal Hilliquin, Emmanuel Chatelus, Violaine Foltz, Severine Guillaume, Michel Rossignol, Lucien Abenhaim, The PGRx-AID Study Group. (France)

10:15am

▶ **Cumulative Risk of Guillain-Barré Syndrome among Vaccinated and Unvaccinated Populations during the 2009 H1N1 Pandemic [416]**

Claudia Vellozzi, Shahed Iqbal, Brock Stewart, Jerry Tokars, Frank DeStefano. (United States)

10:30am

▶ **Effectiveness of Influenza Vaccination in Working Age Adults with Diabetes: A Population-Based Cohort Study [417]**

Darren Lau, Dean T Eurich, Sumit R Majumdar, Alan Katz, Jeffrey A Johnson. (Canada)

10:45am

▶ **Outcome-Based Vaccine Safety Surveillance [418]**

Roger Baxter, Edwin Lewis, Bruce Fireman, Julia McDonald, Nicola P Klein. (United States)

11:00am

▶ **When Marginal Structural Model Assumptions Fail: An Illustration Using Influenza Vaccine Effectiveness [419]**

Leah J McGrath, Stephen R Cole, Abhijit V Kshirsagar, Lily Wang, David J Weber, Til Stürmer, Alan Brookhart. (United States)

11:15am

▶ **Monitoring of Intussusception after Rotavirus Vaccines—United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2012 [420]**

Penina Haber, Manish Patel, Yi Pan, Frank Destefano, James Baggs, Umesh Parashar. (United States)

11:30am-1:30pm

Lunch/Poster Session B/Exhibits (220BC)

Roundtable Discussions (Reserved tables in 220BC)

To foster the ability of the more junior ISPE members to network and new ISPE members to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Monday and Tuesday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

- **Sean Hennessy, FISPE**, Publishing in Pharmacoepidemiology Research
- **Jacques LeLorier, FISPE**, The Importance of Pharmacology in Pharmacology Research
- **Jeremy Rassen**, Propensity Scores and Other Strategies for Confounding Adjustment

ISPE Committee/Council Meetings

–Open to all members and new members.

–Lunch will be available in committee rooms.

- **Bylaws and Policies Committee** (521C)
- **Education Committee** (523)
- **Global Development Committee** (521B)
- **Membership Committee** (521A)
- **Publications Committee** (514C)

12:15-1:00pm

Poster Walks (220BC)

- **BRACE SIG**
- **Databases SIG**
- **Molecular Epidemiology SIG**
- **Pediatrics SIG**

1:00-2:30pm

PLENARY SESSION (517D)**The Patients Voice in Benefit & Risk**

- A number of initiatives are underway to add the patient voice into better understanding the safety and effectiveness of pharmaceutical products in real world use. The Patient-Centered Outcomes Research Institute (PCORI) indicated their interest in obtaining input from patient and caregiver groups to identify specific research questions and understand the value of product effectiveness. The US Food and Drug Administration is collecting data from patients to better understand the patient perspective on unmet medical needs, outcomes of importance to patients and benefit-risk.
- Clinical databases (electronic medical records/ insurance claims) are often used in safety and effectiveness research to provide clinical information on healthcare contacts, e.g. outpatient, inpatient, lab, imaging data. However, these clinical databases often do not directly collect the patients' perspective. Data directly collected from patients through validated Patient Reported Outcomes (PROs) and use of innovative tools such as smart phone technology may help provide a more complete picture of the effectiveness and/or tolerance of a pharmaceutical product. Linking this data to a clinical database may provide even richer information.
- This workshop will focus on current efforts to include the patients' voice in assessing benefit and risk of pharmaceutical interventions.

Speakers:

- **Kate Lapane, FISPE**, *An Overview*
- **Ethan Basch**, *Patient-Reported Outcomes for Collecting Adverse Event Information*
- **Nabarun Dasgupta**, *How the FDA Uses Mobile Apps and Social Media Monitoring to Identify AEs*
- **John Ware**, *Improving Disease-specific and Generic Patient-reported Outcome (PRO) Measures to Better Capture the Beneficial and Adverse Effects of Pharmaceutical Therapies*
- **Neil Minkoff**, *Combining PROs with EMRs to Create a More Holistic View of Patient Experience*
- **Nancy Santanello, FISPE**, and **Til Sturmer, FISPE**, *Summary and Discussion*

2:30-4:00pm –Open to all participants.

ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY (517D)**Annual Meeting****Call to Order and Presidential Address**

- ▶ **Stella Blackburn, FISPE**, ISPE President

Financial Reports

- ▶ **Kate Lapane, FISPE**, Vice President Finance
- ▶ **Judith Jones, FISPE**, Investments

Awards Ceremony**The Ronald D. Mann Best Article Award****The Risk of Guillain–Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009–2010 Seasonal Influenza Vaccines: Results from Self-Controlled Analyses**

Jerome I Tokars, Paige Lewis, Frank DeStefano, Matthew Wise, Melissa Viray, Oliver Morgan, Paul Gargiullo and Claudia Vellozzi

Presenters:

- ▶ **Brian Strom, FISPE**, Editor-in-Chief
- ▶ **Sean Hennessy, FISPE**, Regional Editor for the Americas

Meetings

- ▶ **7th Asian Conference on Pharmacoepidemiology**, Parthasarathi Gurumurthy
- ▶ **2013 ICPE**, Yola Moride, FISPE

Student Awards

—**The Andrew McAfee Award** (*Best abstract submitted by a student/post-doc from a developing country*): **Mary Atieuo Onyango/Kenya**

—**Best Methods Abstract**: **Mugdha Gokhale**

—**Third Best Abstract**: **Sonal Singh**

—**Second Best Abstract**: **Stephan Linden**

—**The Stanley A. Edlavitch Award & Oral Presentation**

(*Best abstract submitted by a student/post-doc*): **Anna Byrjalsen**

Use of Corticosteroids during Pregnancy and in the Postnatal Period and Risk of Asthma in Offspring: A Nationwide Danish Cohort Study [421]

Anna Byrjalsen, Trine Froeslev, Ane Birgitte Telén Andersen, Morten Olsen, Henrik Toft Soerensen. (Denmark)

Induction of ISPE Fellows (FISPE)

- ▶ **Tarek Hammad, FISPE**
- ▶ **Vincent Lo Re, FISPE**
- ▶ **Almut Winterstein, FISPE**

Distinguished Service Award

- ▶ **Byung-Joo Park, FISPE**

Board Transition

Installation of New President: **Til Stürmer, FISPE**

Adjournment

4:00-4:30pm

Break/Posters/Exhibits (220BC)

4:30-6:00pm

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

Advanced Topics on Database Algorithm Development and Validation [422] (517D)

- Jinghua He, Charles E Leonard, Marc B Rosenman, Daniel Mines, Christian Reich. (United States)

Best Practices and Areas of Future Research in the Development of Educational Material To Communicate Risk to Patients and Clinicians [423] (518AB)

- Ann Marie McNeill, Elizabeth Andrews, Alicia Gilsean, Annalisa Rubino, Gerald Dal Pan. (United States)

Impact of the Choice of Reference Set on Performance Testing of Signal Detection Methods [424] (524AB)

- Patrick Ryan, Martijn Schuemie, Niklas Noren, Jan Bonhoeffer, Preci Coloma, Gianluca Trifiro, Miriam Sturkenboom. (Netherlands)

Importance of Sensitivity Analyses for Design Decisions in Comparative Effectiveness Research [425] (520AD)

- Cynthia J Girman, Doug Faries, Xiaochun Li, Timothy Lash, Til Stürmer. (United States)

Looking for Efficient Solutions To Optimize Adherence to Drug Treatment: The Clinical, Health Services Research and Economics Perspectives [426] (520BE)

- Jean-Pierre Grégoire, Robert Gross, Sophie Lauzier, Niteesh Choudry, Lisa Pont. (Canada)

SPONSORED BY THE DRUG UTILIZATION/HEALTH SERVICES RESEARCH SIG

New Approaches To Account for Selection Bias and Confounding by Frail Health Status [427] (520CF)

- Sascha Dublin, Michael Jackson, Tracey Marsh, Soko Setoguchi-Iwata, Wendy Camelo Castillo, M Alan Brookhart. (United States)

Welcoming Advanced Methods into the World of Pregnancy Research [428] (519AB)

- Krista F Huybrechts, Kristin Palmsten, Andrea V Margulis, Sonja Swanson, Jennita Reefhuis, Sonia Hernández-Díaz. (United States)

6:00-7:00pm

Special Interest Group (SIG) Meetings

Open to all members and new members.

- Adherence (518AB)
- AsPEN SIG (524AB)
- Biologics SIG (518C)
- BRACE SIG (520AD)
- Comparative Effectiveness Research SIG (520CF)
- Database SIG (519AB)
- Drug Utilization/Health Services Research SIG (517D)
- Medical Devices SIG (524C)
- Medications in Pregnancy SIG (520BE)
- Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG (525A)
- Pediatrics SIG (525B)

7:30pm-12:30am

Social Event (Montreal Science Centre)

Bring your dancing shoes!

- Admission is by badge or ticket
- Admission includes 2 drinks
- Food will be served

Come and celebrate with us!



- Join your colleagues for dinner, entertainment and dance the evening away! Soulvation will provide the music
- Buses will shuttle from the Convention Center to the Montréal Science Centre. The first buses will depart from the Convention Center at 7:00pm; the last bus will depart from the Science Centre at 12:30am. If it's a nice evening consider walking to the Science Centre (20 minutes).



A shared vision for real-world success

In a future where healthcare efficiency and quality are measured through the lens of 'real-world' insights, external validity demands a focus on the right data sources, scientifically credible research, and actionable communication. IMS is committed to helping you succeed:

- **Largest multi-disciplinary team** of real-world evidence (RWE) experts, based in 18 countries worldwide
- **Credible scientific voice** and deep therapy area knowledge, captured in over 2400 publications
- **Most advanced capabilities** in RWE management and analysis, leveraging relevant IMS proprietary and other key external, third-party data assets
- **Proven expertise** in generating and communicating RWE to advance stakeholder engagement at all levels
- **Market leadership** in developing and adapting robust economic models

Visit the IMS Real-World Evidence Solutions team at ICPE in Montreal, Canada. You can find us at Booths 19 & 20.

RWEinfo@imshealth.com
US +1 (703) 837 5150
Asia Pacific +65 6412 7365
Europe +44 (0) 20 3075 4800
Latin America +52 (55) 50 62 52 00
www.imshealth.com/rwe

7:00am-4:30pm

Registration
(Viger Hall)

7:00am-3:30pm

Speakers' Ready
Room (522C)

7:00-8:00am

Poster Session C
Set-up
(220BC)

7:15-8:15am

2014 ICPE Scientific
Program Committee
Meeting
(516A)

8:00am-1:45pm

Exhibits/Posters
(220BC)8:30-10:00am **CONCURRENT SESSIONS: CONTRIBUTED PAPERS****Around the World in 90 Minutes (518AB)**

Moderators: Frank May, FISPE, & Maribel Salas

8:30am

- ▶ Coverage for Services and Medicines in the Brazilian Unified Health Care System (SUS) – Evidence from a Household Survey [699]
Mariana P Socal. (United States)

8:45am

- ▶ Primary Non-Adherence in Portugal [700]
Claudia Furtado, Joao Pereira. (Portugal)

9:00am

- ▶ Medication Related Problems in Cardio-Metabolic Disease Management in Sub-Saharan Africa: A Systematic Review [701]
Abera B Hadgu, Peter GM Mol, Katja Taxis. (Netherlands)

9:15am

- ▶ Frequency and Risk Factors of Potentially Inappropriate Medications Use in a French Rural Elderly Population: Data from the aml Cohort [702]
Thi-Ha Nguyen, Pernelle Noize, Karine Pérès, Antoine Pariente, Jean-François Dartigues, Driss Berdaï, Fabienne Bazin, Annie Fourier-Réglat. (France)

9:30am

- ▶ Prescription Drug Use in the Last 12 Months of Life: Observations in a Cohort of Elderly Patients [703]
Julia M Langton, Preeyaporn Srasuebku, Nicholas A Buckley, Sallie-Anne Pearson. (Australia)

9:45am

- ▶ Patterns of Testosterone Supplementation Initiation in US Men, 2000–2010 [704]
J Bradley Layton, Dongmei Li, Lily Wang, Julie L Sharpless, M Alan Brookhart. (United States)

Chicken and Egg: Common Drugs, Cancer Risk and Outcome (524AB)

Moderators: Geoffrey Liu & Veronique Kugener

8:30am

- ▶ Prognostic Markers of Bone Metastases and Mortality among Patients with Non-Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy (ADT) in Denmark, 1997-2010 [705]
Mary Nguyen-Nielsen, Alexander Liede, Merete Lund Maegbaek, Michael Borre, Niels Harving, Rohini Hernandez, Henrik Toft Sørensen, Vera Ehrenstein. (Denmark)

8:45am

- ▶ Black Women Are at Increased Risk of Dose-Limiting Chemotherapy Induced Peripheral Neuropathy in Breast Cancer [706]
Rebecca M Speck, Mary D Sammel, John T Farrar, Jun J Mao, Margaret G Stineman, Angela DeMichele, Sean Hennessy. (United States)

9:00am

- ▶ Post-Diagnostic Use of Statins and the Prevention of Mortality and Metastasis in Patients with Prostate Cancer: Nested Case-Control Study [707]
Oriana Hoi Yun Yu, Hui Yin, Serge Benayoun, Armen Aprikian, Gerald Batist, Samy Suissa, Laurent Azoulay. (Canada)

9:15am

- ▶ Relative Risk of Bladder Cancer with Pioglitazone for Diabetes Mellitus: An Updated 8-Year Interim Report of a 10-Year Follow-Up Study [708]
James D Lewis, Brian L Strom, Laurel Habel, Tiffany Peng, Monique Hedderson, Warren Bilker, Charles Quesenberry, Ronac Mamtani, Lisa Nessel, David Vaughn, Assiamira Ferrara. (United States)

9:30am

- ▶ Male Breast Cancer in Users of Finasteride and Dutasteride: A Case-Control Study [709]
Ruben G Duijnhoven, Sabine MJM Straus, Patrick C Souverein, Anthonius de Boer, Arno W Hoes, Marie L De Bruin. (Netherlands)

9:45am

- ▶ Use of Biguanides and the Risk of Colorectal Cancer [710]
Suzanne Dittrich, Marloes T Bazelier, Peter Vestergaard, Ronald Henry, Leo Stolk, Kees Neef, Frank de Vries. (Netherlands)

Effective Choices (CER) (519AB)

Moderators: Sue West, FISPE, & Andrew Bate

8:30am

- ▶ GRACE: A Validated Checklist for Identifying Robust Observational Studies of Comparative Effectiveness [711]
Nancy A Dreyer, Priscilla Velentgas, Kimberly Westrich, Robert W Dubois. (United States)

8:45am

- ▶ Control Treatments in Randomized Controlled Trials Are Often Deemed Not Acceptable in the Context of Care. The Example of Biologics in Rheumatoid Arthritis [712]
Candice Estellat, Florence Tubach, Raphaële Seror, Toni Alfaïate, Philippe Ravaud. (France)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

9:00am

- ▶ **Changing Patterns of Use of Osteoporosis (OP) Medications in the Years Post Launch: Implications for Comparative Effectiveness Research (CER) [713]**

Cynthia D O'Malley, Diane Reams, Julie C Lauffenburger, Jane Der, Lily Wang, MA Brookhart, Cathy W Critchlow. (United States)

9:15am

- ▶ **Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research [714]**

Joshua J Gagne, Katsiaryna Bykov, Richard J Willke, Kristijan H Kahler, Prasun Subedi, Sebastian Schneeweiss. (United States)

9:30am

- ▶ **Comparative Effectiveness of Pazopanib and Sunitinib in Renal Cell Carcinoma Using Real World Data [715]**

Douglas T Steinke, Dionne Lawrence, Geoff Saunders, Fiona Angus, Darren M Ashcroft, Victoria Galvis. (United Kingdom)

9:45am

- ▶ **Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease [716]**

Kevin Haynes, Mark T Osterman, Elizabeth Delzell, Jie Zhang, Meenakshi Bewtra, Colleen Brensinger, Lang Chen, Fenlong Xie, Jeffrey R Curtis, James D Lewis. (United States)

Risky Business (520BE)

Moderators: Deborah Layton & Sarah Frise

8:30am

- ▶ **Impact of Safety Warnings on the Use of Antipsychotics in the Elderly with Dementia in France [717]**

Adeline Gallini, Julie M Donohue, Naïma Oumouhou, Sandrine Andrieu, Maryse Lapeyre-Mestre, Virginie Gardette. (France)

8:45am

- ▶ **Impact of Over-the-Counter Restrictions on Antibiotic Usage in Brazil and Mexico in 2010 [718]**

Yared Santa-Ana-Tellez, Aukje K Mantel-Teeuwisse, Anahi Dreser, Hubert G Leufkens, Veronika J Wirtz. (Netherlands)

9:00am

- ▶ **Impact of FDA Warnings on Long-Acting beta Agonist Use in a State Medicaid Program [719]**

Daniel M Hartung, Luke Middleton, Sheila Markwardt, Kathy Ketchum. (United States)

9:15am

- ▶ **Patient Understanding of Drug Risk: Analysis of Medication Guide Assessments [720]**

Caitlin A Knox, Christian Hampp, Mary Willy, Almut Winterstein, Gerald Dal Pan. (United States)

9:30am

- ▶ **Development and Piloting of an 'Enhanced' Medication Guide Prototype [721]**

Michael J Wolf, Meredith Y Smith. (United States)

9:45am

- ▶ **Patient Comprehension of Risk Information in the ADVAIR® DISKUS® and SEREVENT® DISKUS® Medication Guides: A Cross-Sectional Study of Patients with Asthma or COPD [722]**

Rachael L DiSantostefano, Melissa Beck, Anne M Yeakey, David A Stempel. (United States)

Sexy Hormones (520AD)

Moderators: Colleen Metge & Nicholas Moore, FISPE

8:30am

- ▶ **Oral Glucocorticoids and the Risk of Incident Type II Diabetes Mellitus in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study [723]**

Mohammad Movahedi, Mark Lunt, David Ray, Will Dixon. (United Kingdom)

8:45am

- ▶ **Venous Thromboembolism in Users of a 24-Day Regimen of a Combined Oral Contraceptive Compared to Conventional 21-Day Regimens: Final Results from the INAS-OC Study [724]**

Kristina Bardenheuer, Juergen Dinger, Thai Do Minh. (Germany)

9:00am

- ▶ **The Safety of Oral Contraceptives in Adolescents [725]**

Klaas Heinemann, Juergen Dinger, Kristina Bardenheuer, Suzanne Reed. (Germany)

9:15am

- ▶ **Combined Oral Contraceptive and Venous Thromboembolism – Time Matters [726]**

Anat Fisher, Barbara Mintzes, Colin Dormuth. (Canada)

9:30am

- ▶ **The Implications of 'Off-Label' Use in Primary Care in England: An Example from a Post-Marketing Cohort Study [727]**

Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

9:45am

- ▶ **Menopausal Hormone Therapy and Risks of Cardiovascular Events and Mortality in Female Statin Users – A Population Based Register Study [728]**

Ina Anveden Berglind, Marie Linder, Anna Citarrella, Morten Andersen, Helle Kieler. (Sweden)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

The Down Side of Pregnancy (520CF)Moderators: **Elena Rivero, FISPE, & Janet Hardy****8:30am**▶ **SSRI Use in Pregnancy: A Study in 6 European Databases [729]**

Rachel A Charlton, Rosa Gini, Anna Pierini, Anne Hansen, Ester Garne, Daniel S Thayer, Karen Tingay, Sue Jordan, Aurora Puccini, amanda J Neville, Jens HJ Bos, Lokje TW de Jong-van den Berg, Corinne S de Vries. (United Kingdom)

8:45am▶ **Antidepressant Use near Delivery Increases the Risk of Postpartum Hemorrhage [730]**

Kristin K Palmsten, Sonia Hernández-Díaz, Krista F Huybrechts, Paige L Williams, Karin B Michels, Eric D Achtyes, Helen Mogun, Soko Setoguchi. (United States)

9:00am▶ **In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD): A Nationwide Danish Cohort Study [731]**

Kristina Laugesen, Morten Olsen, Ane Birgitte T Andersen, Trine Frøslev, Henrik T Sørensen. (Denmark)

9:15am▶ **Antidepressant Use in Late Gestation and Breastfeeding Rates at Discharge from Hospital [732]**

Luke E Grzeskowiak, Catherine Leggett, Lynn Costi, Janna L Morrison, Vicki L Clifton. (Australia)

9:30am▶ **The Effect of Regulatory Advisories on Maternal Antidepressant Prescribing, 1995-2007: An Interrupted Time-Series Study of 228,876 Pregnancies [733]**

William V Bobo, Richard A Epstein, Rachel M Hayes, Richard C Shelton, Tina V Hartert, Ed Mitchel, Jeff Horner, Pingsheng Wu. (United States)

9:45am▶ **Specific Selective Serotonin Reuptake Inhibitors (SSRIs) during Pregnancy and Major Cardiac Defects: A National US Cohort Study in Publicly-Insured Women [734]**

Krista F Huybrechts, Kristin Palmsten, Helen Mogun, Mary K Kowal, Soko Setoguchi-Iwata, Sonia Hernández-Díaz. (United States)

10:00-10:30am**Break/Posters/Exhibits (220BC)**

Bayer HealthCare is a globally operating company with sites on all five continents.

Approximately 55,700 people work for the Bayer subgroup in more than 100 countries at all stages of the value-added chain. Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG.

We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products.

We concentrate on five big therapeutic groups in which we make essential contributions to medical progress:

- Cardiovascular and blood diseases
- Oncological diseases
- Ophthalmology
- Women's healthcare
- Imaging techniques

Our Global Epidemiology organization is currently establishing its operations around the world. Opportunities for Epidemiologists with pharmaceutical experience exist at the Associate Director/Senior Epidemiologist and Director level in the US and Europe. To learn more, contact: Montse Soriano-Gabarró at + 49 30 468 194270

For Information about Bayer Healthcare go to
<http://www.bayerhealthcare.com/scripts/pages/en/index.php>

Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.

10:30-Noon

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

ARITMO Final Results: Prediction of the Arrhythmogenic Risk of Antihistamines, Antipsychotics and Anti-Infectives by Integration of Translational Evidence [735] (520CF)

- Miriam C Sturkenboom, Gianluca Trifiro, Antoine Pariente, Peter Rijnbeek, Saad Shakir, Edeltraut Garbe. (Netherlands)

Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources [736] (518AB)

- Vincent Lo Re, Craig Cheetham, Gwen L Zornberg. (United States)

Confounding's Ugly Little Sister: Measurement Bias in Pharmacoepidemiology [737] (517D)

- Almut G Winterstein, Efe Eworuke, Tobias Gerhard. (United States)

Improving Consistency in Findings from Pharmacoepidemiological Studies: The IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Project [738] (520BE)

- Mark CH de Groot, Raymond Schlienger, Robert Reynolds, Helga Gardarsdottir, Juhaeri Juhaeri, Ulrik Hesse, Christiane Gasse, Marietta Rottenkolber, Markus Schuerch, Xavier Kurz, Olaf H Klungel. (Netherlands)

Improving the Science of Regulatory Decision-Making – Advances in 2012/2013 [739] (520AD)

- Stanley A Edlavitch, Gerald J Dal Pan, June M Raine, Bert Leufkens, Jerry Avorn, Songlin Xue. (United States)

Interpreting and Communicating Risk of Medications in Pregnancy, Using SSRIs as an Example [740] (519AB)

- Jennita Reefhuis, William Bobo, Eugene van Puijenbroek, Leyla Sahin, André Picard. (United States)

SPONSORED BY THE MEDICATIONS IN PREGNANCY SIG

Unlocking the Secrets of Free Text through Natural Language Processing: An Introduction for Pharmacoepidemiologists [741] (524AB)

- Sascha Dublin, Imre Solti, Michael E Matheny, Jan A Kors, David Carrell. (United States)

Noon-1:30pm

Lunch/Poster Session C/Exhibits (220BC)

ISPE Board of Directors Luncheon (516A)

(Meeting open to all members; check with staff if you wish to attend)

12:45-1:30pm

Poster Walks (220BC)

- Asian Pharmacoepidemiology Network (AsPEN)
- Biologics
- Drug Utilization/Health Services Research
- Medical Devices

1:30-3:00pm

CONCURRENT SESSIONS:

Elderly (524AB)

Moderators: Antoine Pariente & Sean Hennessy, FISPE

1:30pm

▶ Association between ABCB1/ABCC2 Polymorphisms and Anti-Epileptic Dosages in Ambulatory Elderly: Results from the Rotterdam Study [742]

Raymond Noordam, Nikkie Aarts, Albert Hofman, André G Uitterlinden, Ron HN van Schaik, Bruno H Stricker, Loes E Visser. (Netherlands)

1:45pm

▶ Association between Statin Therapy and Non-Alcoholic Fatty Liver Disease in a Large Population-Based Study [743]

Catherine E de Keyser, Edith M Koehler, Jeffrey NL Schouten, Albert Hofman, Harry LA Janssen, Bruno H Stricker. (Netherlands)

2:00pm

▶ Hospital Readmissions: Using Drug Prescriptions as a Proxy for Severity-of-Illness [744]

Aman D Verma, David L Buckeridge. (Canada)

2:15pm

▶ Use of Intermittent Androgen Deprivation Therapy in Prostate Cancer: A Population-Based Study [745]

Huei-Ting Tsai, David Penson, Miao Jiang, John H Lynch, George Luta, Arnold L Potosky. (United States)

2:30pm

▶ Psychopharmacological Medication Use in Nursing Home Residents with Delirium [746]

Ting-Ying J Huang, Yu-Jung J Wei, Mario Luong, Christine Franey, Patience Moyo, Nicole Brandt, Ilene H Zuckerman, Linda Simoni-Wastila. (United States)

2:45pm

▶ Prescribing Patterns of Anti-Epileptic Drugs for Seizure Prevention after Stroke in the Elderly [747]

Elisabetta Patorno, Barbara Dworetzky, Helen Mogun, Sebastian Schneeweiss. (United States)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Methods 4 (519AB)

Moderators: Ken Rothman, FISPE, & Rob Heerdink

1:30pm

- ▶ **Transparency in Data Preparation for Drug Exposure Using the Clinical Practice Research Datalink and Sensitivity of Results to Various Assumptions [748]**

Mohammad Movahedi, Mark Lunt, Therese Sheppard, Robyn Tamblyn, Nadyne Girard, Will Dixon. (United Kingdom)

1:45pm

- ▶ **Automated Use of Electronic Health Record Text Data To Improve Validity in Pharmacoepidemiology Studies [749]**

Jeremy A Rasssen, Peter M Wahl, Elaine Angelino, Margo I Seltzer, Marc D Rosenman, Sebastian Schneeweiss. (United States)

2:00pm

- ▶ **Quantifying the Role of Stroke as an Intermediate on the Causal Pathway from Antipsychotic Use to Death in Older Adults [750]**

John W Jackson, Tyler J VanderWeele, Deborah Blacker, Sebastian Schneeweiss. (United States)

2:15pm

- ▶ **Acute Kidney Injury in Statin Initiators: Treatment Effect Heterogeneity over the Propensity Score Distribution [751]**

J Bradley Layton, M Alan Brookhart, Michele Jonsson Funk, Ross J Simpson, Jr., Virginia Pate, Til Stürmer, Abhijit V Kshirsagar. (United States)

2:30pm

- ▶ **A Multivariable-Adjusted Rapid Assessment of the Association between Zoledronic Acid and Myocardial Infarction [752]**

Joshua J Gagne, Shirley Wang, Sebastian Schneeweiss. (United States)

2:45pm

- ▶ **Marginal Structural Model (MSM) To Estimate Joint Effect of Osteoporosis (OP) Medications on Serious Infection Using Claims Data [753]**

Fei Xue, Trevor McMullan, Goli Vamshidar, Eric Tchetgen, Haijun Ma, Cathy Critchlow. (United States)

Pediatrics: Potpourri (520CF)

Moderators: Stuart MacLeod & Susana Perez-Gutthann, FISPE

1:30pm

- ▶ **Does Drug Treatment for Attention Deficit / Hyperactivity Disorder (ADHD) Prevent Injuries among Children with ADHD? [754]**

Niklas Schmedt, Rafael T Mikolajczyk, Johannes Horn, Ingo Langner, Christina Lindemann, Edeltraut Garbe. (Germany)

1:45pm

- ▶ **Instrumental Variable Analysis of ADHD Treatment and Serious Adverse Events [755]**

Colin R Dormuth, M Alan Brookhart, Tarita A Miller, Richard L Morrow, Robert W Platt. (Canada)

2:00pm

- ▶ **Prenatal Exposure to Acid-Suppressive Drugs and the Risk of Allergic Diseases in the Offspring: A Cohort Study [756]**

Bianca Mulder, Nynke CCM Schuiling-Veninga, Jens H Bos, Tjalling W de Vries, Susan S Jick, Eelko Hak. (Netherlands)

2:15pm

- ▶ **Development and Validation of an Algorithm To Ascertain Non-Hospitalized Suicide Attempts Using Administrative Claims Data [757]**

Sarah-Gabrielle Beland, Marie Tournier, Marie-Josée Brabant, Brian Greenfield, Larry Lynd, Yola Moride. (Canada)

2:30pm

- ▶ **Potential for Selection Bias in the Context of a Restriction Drug Access Program: The Case of Atomoxetine in Quebec, Canada [758]**

Jason R Guertin, Madeleine Durand, Jacques LeLorier, Lisa Dolovich, Robert Gow, Anne Holbrook, Mitchell AH Levine. (Canada)

2:45pm

- ▶ **Pediatric Drug Safety Surveillance in FDA-AERS, a Description of Adverse Events: A GRiP Study [759]**

Sandra de Bie, Sabine MJM Straus, Katia MC Verhamme, Carmen Ferrajolo, Jan Bonhoeffer, Ian Wong, Miriam CJM Sturkenboom. (Netherlands)

Self-Controlled Studies (520BE)

Moderators: Kenneth Hornbuckle & Annie Fourier-Réglat

1:30pm

- ▶ **Suicide-Related Events in Young People Following Prescription of SSRIs and Other Antidepressants: A Self-Controlled Case Series Analysis [760]**

Linda PMM Wijlaars, Irwin Nazareth, Heather J Whitaker, Stephen JW Evans, Irene Petersen. (United Kingdom)

1:45pm

- ▶ **Drug Synergism of Non-Selective NSAIDs, Coxibs and Low-Dose Aspirin on the Risk of Upper Gastrointestinal Bleeding: A Self-Controlled Case Series Analysis [761]**

Gwen MC Masclee, Vera E Valkhoff, Preciosa M Coloma, Maria de Ridder, Martijn J Schuemie, Ron Herings, Rosa Gini, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Ernst J Kuipers, Johan van der Lei, Miriam CJM Sturkenboom. (Netherlands)

2:00pm

- ▶ **An Application of Multivariate Self-Case Control Series Method for Active Drug Safety Surveillance in an UK EMR [762]**

Xiaofeng Zhou, Rongjun Shen, Sundaresan Murugesan, Andrew Bate. (United States)

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

2:15pm

▶ **A Standardized Modular Program Using Self-Controlled (SC) Methods for Semi-Automated Safety Monitoring [764]**

Shirley V Wang, Sebastian Schneeweiss, Malcolm Maclure, Josh J Gagne. (United States)

2:30pm

▶ **'First-Wave' Exposure-Trend Bias in Self-Controlled (SC) Study Designs for Active Safety Monitoring of Newly Marketed Medications [763]**

Shirley V Wang, Sebastian Schneeweiss, Malcolm Maclure, Josh J Gagne. (United States)

2:45pm

▶ **Self-Control Tree Scan Data Mining for Vaccine Adverse Events [765]**

Martin Kulldorff, Michael Nguyen, Carolyn Balsbaugh, Inna Dashevsky, Robert Davis, Ruth Gil-Prieto, Grace Lee, David Martin, Estelle Russek-Cohen, Robert Ball. (United States)

Sticky Treatments & Sticky Outcomes (520AD)

Moderators: Ulf Bergman, FISPE & Hiraku Kumamaru

1:30pm

▶ **Persistence to Cardiovascular Treatment in Patients with Acute Coronary Syndrome [766]**

Julien Bezin, Régis Lassalle, Abdelilah Abouelfath, Caroline Dureau-Pournin, Cécile Droz-Perroteau, Nicholas Moore, Annie Fourier-Reglat. (France)

1:45pm

▶ **Persistence with Statin Therapy: Does the Level of Lipid Values Influence Medication-Taking Behaviour? [767]**

Anna Citarella, Helle Kieler, Anders Sundström, Marie Linder, Björn Wettermark, Ingegärd Anveden Berglind, Morten Andersen. (Sweden)

2:00pm

▶ **Relationship between Adherence to Preventive Therapies and Mortality Post-Acute Myocardial Infarction (AMI): Examining the 80% Cutpoint [768]**

Julie C Lauffenburger, Gang Fang. (United States)

2:15pm

▶ **Did HEDIS Get It Right? Evaluating the Quality of a Quality Measure [769]**

Gabriel Sanfélix-Gimeno, Jessica M Franklin, William H Shrank, Marie Carlo, Lonny Reisman, Olga Matlin, Troyen A Brennan, Nitesh K Choudhry. (United States)

2:30pm

▶ **Quantitative Risk-Benefit Analysis of Oral Anticoagulants in Patients with Atrial Fibrillation [770]**

Jason C Hsu. (Taiwan)

2:45 pm

▶ **Risk of Stroke after Herpes Zoster Infection - A Self-Controlled Case-Series Analysis [771]**

Lena Kemper, Kathrin Hillebrand, Sigrid Behr, Renate Schulze-Rath, Tania Schink, Edeltraut Garbe. (Germany)

Usefulness of Data Sources for CNS Drugs & Diseases (518AB)

Moderators: Helga Gardarsdottir & Christiane Gasse

1:30pm

▶ **Use of a Common Data Model to Meaningfully Compare Patients Diagnosed with and Treated for Depression among Disparate Databases [772]**

Stephanie Reisinger, Gregory Powell, Brian Dreyfus, Gary Schneider. (United States)

1:45 pm

▶ **Generic Versus Branded Bupropion: Hindsight Using Administrative Data [773]**

Stacie B Dusetzina, Bradley N Gaynes, Til Sturmer, Michele Jonsson-Funk, M Alan Brookhart, Haiden A Huskamp. (United States)

2:00pm

▶ **Use of Varenicline vs Bupropion and Risk of Psychiatric Adverse Events [774]**

Björn Pasternak, Henrik Svanström, Anders Hviid. (Denmark)

2:15pm

▶ **Is Childhood Attention-Deficit (Hyperactivity) Disorder Associated with Atopic Diseases and Skin Infections? A Matched Case-Control Study Using the GPRD [775]**

Eelko Hak, Tjalling W De Vries, Pieter J Hoekstra, Susan S Jick. (Netherlands)

2:30pm

▶ **Factors Associated to Antidepressant Initiation after the Diagnosis of amyotrophic Lateral Sclerosis: A Population-Based Cohort Study in Friuli Venezia Giulia, Italy [776]**

Federica E Pisa, Daniela Drigo, Alessio Bratina, Lorenzo Verriello, Valentina Rosolen, Arianna Sartori, Giada Pauletto, Lucio Lazzarino de Lorenzo, Laura Cecotti, Roberto Eleopra, Gilberto Pizzolato, Fabio Barbone. (Italy)

▶ 2:45pm

Neighborhood Material and Social Deprivation and Use of Antidepressants in Depression [777]

Hichem Kadachi, Jean-Pierre Grégoire, Jocelyne Moisan, Alain Vanassa, Alain Lesage, Marie-Josée Fleury, Josiane Courteau, Claude Bergeron, Sophie Lauzier. (Canada)



3:00-4:30pm

HOT TOPICS SESSION (517D)

Considering the Safety of Compounded Drugs

Chair:

- **John Seeger**, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School/Brigham and Women's Hospital

Panelists:

- **Marion Kainer**, Director, Healthcare, Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health
Investigation of Fungal Meningitis Outbreak
- **Janet Hardy**, Consultant
The Injectable Progestin to Prevent Preterm Birth Example, Comparing and Contrasting it to the Prednisolone Injections/Fungal Meningitis Outbreak Compounding Example
- **Caron G. Solomon**, Deputy Editor, The New England Journal of Medicine
NEJM Editorial Perspective
- **Dianne Lamarre**, President, Ordre des Pharmaciens du Québec
Canadian Perspective and Experience from Having Developed and Implemented Compounding Pharmaceutical Standards and Risk Minimization Strategies

4:30-5:00pm

THE FINAL WORD (517D)

Poster Awards

- **Mary Beth Ritchey**, Poster Walk Chair

Future Meetings

ICPE 2014- Taipei

- **Soko Setuguchi-Iwata**, FISPE, Chair, Scientific Program Committee
- **Yea-Huei Kao Yang**, FISPE, Chair, Local Host Committee

5:00pm

Adjournment of ICPE 2013

SEE YOU NEXT YEAR!


ACPE
Asian Conference on Pharmacoepidemiology

8th Asian Conference On Pharmacoepidemiology

Applying Pharmacoepidemiology to Improve Health Care in Asia

25th Oct 2013
Educational Workshop
Conference and Exhibition Centre
Cyberport, Hong Kong

26-27th Oct 2013
Conference
The University of Hong Kong
Hong Kong



Safe?

Effective?

Better?

**THE RIGHT APPROACH
FOR THE RIGHT QUESTION**

Copyright © 2012 Quintiles

**Quintiles acquires Outcome to offer full spectrum of interventional
and observational research**

Regulators, payers, prescribers and patients demand to know about your product in the real world. That's why Quintiles, a leader in interventional IIIB/IV studies, acquired Outcome Sciences, the unparalleled experts in observational research. Together, we offer the expertise and experience in real-world and late phase research that you need to determine the right approach for the right question. Whatever your research objectives — from monitoring safety and evaluating benefit-risk, to demonstrating effectiveness and gaining market access, to proving efficacy in new indications — our experts provide you with the most comprehensive approach to evidence development.

More at www.quintiles.com.



POSTER SESSION GUIDELINES

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE: Neither ISPE nor the Montreal Convention Center will be responsible for any poster that is left up overnight or is lost or damaged.

POSTER SESSION

Posters will be displayed in Rooms 220BC of the Montreal Convention Center August 26-28. Each day will have a separate poster session. All posters for a specific day's session must be set-up and taken down that day.

- ▶ **Monday, August 26** Poster Session A
- ▶ **Tuesday, August 27** Poster Session B
- ▶ **Wednesday, August 28** Poster Session C

1. Set Up:

- ▶ 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in rooms 220BC of the convention center.

2. Hours:

- ▶ Posters will be displayed from 8:00am-6:00pm on Monday and Tuesday, and from 8:00am-1:45pm on Wednesday.

3. Discussion Time:

- ▶ **General:** Presenters should be at their posters between 12:45-1:15pm on Monday (A) and Wednesday (C); and between 12:15-12:45pm on Tuesday (B)
- ▶ **Poster Walks:** Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters at the following times: Monday & Wednesday 12:45-1:30pm; Tuesday 12:15-1:00pm.

Monday	<ul style="list-style-type: none"> • Adherence • Comparative Effectiveness Research (CER) 	<ul style="list-style-type: none"> • Medications in Pregnancy
Tuesday	<ul style="list-style-type: none"> • Benefit Risk Assessment, Communications & Evaluation (BRACE) • Databases 	<ul style="list-style-type: none"> • Molecular Epidemiology-Biomarkers-Pharmacogenetics • Pediatrics
Wednesday	<ul style="list-style-type: none"> • Asian Pharmacoeconomics Network (AsPEN) • Biologics 	<ul style="list-style-type: none"> • Drug Utilization/Health Services Research • Medical Devices

The poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

A group of judges will select the best poster of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced during The Final Word session at 4:30pm, Wednesday, August 28.

4. Take Down:

- ▶ All posters must be taken down by 6:30pm on Monday and Tuesday, and by 5:00pm on Wednesday.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board corresponding to the number assigned to their poster on that day in the Final Program. The **poster number is the first number listed**. The **abstract number** for use in locating abstracts in the Final Program is listed after the abstract title in brackets []. The Abstracts2View site, accessible on a mobile device, also indicates the poster number and abstract number.

POSTER SPECIFICATIONS

1. Posters must be designed to fit a free-standing fabric poster board approximately **3 feet WIDE x 7 feet HIGH (1 meter WIDE x 2.4 meters HIGH)**. Horizontal posters will not fit the boards; only **VERTICAL/PORTRAIT** posters will be allowed.
2. **Disclosure Statement**
A disclosure statement must accompany each poster. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.
3. **Call4Posters**
Pick-up posters ordered through Call4Posters® in the Exhibit Hall (Room 220BC).

Classical Pharmacoepidemiology

- 1 Association between Antidepressant Use and Sleep Quality: A Population-Based Study [80]**
Nikkie Aarts, Raymond Noordam, Lisette Zuurbier, Albert Hofman, Henning Tiemeier, Bruno H Stricker, Loes E Visser. (Netherlands)
- 2 Glyburide, in Contrast to Gliclazide, Has a Dose-Response Relationship with Adverse Cardiovascular Outcomes in Type 2 Diabetes Patients [81]**
Ahmed Abdelmoneim, Dean Eurich, Ambikaipakan Senthilselvan, Weiyu Qiu, Scot Simpson. (Canada)
- 3 Calcium Channel Blockers and Esophageal Cancer: A Case-Control Analysis [82]**
Claudia Becker, Susan S Jick, Christoph R Meier. (Switzerland)
- 4 Case-Control Analysis on Metformin and Cancer of the Esophagus [83]**
Claudia Becker, Christoph R Meier, Susan S Jick, Michael Bodmer. (Switzerland)
- 7 The Effect of Statins on Influenza Morbidity and Mortality [86]**
Paul Brassard, Jennifer Wu, Brielan Smiechowski, Sophie Dellaniello, Pierre Ernst, Samy Suissa. (Canada)
- 8 Diabetes and the Risk of Incident Gout [87]**
Saskia G Bruderer, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)
- 9 Association of Antibiotic Use with Colorectal Cancer Risk in Type 2 Diabetes Mellitus [88]**
Li-Chiu Wu, Chia-Hsui Chang, Jiun-Ling Wang, Jou-Wei Lin, Mei-Shu Lai. (Taiwan)
- 10 Risk of Tuberculosis and Influenza Associated with Use of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [89]**
Yaa-Hui Dong, Chia-Hsui Chang, Fe-Lin Lin Wu, Li-Jiuan Shen, Claes-Göran Löfdahl, Mei-Shu Lai, Donald A Mahler. (Taiwan)
- 11 The 3.5-Year Mortality Impact of Drugs in Secondary Prevention of Myocardial Infarction in Real-Life (Interim Analysis of the EOLE Cohort) [90]**
Cécile Droz, Caroline Dureau, Daniel Thomas, Nicolas Danchin, Jacques Tricoire, Jacques Bénichou, François Paillard, Serge Herberg, Igor Sibon, François Rouanet, Sahondra Rambelomanana, Hélène Maizi, Marie-Agnès Bernard, Patrick Blin, Nicholas Moore. (France)
- 12 Drug-Associated Acute Liver Failure Leading to Registration for Transplantation in France from the SALT Study, 2005-2007 [91]**
Sinem Ezgi Gulmez, Dominique Larrey, George-Philippe Pageaux, Jeremy Jove, Régis Lassalle, Severine Lignot, Patrick Blin, Nicholas Moore. (France)
- 15 Breast Cancer and Postmenopausal Hormone Therapy in a Japanese Cohort of Women: An Interim Analysis of Japan Nurses' Health Study [95]**
Kunihiko Hayashi, Hideki Mizunuma, Toshiro Kubota, Toshiyuki Yasui, Kota Katanoda, Jung-Su Lee, Kazue Nagai, Shosuke Suzuki. (Japan)
- 16 Trends in the Prevalence and Incidence of ADHD-Drugs among Children, Adolescents, and Adults in Sweden 2006-2012 [96]**
Mikael Hoffmann, Gudrun Jonasdottir-Bergman, Katarina Baatz, Bengt Danielsson, Mårten Gerle, Birgitta Nordstedt Wikner, Peter Salmi. (Sweden)
- 17 Comparison of Validation Studies for the External Control for Confounding by Body Mass Index and Smoking When Assessing the Effects of Metformin Versus Sulfonylureas on Cancer Incidence [97]**
Jin-Liern Hong, Virginia Pate, Michele Jonsson Funk, Emily Ko, Til Stürmer. (United States)
- 18 Comparing the Risk for Breast Cancer in Older Adults Initiating Metformin or Sulfonylureas [98]**
Jin-Liern Hong, Michele Jonsson Funk, Emily Ko, Virginia Pate, Til Stürmer. (United States)
- 19 Ocular Safety of Intravitreal Injection of Age-Related Macular Degeneration (AMD) Treatments in a Prospective Observational Cohort Study in Europe [99]**
Kui Huang, Marla B Sultan, Duo Zhou, Charles S Tressler, Jingping Mo. (United States)
- 20 What Is the Delay in Insulin Therapy Initiation in Patients with T2DM Not Responding to Oral Glucose Lowering Agents? [100]**
Ruth M Mast, Danielle AP Jansen, Piet J Kostense, Iris Walraven, Amber van der Heijden, Rob J Heine, Jacqueline M Dekker, Jacqueline G Hugtenburg, Giel Nijpels. (Netherlands)
- 21 Antiepileptic Drugs and Suicide: A Systematic Review [101]**
Pili Ferrer, Elena Ballarín, Mònica Sabaté, Xavier Vidal, Luisa Ibáñez. (Spain)
- 22 A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis [102]**
Rachel Jawahar, Shiting Yang, Unsung Oh, Kate L Lapane. (United States)
- 24 Prevalence of Potentially Inappropriate Medication Prescribing among Older US Adults Using the New 2012 Beers Criteria [104]**
Marcela Jirón, Virginia Pate, Laura Hanson, Michele Jonsson Funk, Til Stürmer. (Chile)
- 25 Replication Study on the Risk of Liver Injury Associated with the Use of Antibiotics Using a US Database with Linkage with Hospital Data [105]**
Stephanie Tcherny-Lessenot, Yunxun Wang, Juhaeri Juhaeri, Xavier Kurz, Laurent Auclert, Patrick Caubel. (United States)
- 26 Risks of Venous Thromboembolism in Women Using Progestogen-Only Contraception [106]**
Helle Kieler, Anders Sundström, Ingemar Persson, Annica Bergendal. (Sweden)
- 27 Clinical and Health Care Use Characteristics of Patients Newly Prescribed Allopurinol, Febuxostat and Colchicine for Gout [107]**
Seoyoung C Kim, Bernhard MW Schmidt, Jun Liu, Daniel H Solomon, Sebastian Schneeweiss. (United States)
- 28 Aminoglycoside Ophthalmic Agents Use and Risk of Acute Renal Failure in Elderly Patients: A Case-Crossover Design [108]**
Young-Jin Ko, Ji-Young Kim, Nam-Kyung Choi, Joongyub Lee, Hye-Min Kim, Byung-Joo Park. (Republic of Korea)
- 29 Relative Risk of Hip/Femur Fractures during the Initiation Period of alpha-Blockers Therapy in Male Elders [109]**
Chao-Lun Lai, Raymond Nien-Chen Kuo, Ho-Min Chen, Ching-Fen Wu, Hui-Chun Huang, Chih-Hao Wang, Chiu-Lin Lai, Chia-Hsui Chang, Ming-Fong Chen, Mei-Shu Lai. (Taiwan)
- 31 Discontinuation of Statin Therapy Associates with Parkinson's Disease: A Population-Based Study [111]**
Yen-Chieh Lee, Chin-Hsien Lin, Ruey-Meei Wu, Min-Shung Lin, Jou-Wei Lin, Chia-Hsui Chang, Mei-Shu Lai. (Taiwan)
- 32 Baseline Characteristics and Cardiovascular (CV) Comorbidities among United States Males Prior to Testosterone Treatment as Compared to Non-Users [112]**
Hu Li, Karin Benoit, Jonathan Swain, Nancy Ostrowski, Stephen Motsko. (United States)
- 33 Baseline Characteristics and Comorbidities among United Kingdom Males Prior to Testosterone Treatment Compared to Non-Users Stratified by Body Mass Index (BMI) [113]**
Hu Li, Jonathan Swain, Karin Benoit, Nancy Ostrowski, Stephen Motsko. (United States)
- 34 Statins for Prevention of Alzheimer's Disease: Systematic Review and Meta-Analysis [114]**
Sandra Lopez-Leon, Elena Rivero-Ferrer. (Spain)
- 35 Serious Infections Associated with Anti-Tumor Necrosis Factor (anti-TNF) Agents among Rheumatoid Arthritis Patients in Brazil [115]**
Cristiano S Moura, Felipe Ferre, Grazielle D Dias, Adriana M Kakehasi, Augusto A Guerra, Jr., Eli Iola G Andrade, Mariângela L Cherchiglia, Francisco A Acurcio. (Canada)

Monday, August 26
POSTER SESSION A

- 37 Real-Life Usage Patterns and Effectiveness of Sunitinib in Patients with Clear Cell Metastatic Renal Cell Carcinoma: The SANTORIN Study [117]**
Angela Grelaud, Alain Ravaud, Jacques-Olivier Bay, Céline Bairras-Martin, Aurélie Balestra, Christine Chevreau, Marie-Agnès Bernard, Emmanuelle Bignon, Stéphane Culine, Stéphanie Lamarque, Régis Lassalle, Magali Rouyer, Nicholas Moore, Pernelle Noize, Annie Fourrier-Réglat. (France)
- 38 Cetuximab with Irinotecan or Oxaliplatin for 1st-Line Metastatic Colorectal Cancer: Effectiveness in the EREBUS Cohort Compared to Pivotal Trials [118]**
Pernelle Noize, Annie Fourrier-Réglat, Magali Rouyer, Angela Grelaud, Emmanuelle Bignon, Alise Le Monies de Sagazan, Régis Lassalle, Jérémy Jové, Alain Monnereau, Antonio Sa Cunha, Eric François, Emmanuel Mitry, Nicholas Moore, Denis Smith. (France)
- 39 Association of Acetylsalicylic Acid and the Risk of Hospitalization for Vascular Access-Related Infections and Septicemia among Hemodialysis Patients [119]**
Isabelle Normand, Rachel Grinker, Hind Harrak, Naoual Elftouh, Jean-Philippe Lafrance. (Canada)
- 40 Using Epidemiological Registry Data To Provide Background Rate Context for Adverse Events in a Rheumatoid Arthritis (RA) Drug Development Program - A Coordinated Approach [120]**
Fredrik Nyberg, Johan Askling, Jeffrey D Greenberg, Kaleb Michaud, Hisashi Yamanaka, Deborah Symmons, Meilien Ho. (Sweden)
- 41 Validation of the Health Improvement Network for the Study of Psoriatic Arthritis [121]**
Alexis Ogdie, Thorvadur Love, Kevin Haynes, Sean Hennessy, Hyon Choi, Joel Gelfand. (United States)
- 43 The Association between Obesity and Major Bleeding Risk in Warfarin Users in a Community Setting [123]**
Joshua A Roth, Denise Boudreau, Kenneth E Thummel, David L Veenstra. (United States)
- 44 Psychiatric Comorbidity among Children, Adolescents, and Adults Treated with Methylphenidate [124]**
Peter Salmi, Gudrun Jonasdottir-Bergman, Bengt Danielsson, Birgitta Norstedt Wikner, Mårten Gerle, Mikael Hoffmann. (Sweden)
- 45 Co-Prescription of Methylphenidate with Psychotropic Drugs among Children and Adults [125]**
Peter Salmi, Gudrun Jonasdottir-Bergman, Bengt Danielsson, Birgitta Norstedt Wikner, Mårten Gerle, Mikael Hoffmann. (Sweden)
- 46 Evaluating the Impact of the Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain on Opioid Prescribing in Utah, 2002-2009 [126]**
Brian C Sauer, Christy Porucznik, Chia-chen Teng, Jonathan Nebeker. (United States)
- 47 Anti-Malarial Chemoprophylaxis and the Risk of Developing Neuropsychiatric Disorders [127]**
Cornelia Schneider, Miriam Adamcova, Susan S Jick, Mary K Miller, Patricia Schlagenhauf, Hans-Georg Rhein, Christoph R Meier. (Switzerland)
- 48 Risks of Adverse Events in Treated Chronic Hepatitis C Patients with Cirrhosis Compared to without Cirrhosis in Real-World Settings [128]**
Sophie W Shen, Jennifer Wood Ives, Patricia Hines, Dessislava Dimitrova. (United States)
- 49 Use of Azithromycin and Cardiovascular Death [130]**
Björn Pasternak, Henrik Svanström, Anders Hviid. (Denmark)
- 50 QT Interval Prolongation in Elderly Users of Selective Serotonin Reuptake Inhibitors [131]**
Ingrid MM van Haelst, Wilton A van Klei, Hieronymus J Doodeman, Miriam J Warnier, Marie L De Bruin, Cor J Kalkman, Toine CG Egberts. (Netherlands)
- 51 The Association of Oral Fluoroquinolone Use with the Need for Retinal Detachment or Retinal Tear Repair [132]**
Brian L VanderBeek, Kian Eftekhari, Devon Ghodasra, Jinbo Chen, John H Kempen, Kevin Haynes. (United States)
- 52 The SOS Project: Risk of Heart Failure and Use of Nonsteroidal Anti-Inflammatory Drugs—A Meta-Analysis of Observational Studies [133]**
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Jordi Castellsague, Andrea Arfe, Susana Perez-Gutthann. (Spain)
- 53 Cardiovascular Risk with Glitazones and Metformin: Results from a Systematic Review of Observational Studies [134]**
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Andrea V Margulis, Manel Pladevall, Miguel Gil, Silvana Romio, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 54 Beta Blockers and Breast Cancer: Results from a Collaborative Study [135]**
Marco Villa, Stefano Boni, Simona Iodice, Magda Rognoni, Giuseppe Sampietro, Antonio Russo. (Italy)
- 55 Validity Threats in Multi-Center Retrospective Chart Abstraction Studies [136]**
Nataliya Volkova, Lina Titievsky. (United States)
- 56 Effervescent, Dispersible and Soluble Medications Increase Cardiovascular Events [137]**
Jacob George, Waseem Majeed, Thomas M MacDonald, Isla S Mackenzie, Li Wei. (United Kingdom)
- 57 An Epidemiological Study Examining the Risk of Malignancy in Patients with Inflammatory Bowel Disease [138]**
Jessica C Wilson, Raoul I Furlano, Susan S Jick, Christoph R Meier. (Switzerland)
- 58 Factors and Characteristics for Medication Initiation in Type 2 Diabetes Patients in the UK [139]**
Alison K Wright, Martin K Rutter, Richard Emsley, Darren M Ashcroft, Douglas Steinke. (United Kingdom)
- 60 Relative Risk of Myocardial Infarction for Canadian Patients with Psoriasis Treated Systemically as Compared to Patients Treated with Phototherapy [141]**
Annie Levesque, Robert Bissonnette, Sophie Préfontaine, Marie-Eve Lapierre, Jean Lachaine. (Canada)
- 62 Comparative Effectiveness and Safety of Concomitant Use of SSRIs in Combination with NSAIDs or Paracetamol [143]**
Ole Köhler, Liselotte Petersen, Ole Mors, Christiane Gasse. (Denmark)
- 63 Comparative Effectiveness of Oxcarbazepine and Carbamazepine in Adult Patients with Epilepsy [144]**
Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Yea-Huei Kao Yang. (Taiwan)
- 64 Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes Mellitus: A Pairwise and Network Meta-Analysis [145]**
Feng Sun, Kai Yu, Shanshan Wu, Yuan Zhang, Zhirong Yang, Linong Ji, Luwen Shi, Siyan Zhan. (China)
- 65 Frequent Antibiotic Use and Breast Cancer Outcomes [146]**
Heidi S Wirtz, Diana SM Buist, Julie R Gralow, William E Barlow, Shelly Gray, Jessica Chubak, Onchee Yu, Erin Bowles, Monica Fujii, Denise M Boudreau. (United States)

Comparative Effectiveness Research

Drug Safety in Pregnancy and Lactation

- 66 ITP and Pregnancy [147]**
Wendy J Carman, Diego Wyszynski, Cheryl Enger, John D Seeger. (United States)
- 67 Chats about Drugs and Pregnancy on Forum Websites: A French Descriptive Study [148]**
Lucie Cantaloube, Isabelle Lacroix, Vanessa Rousseau, Haleh Bagheri, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 68 Medication Use during Pregnancy: A Multinational Perspective [149]**
Angela Lupattelli, Olav Spigset, Michael J Twigg, Ksenia Zagorodnikova, Ann-Charlotte Mårdby, Myla Moretti, Mariola Drozd, Alice Panchaud, Katri Hameen-Anttila, Andre Rieutord, Romana Gjergia, Marina Odalovic, Debra Kennedy, Gorazd Rudolf, Herbert Juch, Anneke Passier, Ingunn Björnsdóttir, Hedvig Nordeng. (Norway)

Monday, August 26
POSTER SESSION A

Other

- 69 **Medication Discrepancy at Discharge in a Tertiary Hospital in Saudi Arabia [150]**
Hisham Aljadhey, Isra Al-Rashoud. (Saudi Arabia)
- 70 **The Number of Included Older People in Recent Pre-Authorization Trials [151]**
Erna Beers, Dineke C Moerkerken, Toine CG Egberts, Hubert GM Leufkens, Paul AF Jansen. (Netherlands)
- 71 **Expected Timelines To Set-Up an Observational Study in Europe: Example of 4 Pharmaco-Epidemiological Registries [152]**
Sohéla Elkebir, Delphine Bayle, Denitza Muller. (France)
- 72 **Evaluation of Knowledge and Use of Prescription Tools by Hospital Physicians in a Teaching Hospital [153]**
Angeline Faucher, Driss Berdai, Claire Brotons, Annie Fourrier-Reglat, Nicholas Moore. (France)
- 73 **A Cohort Study Examining Aspirin Use and Mortality in Men with Localised Prostate Cancer [154]**
Evelyn M Flahavan, Kathleen Bennett, Linda Sharp, Thomas I Barron. (Ireland)
- 74 **Clinical Pharmacy Interventions in a Tertiary Care Teaching Hospital in Southern India [155]**
Parthasarathi Gurumurthy, Himanshu Patel, Gloria George, Ramesh Madhan. (India)
- 75 **Use of Antidepressants and Risk of Developing First-Time Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Observational Studies [156]**
Parthasarathi Gurumurthy, Krishna Undela, Sharon S John. (India)
- 76 **Eight-Year Results from the US Osteosarcoma Surveillance Study [157]**
David H Harris, Kirk D Midkiff, Alicia W Gilsenan, Nicole Kellier, Daniel Masica, Elizabeth B Andrews. (United States)
- 78 **Medication Safety Resources Available through a New Public Access Repository: A Descriptive Analysis [159]**
John Iskander, Robert Swain. (United States)
- 79 **Medication Adherence in Pediatric Patients with Epilepsy Using Prescription Refilled Rate and Self-Reported Questionnaire [160]**
Shih-Chieh Shao, Edward Chia-Cheng Lai, Yea-Huei Kao Yang, Pheng-Ying Yeh Liu. (Taiwan)
- 80 **Methods Issues in Observational Studies of the Cardiovascular Risk Associated with Glucose-Lowering Medications: Results of a Systematic Review and Evaluation [161]**
Nuria Riera-Guardia, Andrea V Margulis, Manel Pladevall, Cristina Varas-Lorenzo, Susana Perez-Gutthann. (Spain)

- 81 **The Extent and Origin of Resistance to Antituberculosis Drugs in the Netherlands in the Period 1993-2011 [162]**
Carolien Ruesen, Arianne B Van Gageldonk-Lafeber, Gerard de Vries, Connie GM Erkens, Job van Rest, Hester Korthals Altes, Han de Neeling, Miranda Kamst, Dick van Soelingen. (Netherlands)
- 82 **Potential Predictors of Naltrexone Response in Alcohol Dependence: A Systematic Review [163]**
James Garbutt, Amy Greenblatt, Suzanne L West, Laura Morgan, Alexei Kampov-Polevoy, Harmon Jordan, Georgiy Bobashev. (United States)
- 83 **Reliability of Outcome Definitions Using Japanese Standardized Electronic Medical Records Data [164]**
Kaori Yamada, Eiko Tada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)

Pharmacovigilance

- 85 **Public Perception towards Adverse Drug Reaction Reporting in Saudi Arabia [166]**
Hisham Aljadhey, Yaser Albogami. (Saudi Arabia)
- 86 **Evaluation of Knowledge and Barriers among Physicians towards Adverse Drug Reactions (ADRs) Reporting in Saudi Arabia [167]**
Hisham Aljadhey, Dalal Al-Abdulkarim. (Saudi Arabia)
- 87 **Adverse Events Associated with Colchicine Drug Interactions: Analysis of the Public Version of the FDA Adverse Event Reporting System [168]**
Ziyad S Almalki, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)
- 88 **Risk of Major Bleeding with Dabigatran Versus Active Controls: A Systematic Review and Meta-Analysis of Randomised Clinical Trials [169]**
Stefania Antoniazzi, Driss Berdai, Valentino Conti, Philip Robinson, Sonia Radice, Emilio Clementi, Nicholas Moore, Antoine Pariente, Francesco Salvo. (Italy)
- 89 **Evaluation of Signal Scores over Time [170]**
Robert Azadian, Naashika Quarcoo, Nancy Yuen, Greg Powell. (United States)
- 90 **Reducing Words without Losing Clinical Meaning – Can Text Mining Accelerate Review of Spontaneous Reports? [171]**
Bethany Baer, Michael Nguyen, Emily Jane Woo, Scott Winiecki, John Scott, David Martin, Taxiarchis Botsis, Robert Ball. (United States)
- 91 **Pharmacovigilance from a Public Health Point of View – A Survey of Simplified Recording of Adverse Drug Reactions (ADR) in Medical Records [172]**
Ulf Bergman, Erika Höglund, Ingegerd Odar-Cederlöf, Nina Pettersson. (Sweden)
- 92 **Comparison of 7 Patient Information Leaflets (PILs) of Narcotic Pain Medications Marketed by Indian Generic Companies with Original SmPC from Innovator Companies [173]**
Arun K Biswas, Pipasha N Biswas. (United Kingdom)

- 93 **ENCePP Supporting Regulatory Decision Making [174]**
Stella Blackburn, Kevin Blake, Xavier Kurz, Jim Slattery, Henry Fitt, Peter Arlett. (United Kingdom)
- 94 **Post-Marketing Requirements in Diabetes Mellitus in Europe (EMA) and the USA (FDA) [175]**
Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 95 **Post-Marketing Requirements: An Overview of the Therapeutic Areas Targeted by the EMA and the FDA [176]**
Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 97 **Development of Systematic Target Drug Prioritization Process in Korea [178]**
Sooyoun Chung, So-Hyeon Ahn, Sujin Kim, Joo young Cho, Je Yon Kim, Yeun Jung Choi, Byung-Joo Park. (Republic of Korea)
- 98 **Effects of Opioid Analgesic Tablets Resistant to Breaking, Crushing and Dissolving on Patient Safety Outcomes [179]**
Paul M Coplan, Carla A Green, Nancy Perrin, Cynthia I Campbell, Stevan G Severtson, Becki Bucher-Bartelson, Richard Dart, Shannon L Janoff, Nelson E Sessler, Hrishikesh Kale, Jody Green, Howard D Chilcoat. (United States)
- 99 **MIHARI – Medical Information for Risk Assessment Initiative Year 4 [180]**
Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 100 **Classification and Evaluation Algorithm of Drug Safety Information of KFDA [181]**
Jihye Ha, Han Oll Kim, You Jung Kim, Han Sung Na, Myeon Woo Cheong. (Republic of Korea)
- 101 **Reporting Patterns of Adverse Drug Reactions over Recent Years in China: Analysis from Publications [182]**
Jia He, Xiao-fei Ye, Xiao-jing Guo. (China)
- 102 **Post Authorization Safety Study Comparing Quetiapine to Risperidone and Olanzapine [183]**
Edith M Heintjes, Jetty A Overbeek, Fernie JA Penning-van Beest, Gunnar Brobert, Ron MC Herings. (Netherlands)
- 103 **Application of Propensity Score Methods to Japanese Claims Data [184]**
Shingo Higa, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 104 **Quinine Sulfate Use and Hematologic Adverse Events: Active Surveillance in Medicare [185]**
Monika Houstoun, Marsha E Reichman, David J Graham, Sumathi Nambiar, Hala Shamsuddin, S Christopher Jones, Kelly Cao, Michael Wernecke, Chelsea Lam, Chris M Worrall, Thomas E MaCurdy, Jeffrey A Kelman. (United States)

Monday, August 26
POSTER SESSION A

- 105 Outlier Removal Expedites Adverse Drug Reaction Surveillance – Evaluation of a Simple Unmasking Strategy [186]**
Kristina Juhlin, Xiaofei Ye, Kristina Star, G Niklas Norén. (Sweden)
- 106 Comparison of 7 Patient Information Leaflets (PILs) of Anesthetic Drugs Marketed by Indian Generic Companies with Original SmPC from Innovator Companies [187]**
Nilima Justice. (United States)
- 107 Survey of Demand to Postmarketing Adverse Drug Event Reporting Data [188]**
Sujin Kim, Sun Mi Shin, Minsun Kim, Mi Hee Kim, So-Hyeon Ahn, Sooyoun Chung, Byung-Joo Park. (Republic of Korea)
- 108 Low Renal Function in Hospitalized Geriatric Patients: Potentially Serious for Use of Renal Risk Drugs [189]**
Inga Klarin, Ingegerd Odar Cederlöf, Ulf Bergman, Anders Helldén. (Sweden)
- 109 Use of Antiepileptic Drugs and Risk of Infection in Taiwan and Denmark: A Collaborative Cross-National Sequence Symmetry Analysis [190]**
Edward Chia-Cheng Lai, Anton Pottegård, Jesper Hallas, Yea-Huei Kao Yang. (Taiwan)
- 110 Strategies To Optimize Physician Survey Research: Results from a Survey of Urology and Oncology Practitioners in 19 Countries [191]**
Alexander Liede, Kirsty Hope, Alex Graham, Jorge Arellano. (United States)
- 111 Evaluation of Drug Induced Liver or Renal Toxicity with National Health Insurance Claim Database [192]**
Mei-Shu Lin, Ro-Fang Pu, K Arnold Chan, Nen-Chung Chang, Churn-Shiouh Gau. (Taiwan)
- 112 Risk of HBV Reactivation in Patient Receiving Rituximab: Results from Taiwan National Adverse Drug Reaction Reporting System [193]**
Shan-Hu Lin, Pi Huei Chao, Wen-Wen Chen, Angela On. (Taiwan)
- 113 Post-Marketing Study of Denosumab in Male Osteoporosis: A Model Feasibility Assessment [194]**
Angelika Manthripragada, Elizabeth Delzell, Paul Muntner, Jeffrey R Curtis, Wendy Carmen, Haijun Ma, Violetta Hennessey, Fei Xue, Cynthia D O'Malley. (United States)
- 114 Drug Safety and Corporate Governance [195]**
Kathy Moscou. (Canada)
- 115 Pharmacovigilance of Oral Antituberculosis in Indonesian TB Patients [196]**
Ully A Mulyani, Dyah A Perwitasari, Jarir Atthobari. (Indonesia)
- 117 Changes in Prescription Drug Opioid Abuse Following Reformulation of an Abuse Deterrent Product: A National Study of Substance Abuse Treatment Clients [198]**
Scott P Novak, Nathaniel Katz. (United States)
- 118 Results of the Experience with the Use of Varenicline in Daily Practice Using Intensive Monitoring [199]**
Ingrid Oosterhuis, Linda Harmark, Eugene van Puijenbroek. (Netherlands)
- 119 Improving Pharmacovigilance Knowledge and Practice amongst Health Care Providers: A Case Study of Community Pharmacists in Lagos, Nigeria [200]**
Ibrahim Adekunle Oreagba, Ibrahim Abayomi Ogunyinka. (Nigeria)
- 120 Pattern of Adverse Drug Reactions Reported in a South Indian Tertiary Care Teaching Hospital, 2001-2011 [201]**
Bishnu Regmi, Thiyagu Rajakannan, MK Unnikrishnan. (India)
- 121 Development and Validation of an Instrument Classifying Preventable Adverse Drug Events - A Pilot Study [202]**
Linda Ring Eriksson, Anna K Jönsson, Katja Hakkarainen, Staffan Hägg, Thomas Bradley, Henrik Lövborg. (Sweden)
- 122 QT Prolongation and Ventricular Arrhythmias Related to Antidepressants: An Analysis of the French Spontaneous Reporting Database [203]**
Francesco Salvo, Annie Fourrier-Reglat, Miriam Sturkenboom, Emanuel Raschi, Elisabetta Poluzzi, Ugo Moretti, Fabrizio De Ponti, Pascal Auriche, Nicholas Moore, Antoine Pariente. (France)
- 123 Geospatial Analysis of Adverse Event Reports [204]**
Simon Semus, Robert Azadian, Nancy Yuen, Phillip Burstein, Gregory Powell. (United States)
- 124 A Cohort Study of Sitagliptin and Risk of Acute Renal Failure Using Standardized Electronic Medical Record Data [205]**
Eiko Tada, Kaori Yamada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 125 Hit-Miss Model Detects Duplicates Missed by Rule-Based Screening of Individual Case Safety Reports [206]**
Philip M Tregunno, Dorthe Bech Fink, Cristina Fernandez, Niklas G Norén. (United Kingdom)
- 126 Advantages of Using Well Fitting Models To Assess the Effects of Time-Varying Drug Exposures in Prospective Surveillance [207]**
Rolina D van Gaalen, Michal Abrahamowicz, Marie-Pierre Sylvestre, Marie-Eve Beauchamp, David L Buckeridge. (Canada)
- 127 Asymptotic Limit to the Relative Reporting Ratio - A Measure of the Violation of Hidden Assumptions behind Some Disproportionality Measures Used in Signal Detection [208]**
Lionel Van Holle, Vincent Bauchau. (Belgium)
- 128 Signal Detection Based on the Time-to-Onset: Extending a New Method from Spontaneous Reports to Observational Studies [209]**
Lionel Van Holle, Vincent Bauchau. (Belgium)
- 129 Drug Exposure Registry To Monitor Safety of Investigational Product [210]**
Vani Vannappagari, Amy Sessoms, David Margolis, Lloyd Curtis, Kenne Mountford, Elizabeth Villeponteaux, Tamara Murry, Margaret Richards. (United States)
- 130 Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis [211]**
Shanshan Wu, Yuelun Zhang, Feng Sun, Siyan Zhan. (China)

Risk Management / Risk Minimization/Communication

- 131 The Opportunities and Challenges of Delivering the Quetiapine Post-Authorization Safety Studies (PASS); a Diverse Program of Work [212]**
Robert S Brody, Leigh Jefferies, Sherry Liu, Charles L Liss, Phil Damstetter, Lei Chen, Raj Tummala, Dhaval G Desai. (United States)
- 132 Assessing Current Awareness, Perception and Knowledge of Pharmacists on Anti-Counterfeiting Efforts in Singapore [213]**
Hsien Jie Earl Tan, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 133 Thalidomide Imported by the Individual Doctors and Its Use in Japan [214]**
Yukari Kamijima, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 134 The Observational Safety Evaluation of Asenapine (OBSERVA) Study: Rationale and Design [215]**
Deborah Layton, Felicity Mitchell, Saad AW Shakir. (United Kingdom)
- 135 Methodological Considerations in Evaluating the Safety of Novel Anticoagulants in Secondary Care Setting in the UK: Defining the Contextual Comparator Cohort [216]**
Deborah Layton, Miranda Davies, Alison Evans, Saad AW Shakir. (United Kingdom)
- 136 First-Year Review of Implementation of the Legal Requirements for Labels and Package Inserts of Proprietary Chinese Medicines [217]**
Ching-kan Jackie Leung, Chi-hang Kevin Lam, Man-kin Ronald Lam. (China)
- 137 Effectiveness of Risk Minimization Interventions in Drug Safety: An Assessment of Methodological Gaps [218]**
Yola Moride, Lenhangbong Nkeng, Inna Gridchyna, Anne-Marie Cloutier, Camille Craig, Sarah Frise. (Canada)
- 138 Observational Methods and Post Authorization Studies: Lessons Learned from Bosentan European Risk Management [219]**
Erwan Muros-Le Rouzic, Monika Brand, Per Nilsson, Daniel Rosenberg. (Switzerland)

- 139 Characteristics of Patients with Aberrant Behaviours Using Fentanyl Citrate Buccal Tablets: Results from a Post-Marketing Cohort Study [220]**

Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

- 140 Number of Biochemical Tests as a Trigger for Adverse Drug Events [221]**

Rianne J Zaai, Anouk D Lindemans, Ryan R Boedhrum, Jasperien E van Doormaal, Jos GW Kosterink, Flora M Haaijer-Ruskamp, Arnold G Vulto, Patricia MLA van den Bemt, Peter GM Mol. (Netherlands)

Adherence SIG

- 141 Cost-Effectiveness of Statins for Primary Prevention in Newly Diagnosed Type 2 Diabetes Patients: An Illustration for the Netherlands [244]**

Folgerdiena M de Vries, Petra Denig, Sipke T Visser, Eelko Hak, Maarten J Postma. (Netherlands)

- 144 Metformin Use in Prostate Cancer and the Risk of Death and Metastasis in Patients with Type 2 Diabetes [225]**

Leah Bensimon, Hui Yin, Samy Suissa, Michael N Pollak, Laurent Azoulay. (Canada)

- 146 Self-Reported Visual Analogue Scale Has Poor Sensitivity for Antiretroviral Non-Adherence in Botswana [242]**

Paul D Sonenthal, Scarlett Bellamy, Xiaoyan Han, Bakgaki Ratskaa, Gilbert Chimbengo, Thelma Ngoni, Tumelo Rantleru, Mosepele Mosepele, Elizabeth Lowenthal, Andrew P Steenhoff, Brian L Strom, Gregory P Bisson, Robert Gross. (United States)

- 147 Association of Patient and Drug Characteristics with Adherence and Persistence [227]**

Nikkie Aarts, Raymond Noordam, Albert Hofman, Bruno H Stricker, Loes E Visser. (Netherlands)

- 149 Adherence Explored as Patient-Centered Medication Management: Results of a Literature Review and Stakeholder Workshop [234]**

Jennifer L Kuntz, Carmit K McMullen, Meredith L Vandermeer, Maureen H Rumpitz, Mark C Hornbrook. (United States)

- 150 Beliefs about Medicines in Dutch Acenocoumarol and Phenprocoumon Users [236]**

Talitha I Verhoef, William K Redekop, Marcel L Bouvy, Brenda Dorenbos, Zamiera Karwar, Rianne MF van Schie, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)

- 151 Antidepressant Utilization after Hospitalization with Depression: A Comparison between Non-Western Immigrants and Danish-Born Residents [237]**

Helle Wallach Kildemoes, Louise Thirstrup Thomsen, Margit Kriegbaum, Marie Louise Norredam. (Denmark)

- 152 Guidelines Adherence in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes: Comparing the Use of Metformin in Quebec Pre and Post-Canadian Diabetes Association Guidelines [238]**

Ting-Yu Wang, Eguale Tewodros, Robyn Tamblyn. (Canada)

- 153 Access to Medicines among the Brazilian Adult Population with Chronic Diseases [239]**

Anamaria Zaccolo. (Brazil)

- 154 Antihypertensive Persistence in Older Americans: Intent-To-Treat vs As-Treated Analysis [241]**

Wendy Camelo Castillo, Xiaojuan Li, Ross J Simpson, Jr., Virginia Pate, Til Sturmer, Michele Jonsson Funk. (United States)

- 156 Tumor Necrosis Factor Treatment Patterns in Medicare Patients with Inflammatory Conditions [245]**

Li Wang, Ahong Huang, Elyse Fritschel, Onur Baser. (United States)

- 157 Factors Associated with Reported Difficulty Taking Antiretroviral Therapy in Brazilian Patients [246]**

Celline C Almeida, Maria das Graças B Ceccato, Maria Inês B Battistella, Mark DC Guimarães, Francisco A Acurcio. (Brazil)

- 158 The Evaluation of Various Published Scales To Assess the Patient's Adherence to Medication [247]**

Josip Culig, Marcel Leppee, Marija Skes, Mario Malovic. (Croatia)

- 159 Attitudes towards Medication Use in a General Population of Adolescents [248]**

ES Koster, ML Bouvy, C Hakkers, T Hosman, L Nelemans, ER Heerdink. (Netherlands)

Comparative Effectiveness Research (CER) SIG

- 160 Comparative Effectiveness of Biologic DMARDs in Older and Disabled Patients with Rheumatoid Arthritis (RA) in Medicare [249]**

Huifeng Yun, Fenglong Xie, Lang Chen, Shuo Yang, Kenneth G Saag, David Harrison, George Joseph, Jeffrey R Curtis. (United States)

- 161 Opioid Analgesic Dosage Strength as a Predictor of Overdose Risk in the UK [250]**

Paul Coplan, Charles Wentworth, Nelson Sessler, Jerod Downing, Louis Alexander, Howard Chilcoat. (United States)

- 162 Application of a Cox Model across a Refunds Database: A New Approach To Compare Selective Serotonin Reuptake Inhibitors (SSRI) [251]**

Emilie Peron, Jean-Benoit Hardouin, Véronique Sebillé, Anicet Chaslerie, Jacques Pivette, Pascale Jolliet, Caroline Victorri-Vigneau. (France)

- 163 Treatment in the Morning Versus Evening (TIME) with Antihypertensives: A Pilot Study [252]**

David A Rorie, Thomas M MacDonald, Robert Flynn, Isla Mackenzie, Claudine Jennings, Lewis McConnachie, Ian Ford. (United Kingdom)

- 164 Thiazolidinedione Use and Risk of Hospitalization for Pneumonia in Type 2 Diabetes: Population Based Matched Case-Control Study [253]**

Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan Weiner, Jeanne Clark, Jodi B Segal. (United States)

- 165 Long-Term Effectiveness of Ribavirin Plus Pegylated Interferon Combination Therapy for Patients with Dual Hepatitis C and B in Taiwan: A Population-Based Study [255]**

Yu-Tseng Chu, Chun-Jen Liu, Wen-Yi Shau, Yaa-Hui Dong, Raymond NC Kuo, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)

- 166 The Effect of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy [256]**

Mirko Di Martino, Silvia Cascini, Nera Agabiti, Lisa Bauleo, Ursula Kirchmayer, Danilo Fusco, Luigi Pinnarelli, Valeria Belleudi, Claudio Voci, Riccardo Pistelli, Elisabetta Patorno, Marina Davoli, The OUTPUT Study Group. (Italy)

- 167 Prioritizing Comparative Effectiveness Research: Utility of Disease-Specific Spending Estimates [258]**

Daniel M Huse, William D Marder. (United States)

- 168 Does the Risk Reduction Provided by Longer Durations of Clopidogrel Use after Stent Placement in Taiwan's National Health Insurance [259]**

Yen-Yun Yang, Yi-Chun Yeh, Chao-Lun Lai, Chiu-Ling Lai, Mei-Shu Lai. (Taiwan)

- 169 Effectiveness of Cholinesterase Inhibitors for Mild to Moderate Alzheimer's Disease: A Systematic Review of Observational Studies [260]**

Marie-Laure Laroche, Laure Paravisini, Marion Lassalle, Louis Merle. (France)

- 170 Comparative Effectiveness Research (CER): Where to Begin? A Literature Review of CER Methods Guides [261]**

Robert O McConeghy, Nicolle M Gatto, Aisling R Caffrey. (United States)

- 171 Improving the Validity of CER through Principled Exploration of Data [262]**

Anne-Marie Meyer, Huan Liu, Christina Mack, William R Carpenter, M Alan Brookhart. (United States)

- 173 Do SSRIs Increase the Risk of Gastrointestinal Adverse Effects? [264]**

Koen Pouwels, Arno Kalkman, Daan Schagen, Sipke Visser, Eelko Hak. (Netherlands)

- 174 Angiotensin-Converting Enzyme Inhibitor Treatment and the Development of Urinary Tract Infection [265]**

Koen Pouwels, Sipke Visser, Jens Bos, Eelko Hak. (Netherlands)

Monday, August 26
POSTER SESSION A

- 175 Feasibility of Linking Administrative Claims Data to Institution-Specific Laboratory and Electronic Health Record Data for Comparative Effectiveness Research [266]**
John D Seeger, Andrew T Rothman, Marie D Gerhard-Herman, Jessica J Jalbert, Louis L Nguyen, Chi-Ying Chen, Lauren A Williams, Soko Setoguchi. (United States)
- 176 FDA's Partnership in Applied Comparative Effectiveness Sciences [267]**
Jodi B Segal, Michael Rosenblum, Gary Rosner, Emily Little, Sam Ogunbo, Sonal Singh, Ravi Varadhan, Sean Tunis. (United States)
- 178 Comparative Effectiveness of Pharmacologic and Mechanical Strategies for Prevention of VTE among Special Populations [270]**
Sonal Singh, Elliott Haut, Daniel Brotman, Ritu Sharma, Yohalakshmi Chelladurai, Kenneth Shermock, Sosena Kebede, Jodi Segal. (United States)
- 179 Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-Analysis [271]**
Mina Tadrous, Lindsay Wong, David N Juurlink, Murray Krahn, Linda E Levesque, Muhammad M Mamdani, Suzanne M Cadarette. (Canada)
- 180 The Comparative Safety and Effectiveness of Sitagliptin in Patients with Type 2 Diabetes and Heart Failure [272]**
Daniala L Weir, Finlay A McAlister, Sentil Senthilselvan, Jason R Dyck, Jasjeet K Sandhu-Minhas, Dean T Eurich. (Canada)
- 181 Adjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer Patients: A Meta-Analysis of Published Randomized Trials [273]**
Ying Xia, Boyang Bian, Elizabeth Costea, Jeff Guo, Christina Kelton. (United States)
- 182 Comparative Effectiveness of Interferon and Pegylated Interferon Against Chronic Hepatitis B in Taiwan [274]**
Chun-Jen Liu, Yi-Chun Yeh, Raymond NC Kau, Chiu-Ling Lai, Yen-Yun Yang, Mei-Shu Lai, Pei-Jer Chen. (Taiwan)
- 183 Comparative Effectiveness of Lamivudine and Interferon or Pegylated Interferon Against Chronic Hepatitis B in Taiwan [275]**
Yi-Chun Yeh, Chun-Jen Liu, Chiu-Ling Lai, Raymond NC Kuo, Ho-Min Chen, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 184 Balance Measures for Determining Optimal Caliper Width in Propensity Score Matching: A Simulation Study [277]**
M Sanni Ali, RHH Groenwold, Svetlana V Belitser, Wiebe R Pestman, Arno W Hoes, Kit CB Roes, A de Boer, Olaf H Klungel. (Netherlands)
- 186 Propensity Score Estimation To Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics [279]**
Stacie B Dusetzina, Christina DeFilippo Mack, Til Stürmer. (United States)

- 187 The Complex Role of the Prescriber in Comparative Effectiveness Research [280]**
Jessica M Franklin, Sebastian Schneeweiss, Krista F Huybrechts, Robert J Glynn. (United States)
- 188 Using Covariate Data To Inform Large-Scale Studies and Application in the Global Registry Program on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) [281]**
Jessica M Franklin, Kristina Zint, Jeremy A Rassen, Sebastian Schneeweiss, Dorothee B Bartels. (United States)
- 189 Combined Disease Risk Score Stratification and Propensity Score Matching When Comparing Multiple Drugs [282]**
Joshua J Gagne, Robert J Glynn, Sebastian Schneeweiss. (United States)
- 190 Differential Diagnostic Work-Up among Initiators of Antihypertensive Drugs [283]**
Mugdha Gokhale, Virginia Pate, J Bradley Layton, Til Sturmer. (United States)
- 191 Confounding by Indication in Comparative Effectiveness Research: Does Adding Registry to Claims Data Make a Difference? [285]**
Jessica J Jalbert, John D Seeger, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)
- 193 Severity Index for Rheumatoid Arthritis: Impact on Healthcare Costs and Utilization [288]**
Onur Baser, Juan Du, Lin Xie, Anne H Dysinger, Li Wang. (United States)
- 194 A Validated Outcomes Measure To Assist the Pharmacoepidemiological Study of Opiate Maintenance Treatment [289]**
Hannu Alho, Icro Maremmanni. (Finland)

Medications in Pregnancy SIG

- 195 Design and Feasibility of a Study Using the Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) To Assess the Risk of Spontaneous Abortion (SA) Following Administration of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvant [290]**
Dominique Rosillon, Corinne Willame, John Logie, Sylvia Taylor, Vincent Bauchau, Maria-Genalin Angelo, Julia Zima, Judith van den Bosch, Tjeerd van Staa, Rachael Boggon, Christina Chambers, Sonia Hernandez-Diaz, Laurence Baril. (Belgium)
- 196 Lessons Learned from Implementation of a Prospective, Observational Cohort Study To Assess Risk of Spontaneous Abortion (SA) Following Administration of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine around Conception [291]**
Christina Chambers, Diana Johnson, Ronghui Xu, Dominique Rosillon, Judith van den Bosch, Laurence Baril, Sylvia Taylor. (United States)

- 197 Is There Any Evidence for Fetal Harm with Prolonged Use of Magnesium Sulfate in Pregnant Women? [292]**
Syed Rizwanuddin Ahmad, Mark S Miller, Shelley R Slaughter. (United States)
- 198 Impact of the FDAAA on Post-Marketing Commitments Related to Pregnancy and Lactation [293]**
Jessica D Albano, Susan Sinclair Roberts. (United States)
- 199 The Use of Medications Pregnancy Categories among Healthcare Professionals in Saudi Arabia Hospitals [295]**
Thamir M Alshammari, Adel A Alrwisan, Majed Aljeraisy, Hisham Aljadhey. (Saudi Arabia)
- 200 Safety of Neuraminidase Inhibitors during Pregnancy: A Comparative Study in the EFEMERIS Database [296]**
Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel, Isabelle Lacroix. (France)
- 201 First Trimester Exposure to Sertraline and the Risk of Major Congenital Malformations in a Cohort of Depressed Women [297]**
Anick Berard, Odile Sheehy, Vivian Leung. (Canada)
- 202 Risk of Preterm Delivery in Women with Inflammatory Bowel Disease – Effects of Disease Activity and Drug Exposure [298]**
Gabiella Bröms, Marie Linder, Fredrik Granath, Olof Stephansson, Maria ElMBERG, Helle Kieler. (Sweden)
- 203 Use of Glyburide Versus Insulin for Treatment of Gestational Diabetes in the U.S., 2000-2010 [300]**
Wendy Camelo Castillo, Kim Boggess, Til Sturmer, M Alan Brookhart, Daniel K Benjamin, Jr.. (United States)
- 204 Meta-Analysis of the Use of Assisted Reproductive Technologies and the Risk of Multiple Birth and Major Congenital Malformations [302]**
Sonia Chaabane, Lucie Blais, Fraser William, François Bissonnette, Patricia Monnier, Seang Lin Tan, Jacquetta Trasler, Anick Bérard. (Canada)
- 205 Congenital Malformations in the Offspring of Women with Asthma [303]**
Rachel Charlton, Julia Snowball, Kourtney Davis, Corinne de Vries. (United Kingdom)
- 206 Healthcare Databases in Europe for Studying the Safety of Medicine Use during Pregnancy [304]**
Rachel Charlton, Amanda Neville, Sue Jordan, Anna Pierini, Kari Klungsoyr, Anne-Marie Nybo Andersen, Christine Damase-Michel, Lolkje de Jong-van den Berg, Corinne de Vries. (United Kingdom)

POSTER SESSION A

- 207 Outcomes of Pregnancies for Women Prescribed Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists in Semester 2 or 3 [305]**
Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)
- 208 Treatment of Acute Asthma Exacerbations during and outside Pregnancy at a Canadian Teaching Hospital [306]**
Benoit Cossette, Amélie Forget, Marie-France Beauchesne, Catherine Lemière, Pierre Larivée, Évelyne Rey, Lucie Blais. (Canada)
- 209 EXPECT Enrollment: Impact of Recruitment Strategy on Enrollment in the Xolair® Pregnancy Registry [307]**
Deborah Covington, Vivian Wang, Gillis Carrigan, Nicole Hurst, Joachim Veith, Hubert Chen. (United States)
- 210 Which Therapeutic Option Is the Safest for the Fetus in the Treatment of Maternal Asthma: Higher Dose Inhaled Corticosteroids or Long-Acting beta2-Agonists Plus Lower Dose Inhaled Corticosteroids? [309]**
Sherif Eltonsy, Amélie Forget, Marie-France Beauchesne, Lucie Blais. (Canada)
- 211 Best Practices for Pregnancy Registries [310]**
Richard Gliklich, Nancy Dreyer, Sonia Hernandez-Diaz, Janet Cragan, Melissa Tassinari, Deborah Covington, Sara Ephross, Christina Chambers, Elise Berliner, Michelle Leavy, Laura Khurana. (United States)
- 212 Use of Serotonin Reuptake Inhibitors in Late Gestation and Lactation Difficulties [311]**
Luke E Grzeskowiak, Catherine Leggett, Lynn Costi, Janna L Morrison, Vicki L Clifton. (Australia)
- 213 Prenatal Antidepressant Exposure and Child Behavioural Outcomes at 7-Years of Age [312]**
Luke E Grzeskowiak, Janna L Morrison, Tina B Henriksen, Bodil H Bech, Jorn Olsen, Carsten Obel, Lars H Pedersen. (Australia)
- 214 Use of Acid-Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Case-Crossover Study Using the General Practice Research Database [313]**
Eelko Hak, Bianca Mulder, Nynke CM Schuiling-Veninga, Tjalling W De Vries, Susan S Jick. (Netherlands)
- 215 Prenatal Exposure to Antidepressants and Motor Development in the Three Years Old Child. Results from MoBa, a Large Population Based Pregnancy Cohort in Norway [314]**
Marte Handal, Svetlana Skurtveit, Kari Furu, Eva Skovlund, Sonia Hernandez-Diaz, Wenche Nystad, Randi Selmer. (Norway)
- 216 Reproductive Calls to the Norwegian Poison Information Center - Women Are Frightened of Exposures to Gases and Household Chemicals, Not Only Medicines [315]**
Gro C Havnen, Ann-Christin Olsen, Hedvig Nordeng. (Norway)
- 217 Pregnancy Outcome in Women Exposed to Dopamine Agonists during Pregnancy: A Study in EFEMERIS Database [316]**
Caroline Hurault-Delarue, Jean-Louis Montastruc, Anna-Belle Beau, Isabelle Lacroix, Christine Damase-Michel. (France)
- 218 Antidepressant Medication Use during Pregnancy and the Risk of Preterm Birth [317]**
Krista F Huybrechts, Reesha C Shah, Jerry Avorn, Adam C Urato. (United States)
- 219 In Utero Exposure to Antipsychotics and Congenital Malformations - A Nation Wide Cohort Study [318]**
Espen Jimenez-Solem, Jon T Andersen, Nadia L Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)
- 220 Topical Pharmacological Treatment of Hemorrhoids during Pregnancy and Congenital Malformations – A Nation-Wide Cohort Study [319]**
Espen Jimenez-Solem, Jon T Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)
- 221 Can We Rely on Pharmacy Claims Databases To Ascertain Maternal Use of Medications during Pregnancy? [320]**
Katherine Jobin Gervais, Odile Sheehy, Anick Bérard. (Canada)
- 222 How Much Ortho-Phthalate May Be Present in Medications and Dietary Supplements? [321]**
Katherine E Kelley, Mark Böhlke, Allen A Mitchell, Russ Hauser, Sonia Hernández-Díaz. (United States)
- 223 Veinotonics in Pregnancy: A Comparative Study in the EFEMERIS Database [322]**
Isabelle Lacroix, Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 224 Safety of Influenza AH1N1 Pandemic Vaccination during Pregnancy: A Comparative Study in the EFEMERIS Database [323]**
Isabelle Lacroix, Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 225 First Trimester Exposure to Bupropion and Cardiac Defects [325]**
Carol Louik, Stephen Kerr, Allen A Mitchell. (United States)
- 227 The Fetal Safety of Macrolides – A Systematic Review and Meta-Analysis [327]**
Hedvig Nordeng, Myla Moretti, Gideon Koren. (Norway)
- 228 Validity of Maternal and Infant Outcomes within Medicaid Data [328]**
Kristin K Palmsten, Krista F Huybrechts, Mary K Kowal, Sonia Hernández-Díaz. (United States)
- 229 Antidepressant Use Late in Pregnancy and Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN) among Low-Income Women [329]**
Kristin K Palmsten, Krista F Huybrechts, Mary K Kowal, Helen Mogun, Soko Setoguchi, Sonia Hernández-Díaz. (United States)
- 230 Drug Use in Pregnancy, Gestational Age and Date of Delivery: Comparison of Health Database and Self-Reported Information in a Cohort [330]**
Federica E Pisa, Anica Casetta, Elena Clagnan, Elisa Michelesio, Fabio Barbone. (Italy)
- 231 Perception of Teratogenic Risk Related to Medications: Agreement between Two Techniques of Measuring [331]**
Emília S Pons, Luciano P Guimarães, Daniela R Knauth, Tatiane S Dal-Pizzolo. (Brazil)
- 232 Validation of Pregnancy Information in the German Pharmacoepidemiological Research Database (GePaRD) [333]**
Niklas Schmedt, Rafael T Mikolajczyk, Angela A Kraut, Edeltraut Garbe. (Germany)
- 234 Antimalarial Drug Use during Pregnancy and the Risk of Low Birth Weight (LBW): A Systematic Review [336]**
Muanda MT Tsobo, Anick AB Bérard. (Canada)
- 235 Zidovudine Exposure during Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry [337]**
Vani Vannappagari, Jessica Albano, Hugh Tilson, Conway Gee, Anisha Gandhi, Nana Koram, Catherine Ryan. (United States)
- 236 Health Beliefs, Attitudes and Knowledge of Expectant Mothers Regarding Medicine and Substance Use in Pregnancy: A Literature Review [338]**
Mariam I Wahab, Alastair G Sutcliffe, Ian CK Wong, Yogini H Jani. (United Kingdom)
- 237 Complementary and Alternative Medicine Use in the First Trimester: Safety Perceptions and Preference of Pregnant Women [339]**
Mariam I Wahab, Alastair G Sutcliffe, Ian CK Wong, Yogini H Jani. (United Kingdom)
- 238 Exposure to Inhalation Zanamivir during Pregnancy and Pregnancy Outcomes [340]**
Alec Walker, Vani Vannappagari, Rebecca Buus, Deborah Covington, Emily Bratton, Mary Thompson. (United States)
- 239 Dispensing of Potential Teratogenic Drugs before and during Pregnancy: A Population Based Study [341]**
Inge M Zomerdijk, Rikje Ruiters, Leanne MA Houweling, Ron MC Herings, Sabine MJM Straus, Bruno H Stricker. (Netherlands)
- 240 Drug Dispensing before and during Pregnancy and Congenital Malformations: A Population Based Study [342]**
Inge M Zomerdijk, Rikje Ruiters, Leanne MA Houweling, Ron MC Herings, Sabine MJM Straus, Bruno H Stricker. (Netherlands)

Monday, August 26
POSTER SESSION A

241 Are Women with Major Depression in Pregnancy Identifiable in Population Health Data? [343]

Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

242 Relation between the Prevalence of Attention Deficit and Hyperactivity Disorders (ADHD) and Autism Spectrum Disorders (ASD), and Maternal Depression and Antidepressant Use during Pregnancy [345]

Anick Berard, Odile Sheehy, Takoua Boukris. (Canada)

243 Adverse Developmental Events Reported to FDA in Association with Maternal Use of Topiramate in Pregnancy [346]

Sonia Tabacova, Ana Szarfman. (United States)

244 Prenatal Antidepressant Exposure and Neurodevelopmental Outcomes in a Cohort of Typically-Developing Children [347]

Mollie E Wood, David Kennedy, Jean A Frazier, PING Research Group. (United States)

245 First Trimester Fluoxetine Use and Major Malformations: A Meta-Analysis of Epidemiological Studies [348]

Yu Yan, Yingkai Cheng, Brenda Crowe, Rashna Chhabra-Khanna, Angelo Camporeale, Lauren Marangell. (United States)

Poster Walk - Adherence SIG

246 Medication Adherence and Severe Asthma Exacerbations: Systematic Review [226]

Marjolein Engelkes, Hettie M Janssens, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)

247 Predicting Persistence with Antidepressant Treatment at 6 Months [228]

Greta A Bushnell, Til Stürmer, Virginia Pate, Alice D White, Sonja Swanson, Deborah Azrael, Matthew Miller. (United States)

248 Persistence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer – Accounting for Temporary Treatment Discontinuations [232]

Laetitia Huiart, Cyril Ferdynus, Sophie Dell'Aniello, Roch Giorgi, Samy Suissa. (France)

249 Adherence and Persistence to Hormonal Therapy in Breast Cancer: A Meta-Regression To Summarize the Available Data [233]

Laetitia Huiart, Cyril Ferdynus, Roch Giorgi. (France)

250 Effectiveness of the Persistence Telephone Assessment and Communication Program for Patients with Treated Depression: Pragmatic Randomized Controlled Trial [235]

Yola Moride, Guillaume Galbaud du Fort, Marie Tournier, Marie-Eve Alary, Michel Rossignol, Thierry Ducruet, Jean Lachaine, Jean-Pierre Bonin, Jean-Paul Collet. (Canada)

251 Guidelines Adherence in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes: Comparing the Use of Metformin in Quebec Pre and Post-Canadian Diabetes Association Guidelines [238]

Ting-Yu Wang, Eguale Tewodros, Robyn Tamblyn. (Canada)

252 Potential Impact of Errors in the Days Supply of Osteoporosis Medications on Estimates of Drug Adherence [240]

Andrea M Burden, Michael J Patterson, Andrea Gruneir, Suzanne M Cadarette. (Canada)

Poster Walk - Comparative Effectiveness Research (CER) SIG

253 Comparative Effects of Different Combination Antiretroviral Therapies on the Risk for Myocardial Infarction among HIV Patients Enrolled in Medicaid: A New User, Active Comparator Cohort Study [254]

Emily S Brouwer, Sonia Napravnik, Joseph J Eron, Jr., Ross J Simpson, Jr., Brant Stalzer, Michelle Floris-Moore, Michael Vinikoor, Til Stürmer. (United States)

254 Registry of Patient Registries (RoPR): Advancing Registries for Comparative Effectiveness Research [257]

Richard E Gliklich, Daniel Levy, Daniel M Campion, Michelle Leavy, Jannette Karl, Elise Berliner, Laura Khurana, Willet Hossfeld. (United States)

255 Confounding by Indication in Comparative Effectiveness Research: Does Adding Registry to Claims Data Make a Difference? [268]

Jessica J Jalbert, John D Seeger, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)

256 Dose and Duration Relationship between Pioglitazone and Associated Risk of Bladder Cancer: A Systematic Review and Meta-Analysis [269]

Richard Turner, Chun S Kwok, Chen Chen-Turner, Chinedu Maduakar, Sonal Singh, Yoon K Loke. (United States)

257 Assessment of Balance in Propensity Score Analysis in the Medical Literature: A Systematic Review [276]

M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitser, Wiebe R Pestman, Arno W Hoes, Kit CB Roes, A de Boer, Olaf H Klungel. (Netherlands)

258 Instrumental Variable Analyses Using Nursing Home Prescribing Preferences for Comparative Effectiveness Research [284]

Krista F Huybrechts, Tobias Gerhard, Jessica M Franklin, Raisa Levin, Stephen Crystal, Sebastian Schneeweiss. (United States)

259 Quantitative Verification of Instrumental Variables Assumption Using Balance Measures [287]

M Jamal Uddin, M Sanni Ali, Rolf HH Groenwold, Wiebe R Pestman, Svetlana V Belitser, Arno W Hoes, Anthonius de Boer, Kit CB Roes, Olaf H Klungel. (Netherlands)

Poster Walk - Medications in Pregnancy SIG

260 Public Perception of Risk Factors for Birth Defects: HealthStyles, 2010-2011 [299]

Shenita R Peterson, Meghan T Frey, Suzanne M Gilboa, Cheryl S Broussard. (United States)

261 Hypertension and Patterns of Prescription of Antihypertensive Medications during Pregnancy Using THIN Database [301]

Lucia Cea Soriano, Brian T Bateman, Luis A Garcia Rodriguez, Sonia Hernandez-Diaz. (Spain)

262 Prospective Enrollment in Pregnancy Registries: Definitions and Potential Impact on Birth Defect Prevalence [308]

Deborah Covington, Amanda Golembesky, Deanna Hill, Nicole Hurst, Paige Churchill, Laura McKain. (United States)

263 Risks and Safety of Pandemic H1N1 Vaccine in Pregnancy: Preterm Birth and Specific Defects [324]

Carol Louik, Katherine Ahrens, Stephen Kerr, Junhee Pyo, Christina Chambers, Kenneth L Jones, Michael Schatz, Allen A Mitchell. (United States)

264 Hypertensive Disorders and Antihypertensive Medication during Pregnancy and the Risk of Birth Defects: A Case-Control Study [332]

Marleen MHJ van Gelder, Carla M Van Bennekom, Carol Louik, Martha M Werler, Nel Roeleveld, Allen A Mitchell. (Netherlands)

265 Prenatal Exposure to Antidepressants and Language Competence at 3 Years of Age. Results from a Large Population Based Pregnancy Cohort in Norway [334]

Svetlana Skurtveit, Randi Selmer, Christine Roth, Sonia Hernandez-Diaz, Marte Handal. (Norway)

266 Identification of Pregnancy by a Coding Algorithm in a U.S. Administrative Healthcare Database [344]

Hoa V Le, Chi T Truong, Charlotte F Carroll, Julie L Priest, Sara A Ephross, Carlyne M Averell. (United States)

▶ **END SESSION A**

Benefit Risk Assessment and Risk Communication

- 1 **Aspirin Use in Prostate Cancer and the Risk of Death and Metastasis [429]**
Jonathan Assayag, Laurent Azoulay, Hui Yin, Michael N Pollak, Samy Suissa. (Canada)
- 2 **The Clinical Benefit of Warfarin in Patients with Atrial Fibrillation in Taiwan [430]**
Chia-Hsien Chang, Yea-Huei Kao Yang, Li-Jen Lin, Swu-Jane Lin. (Taiwan)
- 3 **The Role of the thorough QT Study in Drug Development [431]**
Frank A Holtkamp, Pieter A de Graeff, Peter GM Mol. (Netherlands)
- 4 **Use of Glucocorticoids and Risk of Breast Cancer Recurrence [432]**
Lone W Lietzen, Deirdre P Cronin-Fenton, Thomas P Ahern, Henrik T Sørensen, Peer Christiansen, Anders B Jensen, Timothy L Lash. (Denmark)
- 5 **Acute Non-Steroidal Anti-Inflammatory Drug Exposure in Asthma: A Meta-Analysis of Clinical Trials [433]**
Daniel R Morales, Virginia H Santiago, Brian Lipworth, Cathy Jackson, Peter Donnan, Bruce Guthrie. (United Kingdom)
- 6 **Acute β -Blocker Exposure in Asthma: A Meta-Analysis of Randomized Controlled Trials [434]**
Daniel R Morales, Cathy Jackson, Peter T Donnan, Brian J Lipworth, Bruce Guthrie. (United Kingdom)

Methods

- 7 **Identification of Incident Cardiovascular Events Using a Computerized Hospital Database: A Feasibility Study [435]**
Julien Bezin, Maelys Touya, Cécile Lebrun, Véronique Gilleron, Antoine Pariente, Annie Fourrier-Reglat, Nicholas Moore. (France)
- 8 **Are Patients Classified as Antiretroviral Therapy Naïve Using Administrative Data Truly Naïve Based on Comprehensive Medical Record Reviews? An Exploration Using an HIV Clinical Cohort [436]**
Emily S Brouwer, Daniela C Moga, Joseph J Eron, Jr., Sonia Napravnik. (United States)
- 9 **Factors Affecting the Association of Cancer Risk among Patients Treated with Anti-Diabetic Medication [437]**
Anna But, Haining Wang, Marie L De Bruin, Satu Männistö, Jari Haukka. (Finland)
- 10 **Comparison of Comorbidity Ascertainment Using the End-Stage Renal Disease Medical Evidence Form 2728 Versus Medicare Claims Data [438]**
Anne M Butler, Abhijit V Kshirsagar, Lily Wang, M Alan Brookhart. (United States)

- 11 **Uptake of Methodological Innovation in Pharmacoepidemiology: Disease Risk Score Co-Authorship Network Analysis [439]**
Patrick R Edwards, Giulia Consiglio, Mina Tadrous, Suzanne M Cadarette. (Canada)
- 12 **Identifying Patients in Electronic Healthcare Data When No Diagnostic Codes Are Available for the Disease of Interest: Critical Limb Ischemia Example [440]**
Jennifer Campbell, George Geroulakos, Tjeerd van Staa. (United Kingdom)
- 13 **Changes in Daily Dose over Time from Longitudinal Data of Tianeptine Users: Convergence of Two Different Approaches [441]**
Cedric Collin, Fanny Feuillet, Caroline Victorri-Vigneau, Marie-Anne Courne, Jean-Benoit Hardouin, Veronique Sebillé. (France)
- 14 **Artificial Intelligence for Drug-Drug Interaction Prediction - A Systematic Review [442]**
Felipe Ferre, Vania E Araujo, Marina AA Machado, Francisco A Acurcio, Wagner Meira Junior. (Brazil)
- 15 **Confounding Control by Traditional Covariate Adjustment, Propensity Score Matching, and High Dimensional Propensity Score in a Cohort Study [443]**
Shujun Gao, Wanju Dai, Ling Zhang, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 16 **Approaches to Long-Term Surveillance for Rare Cancer Events [444]**
Alicia W Gilsenan, David H Harris, Kirk D Midkiff, Elizabeth B Andrews, Nicole A Kellier, Daniel N Masica. (United States)
- 17 **Impact of Censoring on Estimates of Adverse Drug Effects: A Simulation Study [445]**
Rolf H Groenwold, Tjeerd P van Staa, Anthonius de Boer, Olaf H Klungel. (Netherlands)
- 18 **Measures of "exposure Needed for One Additional Patient To Be Harmed" in Population-Based Case-Control Studies [446]**
Jesper Hallas, Rene Depont Christensen, Til Stürmer, Anton Pottegård. (Denmark)
- 19 **Impact of PSA Doubling Time (DT) Calculation Method on Estimate of Association with Bone Metastases in a Cohort of Prostate Cancer Patients Treated with Androgen Deprivation Therapy (ADT) [447]**
Rohini K Hernandez, Jonas Banefelt, Johan Mesterton, Jan Stålhammar, Bo-Eric Persson, Chunlei Ke, Patrik Sobocki, Alexander Liede. (United States)
- 20 **Identification of Patients with Chronic Kidney Disease from National Health Insurance Claims Data in Taiwan: A Validation Study [448]**
Cheng-Yang Hsieh, Chih-Hung Chen, Yea-Huei Yang Kao. (Taiwan)
- 21 **Doubly Robust Estimator: Effects of Variable Selection into Component Models on Efficiency [449]**
Michele Jonsson Funk, Virginia Pate, Til Stürmer. (United States)

- 22 **Antidepressant Treatment (ADT) Following a Cancer Diagnosis: Investigation in a Cohort of Older Patients [407]**
Sallie-Anne Pearson, Michal Abrahamowicz, Preeyaporn Srasuebkul, Nicholas Buckley. (Australia)
- 23 **The Impact of Methods Used for Case Ascertainment on the Association between Restless Legs Syndrome (RLS) and Cardiovascular Disease (CVD) [451]**
Linda Kalilani, Erwin Schollmayer, Mahnaz Asgharnejad, Kimberly Moran, David Miller. (United States)
- 24 **Conformity between Protocol Eligibility Criteria for Electronic Patient Identification: A Comparison of Clinical Trials [452]**
Allise G Kamauu, Stephen OT Agbor, Aaron WC Kamauu. (United States)
- 25 **Validation of the Telephone-Administered Age and Stage Questionnaire and the Revised-Prescreening Denver Questionnaire: Results from the OTIS Antidepressants in Pregnancy Study [453]**
Fatiha Karam, Anick Bérard, Odile Sheehy, Marie-Claude Huneau, Gerald Briggs, Christina Chambers, Adrienne Einarson, Diana Johnson, Kelly Kao, Gideon Koren, Brigitte Martin, Janine Polifka, Sara Hammer Riordan, Mark Roth, Sharon Lavigne Voyer, Lori Wolfe, OTIS Research Committee. (Canada)
- 26 **A Comparison of Event-Based Versus Case-Based Methods for Detection of Signals of Disproportionality with Variable Age Distributions [454]**
Nicole Kellier, Qianyi Zhang, Kenneth Hornbuckle. (United States)
- 28 **Is the Physician's Preference of Antipsychotic Medications a Valid Instrumental Variable in the German Pharmacoepidemiological Research Database? [456]**
Bianca Kollhorst, Edeltraut Garbe. (Germany)
- 29 **Statistical Methods for Estimating Treatment Effects from Randomized Clinical Trials in the Presence of Non-Randomized Post-Study Therapies [457]**
Larry F Leon, Bann-Mo Day, Sylvia Hu. (United States)
- 30 **Signal Refinement of Drug-Induced Thrombocytopenia Using the Health Information Network (THIN) Database [458]**
Qing Liu, Manfred Hauben, Andrew J Bate. (United States)
- 31 **Quality Assessment of Observational Studies in a Drug-Safety Systematic Review—comparison of Two Tools, the Newcastle-Ottawa Scale and the RTI Item Bank [459]**
Andrea V Margulis, Manel Pladevall, Nuria Riera-Guardia, Cristina Varas-Lorenzo, Lorna Hazell, Susana Perez-Gutthann. (Spain)
- 32 **Consequences of Violating Model Assumptions: An Example Using Healthcare Claims Data [460]**
Rayna K Matsuno, Aditi Kadakia, Laura Wallace. (United States)

Tuesday, August 27
POSTER SESSION B

- 33 Comparison of Covariate Selection Approaches for Propensity Score (PS) Derivation for Multiple Health Outcomes of Interest (HOIs): An Empirical Example [461]**
Ann Marie McNeill, Cynthia J Girman, Zhiwen Liu, Robert J LoCasale, Richard Wyss, Ying Su, Til Sturmer. (United States)
- 34 Comparison of Case-Cohort Data Analyses Using Data of Cases/Subcohort Members Only and Data of Entire Cohort [462]**
Nobuhiro Ooba, Akira Wakana, Tsugumichi Sato, Takuhiro Yamaguchi, Kiyoshi Kubota. (Japan)
- 35 Investigator-Specified vs. Empirical Covariate Selection for Confounding Adjustment in Studies with Infrequent Outcomes: Anticonvulsants and Cardiovascular Risk [463]**
Elisabetta Patomo, Robert Glynn, Sonia Hernandez-Diaz, Jun Liu, Sebastian Schneeweiss. (United States)
- 36 Validation of the Adjusted Sequence Ratio in Prescription Sequence Symmetry Analysis: A Simulation Study [464]**
Nicole Pratt, Jenni Ilomaki, Chris Raymond, Elizabeth Roughead. (Australia)
- 37 Defining a Denominator Population for Linked Datasets [465]**
Shivani Puri, Tim Williams, Susan Eaton. (United Kingdom)
- 39 Missing Data in Modified-PEM (M-PEM) Studies; an Application of Multiple Imputation [467]**
Ian Ratcliffe, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 40 Estimation of the Incidence Rate of Very Rare Diseases - A Case Study of Multicentric Castleman's Disease [468]**
Dana Y Teltsch, Richard S Swain, Don W Robinson, Jr., Marie-Pierre Desrosiers, Philip Rotella, Krista A Payne, Matthew W Reynolds. (United States)
- 41 Comparison of a Targeted Maximum Likelihood Estimator to Other Estimation Techniques for the One Year Risk of Myocardial Infarction among New Users of High vs. Low Potency Statins [469]**
Jonathan V Todd, Michele Jonsson-Funk, Bradley Layton, Virginia Pate, MA Brookhart. (United States)
- 42 TrialViz: A Feasibility Tool Based upon the CPRD GOLD Primary Care Database [470]**
Tim Williams, Shivani Puri, Joss Wickson, Rosemary Tate, Natalia Beloff, Tjeerd van Staa, Adrian Bleach, John Cuthbert. (United Kingdom)
- 43 Predicting a Missing Baseline Value in a Rare Disease Registry Using Extrapolation of Mixed Models Estimates [471]**
Amanda B Wilson. (United States)
- 44 Inclusion of Variables Associated with Exposure but Not Outcome Can Compromise Propensity Score-Based Adjustments – Examination of a Real-Life Example in Pediatric Psychopharmacology [472]**

- Almut G Winterstein, Joseph A Delaney, Paul Kubilis, Stephen Crystal, Tobias Gerhard. (United States)
- 45 Development of a Claims-Based Algorithm To Identify Prolia Use in Medicare Data [473]**
Nicole C Wright, Rui Chen, Tarun Arora, Huifeng Yun, Elizabeth S Delzell, Jeffrey R Curtis. (United States)
- 46 The Validity of Claims-Based Algorithms To Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw [474]**
Nicole C Wright, Tarun Arora, Wilson K Smith, Ashley N Milford, Mark Marchant, Boni Elewski, Jeffrey R Curtis, Meredith L Kilogre, Michael Morrisey, Kenneth G Saag, Monika M Safford, Elizabeth S Delzell. (United States)
- 47 Evaluation of Analytical Method Performance Using Observational Medical Dataset Simulator (OSIM2) [475]**
Jasmanda Wu, Ling Zhang, Juhaeri Juhaeri, Wanju Dai, Patrick Caubel. (United States)
- 48 Validation of Stroke in the Clinical Practice Research Datalink (CPRD) [476]**
Esther H Zhou, Kate Gelperin, David J Graham, Yulan Ding, Mark Levenson, Martin Rose, Shannin F Davillier, Tarek A Hammad. (United States)
- 49 A High-Performing, SEER-Validated Algorithm for Identifying Patients with Incident Cancer of the Esophagus or Cardia Using Medicare Claims Data [477]**
David J Graham, Katlyn Calia, Lorene Nelson, Jeff Yang, Jay Bhattacharya, Thomas E MaCurdy, Chris Worrall, Jeffrey A Kelman. (United States)
- 50 Algorithms To Identify Pancreatic Cancer and Thyroid Neoplasm from Health Insurance Claims Data [478]**
Caihua Liang, Bruce R Turnbull, Kathleen E Skerry, Kwame Appenteng, Stephen P Motsko, David D Dore. (United States)
- 51 Validation of Outcome Definition of Acute Renal Failure in Japanese Electronic Medical Records Data [479]**
Kaori Yamada, Eiko Tada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- Pediatrics**
- 52 Adverse Events Associated with Pediatric Use of Proton Pump Inhibitors: Analysis of the FDA Adverse Event Reporting System [480]**
Abdullah K Alahmari, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)
- 53 Do EMA and FDA Have Different Opinions/ Requirements in Terms of Pediatric Studies for Sitagliptin (Alone or in Combination)? [481]**
Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 54 Did the Dutch Pneumococcal Vaccination Campaign Decrease the Need for Antibiotics in Children? [482]**
Giedre Gefenaite, Maarten J Bijlsma, Jens Bos, Eelko Hak. (Netherlands)

- 56 Period Prevalence of Therapy Combination and Switching among Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) Treated with Stimulants in the Canadian Province of Quebec [484]**
Jean Lachaine, Vanja Sikirica, Martin Cloutier, Leila BenAmor, Paul Hodgkins, Judy van Stralen, Valeire Carter, Annie Guerin. (Canada)
- 57 Quantitative Vaccine Safety Signal Detection Techniques Using Vaccine Adverse Event Reporting System (VAERS) [485]**
Huifang Liang, Motonobu Sakaguchi. (United States)
- 58 Acne and Lifestyle: Results of a Survey on a Representative Sample of the French Population [486]**
Pierre Wolkeinstein, Sébastien Branchoux, Charles Taieb. (France)
- 59 Children with Atopic Dermatitis: Monitoring a French Cohort over a Nine-Year Period [487]**
Charles Taieb, Laurent Misery. (France)
- 60 Atopic Dermatitis: Evaluation of 2 Different Drug Related Managements [488]**
Charles Taieb. (France)

Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG

- 61 Entacapone Containing Drugs Use and Risk of Death: Analysis of FDA AERS (FAERS) Database [489]**
Thamir M Alshammari, Eman N Almutairi. (Saudi Arabia)
- 62 Risk of Severe Ventricular Arrhythmia among Outpatient Receiving Fluoroquinolones in Taiwan [490]**
Hsu-Wen Chou, Chao-Lun Lai, Jiun-Ling Wang, Chia-Hsui Chang, Mei-Shu Lai. (Taiwan)
- 63 Impact of Previous Suicide Attempts and Family History of Psychiatric Disease on the Size of the Association between Antiepileptic Drugs and Suicide Related Events [491]**
Christiane Gasse, Aske Astrup, Henrik Støvring, Ole Mors, Jakob Christensen. (Denmark)
- 64 Estimating the Association between QT Prolongation and SSRI Utilization from the FDA's Adverse Event Reports [492]**
Jing Guo, Jeff J Guo, Christina ML Kelton, Patricia Wigle. (United States)
- 65 A Systematic Review of the Adverse Effects of Atypical Antipsychotics in the Elderly Population [494]**
Neeraja Krishnaswamy, Andrew Zullo, David D Dore. (United States)
- 66 A Pragmatic Score To Predict the Risk of Clostridium difficile Infection among Patients Receiving a Fluoroquinolone Antibiotic [495]**
Jennifer L Kuntz, Eric S Johnson, Xiuhai Yang, Micah L Thorp, David H Smith. (United States)

Tuesday, August 27
POSTER SESSION B

- 67 Background Rates of Other New Primary Malignancies among Locally Advanced and Metastatic Melanoma Patients: A SEER-Medicare Study [496]**
Haojie Li, Thao Vo, Samantha St. Laurent, Monica Kobayashi, Jeanenne Nelson. (United States)
- 68 New-Onset Non-Melanoma Malignant Skin Lesions and Non-Cutaneous Squamous-Cell Carcinoma among Metastatic Melanoma Patients in Denmark [497]**
Haojie Li, Lars Pedersen, Mette Nørgaard, Sinna Ulrichsen, Sandra Thygesen, Henrik Sørensen, Jeanenne Nelson. (United States)
- 69 Does Research Design Predict Estimated Risks of Venous Thromboembolism with Drospirenone-Containing Oral Contraceptives? [498]**
Barbara Mintzes, Anat Fisher, Guillermina Perez, Soufi Sam. (Canada)
- 70 Lay Media Attention for Serious Drug Safety Issues in the Netherlands [499]**
Valerie Damoiseaux, Sigrid Piening, Sabine Straus, Flora M Haaijer-Ruskamp, Peter GM Mol. (Netherlands)
- 71 The Additional Value of an e-Mail To Inform Healthcare Professionals of a Drug Safety Issue [501]**
Sigrid Piening, Pieter A de Graeff, Sabine MJM Straus, Flora M Haaijer-Ruskamp, Peter GM Mol. (Netherlands)
- 72 Pattern and Determinants of Self Medication in a Nigerian Urban Population- "The Silent Epidemics" [502]**
Olayinka O Ogunleye, Adesola F Yinka-Ogunleye, Sunday O Ogundele, Kazeem A Oshikoya. (Nigeria)
- 73 Changes in Number of Spontaneous Adverse Event Reports of Drug Abuse, Intentional Drug Misuse, Medication Error, and Overdose after Reformulation of OxyContin [503]**
Nelson E Sessler, Jared M Downing, Howard D Chilcoat, Todd F Baumgartner, Paul M Coplan. (United States)
- 74 Statin Therapy and Incident Cataract: A Meta-Analysis [508]**
Carlos Alves, Ana F Macedo, Diogo Mendes, Francisco Batel Marques. (Portugal)
- 75 Comorbidities and Medication Use in Lupus Nephritis Patients – A Comparison of Result across Case Identification Algorithms [509]**
Kathleen M McCarty, Douglas Clark, Wei-Shi Yeah. (United States)
- 76 Assessment of Tolerance of Pain Treatment in Cancer Management [510]**
Zineb Mesbahi, Samir Ahid, Bouchra Meddah, Zakaria Belkhadir, Yahia Cherrah. (Morocco)
- 77 Health-Care Professionals' Perspectives on Multi-Dose Dispensed Medicines [511]**
Carola Bardage, Anders Ekedahl, Lena Ring. (Sweden)
- 78 Drug Use and Polypharmacy in Rehabilitation Center Inpatients Following Acquired Brain Injury: A Cross-Sectional Survey in Italy [512]**
Giorgia Cosano, Tullio Giorgini, Emanuele Biasutti, Fabio Barbone, Federica E Pisa. (Italy)
- 79 Relative Effectiveness of Paracetamol in Patient with Knee and Hip Osteoarthritis [513]**
Lamia Grimaldi-Bensouda, Raphaelle Beau-Ledjstrom, Michel Rossignol, Bernard Avouac, Lucien Abenheim. (United Kingdom)
- 80 Risk of Suicide Attempts Associated with Anti-epileptic Drugs: A Case-Control Study Looking at the Effect of Differing Design Options [514]**
Lamia Grimaldi-Bensouda, Frédéric Rouillon, Vincent Caillard, Nicolas Dantchev, Jean Louis Terra, Michel Lejoyeux, Xavier Kurz, Lucien Abenheim. (France)
- 81 Benefits of Different Propensity Score Methods for Evaluation of Associations and Channeling Bias over Time: Pneumonia and Inhaled Corticosteroid in a COPD New User Cohort [515]**
Hoa V Le, Rachael L DiSantostefano, Tim Sampson, Chi T Truong, Kourtney J Davis. (United States)
- 82 Knowledge and Awareness of Healthcare Professionals (HCPs) toward Pharmacovigilance Concept in Saudi Arabia [516]**
Thamir M Alshammari, Yazeed M Ghawaa, Khaled B Alamri, Noura A AlOhal. (Saudi Arabia)
- 83 Data Sources Supporting Safety Warnings and the Correspondence Scientific Evidence Published in Literature: A Descriptive Study [517]**
Carlos Alves, Ana F Macedo, Francisco Batel Marques. (Portugal)
- 84 Feasibility of Using Australian GP Prescribing Data for Pharmacovigilance [518]**
Malcolm B Gillies, Filippo Galgani, Guy Tsafnat, Adam Dunn, Nancy Huang, Margaret Williamson. (Australia)
- 85 Evaluation of General Public Perceptions Towards Adverse Drug Reactions Reporting [519]**
Mohammed Ahmed Alshakka, Mohamed Izham Mohamed Ibrahim, Mohamed Azmi Ahmed Hassali. (Malaysia)
- 86 Cellulitis Reported to the Canadian Adverse Events Following Immunization Surveillance System (1987-2012) [520]**
Barbara Law, Julie Lafleche. (Canada)
- 87 Reductions in Fatalities Following Introduction of a Reformulated Opioid with Abuse-Deterrent Properties [521]**
Nelson E Sessler, Jared M Downing, Hrishikesh P Kale, Barbara Harding, Howard D Chilcoat, Todd F Baumgartner, Paul M Coplan. (United States)
- 88 Risk Minimization Plans in Developing Countries: A Cross Sectional Survey of Isotretinoin Use in Saudi Arabia [522]**
Adel A Alrwisan, Thamir M Alshammari, Hisham S Aljadhey. (Saudi Arabia)
- 89 The Impact of Pharmacist-Led Educational Interventions on the Use of High-Risk Abbreviations in a Saudi Arabian Hospital and Emergency Centers [524]**
Abdul Haseeb, Win W Watjana, AbdulRahman Bakhs, Alaa A Mously, Rasha A Almubarak, Asmaa Z Gadibalban, Bashayir F Al-Ibrahim, Rawan A Ikram. (Saudi Arabia)
- 90 Development of a Clinical Prediction Model for an INR \geq 4.5 in Hospitalized Patients Treated with Vitamin K Antagonists [525]**
Anouk D Lindemans, Nico JC van Blijderveen, Marieke JHA Kruij, Miriam CJM Sturkenboom, Arnold G Vulto, Yvonne Vergouwe, Patricia MLA van den Bemt. (Netherlands)
- 91 Diabetes Screening of Adults Receiving Anti-psychotics: A U.S. State Survey of Prescribers [526]**
Elaine H Morrato, Elizabeth J Campagna, Eva Dibert, Joseph Parks. (United States)
- 92 Adoption of a Clinical Checklist as a Risk Minimization Tool in China [527]**
Meredith Y Smith, Ning Wang. (United States)
- 93 Characterization and Factors Associated with Post-Transplant Headaches: A Retrospective Survey Study [528]**
Ying Xia, Elizabeth Costea, Boyang Bian, Carolyn Dosen, Gautham Mogilishetty, Jill Boone, Jeff Guo. (United States)
- 94 Attitudes and Beliefs on the Use of Non-Prescription Medicines in Singapore [529]**
Yong Bing Ng, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 95 Methods To Evaluate Additional Risk Minimization Measures: A Systematic Review [531]**
Inge M Zomerdijk, Kelly Mentink, Christine C Gispen-de Wied, Miriam CJM Sturkenboom, Sabine MJM Straus. (Netherlands)

Database SIG

- 96 Drospirenone and Risk for Venous Thromboembolism; a Comparison by Dosage of Ethinyl-Estradiol [532]**
Steven T Bird, James M Brophy, Mahyar Etminan, Joseph AC Delaney, Abraham G Hartzema. (United States)
- 97 Fluoroquinolones and Risk for Acute Kidney Injury [533]**
Steven T Bird, Mahyar Etminan, James M Brophy, Abraham G Hartzema, Joseph AC Delaney. (United States)
- 98 Need for Collaborative International Vaccine Benefit-Risk Studies in Low-Income Countries: A Pilot Project [534]**
Daniel Weibel, Caitlin Dodd, Steve Black, Hector Izurieta, Osman Sankoh, Kayla Laserson, Robert Chen, Esperanca Sevens, Abraham Odoro, Jan Bonhoeffer, Miriam CJM Sturkenboom. (Netherlands)

Tuesday, August 27
POSTER SESSION B

- 100 Creating Treatment Episodes for Biologic Medications from Pharmacy and Medical Claims [536]**
 Kathy Hardis Fraeman, Dena Ramey, Vinay Mehta, Stephan Lanes. (United States)
- 101 Use of the French Claims and Hospitalisations Database To Estimate the Prevalence and Incidence of Parkinson's Disease in France [537]**
 Patrick Blin, Caroline Dureau, Adeline Grolleau, Emmanuel Corbillon, Jérémy Jové, Régis Lassalle, Nathalie Poutignat, Alexandra Foubert-Samier, Cécile Droz, Nicholas Moore. (France)
- 102 Audit of the Effect of Relative Age on Morbidity among Children in the Health Improvement Network (THIN) UK Data [538]**
 Michelle Johnson, Piers Mook, Mary Thompson, Alison Bourke. (United Kingdom)
- 103 Chronic Hepatitis B Virus Infection among U.S. Medicaid Enrollees, 2000-2007 [539]**
 Dana D Byrne, Craig W Newcomb, Dena M Carbonari, Melissa S Nezamzadeh, Kimberly BF Leidl, Maximilian M Herlim, Yu-Xiao Yang, Sean Hennessy, Jay R Kostman, Mary B Leonard, Russell Localio, Vincent Lo Re III. (United States)
- 104 Seizure and Associated Factors in Patients with Different Types of Dementia [540]**
 Yingkai Cheng, Paula T Trzepacz, Curtis Chang, Ann Marie Hake, Eric R Siemers. (United States)
- 106 Diabetes as a Risk Factor for Herpes Zoster: Results of an Insurance Claims Database Study in the United States [543]**
 Adrienne P Guignard, Michael Greenberg, Chao Lu, Dominique Rosillon, Vani Vannappagari. (Belgium)
- 107 Profile of Patients with Gastric Cancer in the US Using Administrative Claims Data [544]**
 C Hirst, J Ryan, O Tunceli, B Wu, DM Kern. (United Kingdom)
- 108 Posterior Reversible Encephalopathy Syndrome in the IMS Oncology Database: Case Definition, Epidemiology, and Patient Profile [545]**
 Cinira Lefevre, Dale Quentin Marmaduke, Rohit Noghnan, Ben Cheng, Hugo Xavier, Yu Yan. (United Kingdom)
- 109 Prevalence of Depression in Patients with Type 2 Diabetes in Quebec: A Population-Based Cohort Study [546]**
 Carlotta Lunghi, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
- 110 Agreement between Claims and Electronic Medical Records Data for CHF in Inpatients [547]**
 Marc Rosenman, Jinghua He, Joel Martin, Kavitha Nutakki, Irmina Gradus-Pizlo, Siu L Hui. (United States)
- 111 Database Queries for Hospitalizations for Acute CHF: Flexible Methods and Validation Based on Set Theory [548]**
 Marc Rosenman, Jinghua He, Joel Martin, Kavitha Nutakki, George Eckert, Kathleen Lane, Irmina Gradus-Pizlo, Siu L Hui. (United States)
- 112 Prevalence and Incidence of Idiopathic Pulmonary Fibrosis in UK Healthcare Databases, GPRD and THIN; Need for an IPF Registry [549]**
 Paula L Thompson, Stephanie Chretien, Francoise Bugnard, William C Maier, Rory Cameron, Mark Fisher, Christophe Giot, Christian Hill, Imran Kausar. (United Kingdom)
- 113 Incidence, Co-Morbidities, and Risk Factors of Age-Related Macular Degeneration [550]**
 Zdravko P Vassilev, Luis A García-Rodríguez, Montse Soriano-Gabarró, Ana Ruigomez. (United States)
- 114 The Epidemiology of Herpes Zoster (HZ) and Its Complications in Medicare Cancer Patients [551]**
 Mihran A Yenikomshian, Ann S LaCasce, Arthur T Skarin, Alex Trahey, Adrienne Guignard, François F Haguinet, Paul E Karner, Mei S Duh. (United States)
- 115 Benzodiazepine Use and Risk of Dementia: A Case Control Study Using the Quebec Claims Database [552]**
 Sophie Billioti de Gage, Yola Moride, Thierry Ducruet, Tobias Kurth, Helene Verdoux, Karine Peres, Antoine Pariente, Bernard Begaud. (France)
- 116 Validation of the National Health Insurance Research Database in Taiwan with Acute Myocardial Infarction Cases [553]**
 Ching-Lan Cheng, Cheng-Han Lee, Po-Sheng Chen, Yi-Heng Li, Swu-Jane Lin, Yea-Huei Kao Yang. (Taiwan)
- 117 Adverse Events of Ribavirin Plus Pegylated Interferon Combination Therapy for Hepatitis C Patients in Taiwan: A Population-Based Study [554]**
 Yu-Tseng Chu, Chun-Jen Liu, Wen-Yi Shau, Chi-Shin Wu, Yaa-Hui Dong, Raymond NC Kuo, Chiu-Ling Lai, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 118 Characteristics of Initiators of Asthma Maintenance Medications in 10 Health Care Populations [555]**
 Catherine B Johannes, Lisa J McQuay, Patricia Tennis, Carlos A Camargo, Jr., Michael Schatz, Kirk D Midkiff, Stephan Lanes, Rachael DiSantostefano, Kourtney J Davis. (United States)
- 119 Using Automated Healthcare Databases To Study Insomnia in Real World [556]**
 Zhiwen Liu, William Joseph Herring, Cynthia Silber, Edward A Bortnichak, Weifeng Xu, Jay D Pearson. (United States)
- 120 Risk of Upper Gastrointestinal Bleeding with Cyclo-Oxygenase-2 Inhibitors and Nonselective NSAIDs Plus Gastroprotective Agents: What To Prefer? [557]**
 Gwen MC Masclee, Vera E Valkhoff, Eva M van Soest, R Schade, Giampiero Mazzaglia, Mariam Molokhia, Gianluca Trifiro, Jay L Goldstein, Sonia Hernández-Díaz, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)
- 121 Harmonization of Diagnoses for Acute Pancreatitis Identification from Different Databases in the SAFEGUARD Project [558]**
 Gwen MC Masclee, Silvana Romio, Ingrid A Leal, Giorgia De Berardis, Irene Bezeemer, Miguel Gil, Elisa Martín, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Miriam CJM Sturkenboom. (Netherlands)
- 122 Harmonization of Acute Myocardial Infarction Identification from Different Databases in the SAFEGUARD Project [559]**
 Gwen MC Masclee, Miriam CJM Sturkenboom, Ingrid A Leal, Giorgia De Berardis, Irene Bezeemer, Miguel Gil, Elisa Martín, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Silvana Romio. (Netherlands)
- 123 The Effect of Daily Dose of Individual NSAIDs on the Risk of HF in the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project [560]**
 Federica Nicotra, Andrea Arfè, Antonella Zambon, Tania Schink, Bianca Kollhorst, Huub Straatman, Ron Herings, Miriam Sturkenboom, Giovanni Corrao. (Italy)
- 124 Use of Glucocorticoids and 30-Day Mortality after Colorectal Cancer Surgery; a Nationwide Cohort Study in Denmark [561]**
 Eva B Ostenfeld, Anders H Riis, Ole Thorlacius-Ussing, Rune Erichsen, Henrik T Sørensen. (Denmark)
- 125 Validation of Hospital Discharge Diagnoses and Laboratory Measurements To Identify Patients with Idiopathic Acute Liver Injury [564]**
 Renate Udo, Anke-Hilse Maitland-van der Zee, Toine CG Egberts, Hubert GM Leufkens, Wouter W van Solinge, Marie L De Bruin. (Netherlands)
- 126 A Cohort Analysis To Measure the Effect of Orlistat or Bariatric Surgery on Weight and Body Mass Index in a General UK Population Sample [565]**
 Ian J Douglas, Krishnan Bhaskaran, Liam Smeeth. (United Kingdom)
- 127 Antidepressant Prescribing in Five European Countries: Application of Common Methods To Assess the Variation in Prevalence [566]**
 V Abbing-Karahagopian, C Huerta, PC Souverein, F de Abajo, HGM Leufkens, J Slattery, Y Alvarez, M Montserrat, M Gil, U Hesse, G Requena, F de Vries, M Rottenkolber, S Schmiedl, R Reynolds, R Schlinger, M de Groot, OH Klungel, TP van Staa, L van Dijk, ACG Egberts, H Gardarsdottir, ML De Bruin. (Netherlands)

Tuesday, August 27
POSTER SESSION B

128 Is the CPRD GOLD Population Comparable to the U.K. Population? [567]

Jennifer Campbell, Daniel J Dedman, Susan C Eaton, Arlene M Gallagher, Tim J Williams. (United Kingdom)

129 Effects of Glargine in Patients with Type 1 Diabetes in Belo Horizonte, Brasil [568]

Ana Luísa Caires de Souza, Francisco Assis Acurcio, Augusto Afonso Guerra, Júnior, Renata Cristina Rezende Macedo do Nascimento, Leonardo Maurício Diniz. (Brazil)

130 Translating Prescribing Data into Practice – Down Under [569]

Nancy PT Huang, Margaret Williamson, Reital Minogue. (Australia)

131 Times Trends in Antihypertensive Drug Use and Hypertension in Cohort Database 2005-2009 of Employees of Oil and Gas Mining in East Kalimantan, Indonesia [570]

Iwan Dwiprahasto, Erna Kristin, Dwi Indria Anggraini. (Indonesia)

132 Utilisation Patterns of Inhaled Corticosteroids in Patients with Asthma: A Study Using the UK Clinical Practice Research Datalink (CPRD) [571]

Alison L Nightingale, Julia Snowball, Rachel A Charlton, Corinne S de Vries. (United Kingdom)

133 Anticholinergic Load as a Modifiable Risk Factor of Sitter Use in Acute Care Hospitals [572]

Ariane Lessard, Anne-Marie Charbonneau-Allard, Fluet Jessicat, Christian M Rochefort, Robyn M Tamblin, Louise Mallet. (Canada)

134 Use of Antidepressant Drugs among Diabetic Population: A Prescription Sequence Symmetry Analysis [573]

Muhammad Saeed, Max Petzold, Morten Andersen, Anders Carlsen. (Sweden)

135 Therapeutic Consequences of Dextropropoxyphene Withdrawal in France [574]

Cheikh Tamberou, Catherine Cornu, Emilie Chretien, Laurent Letrilliart, François Gueyffier, Laurent Laforest, Elodie Chaissac, Eric Van Ganse, Comité Douleur-Anesthésie loco-Régionale French Society of Anesthesia and Intensive Care, Frederic Aubrun. (France)

136 Changes in Therapeutic Management of COPD between 2006 and 2001: French Claims Data [575]

Laurent Laforest, Cheikh Tamberou, Marine Ginoux, Chu-Philippe Ya, Gilles Devouassoux, Nicolas Roche, Cristos Chouaid, Eric Van Ganse. (France)

137 Comparison of Six Electronic Healthcare Databases in Europe Using Standardized Protocols: A Descriptive Study on the Incidence of Cancer [576]

Ana S Afonso, Mark CH De Groot, Rianne Van den Ham, Marie L Bruin, Consuelo Huerta Alvarez, Miguel Gil, Ulrik Hesse, Pernille F Rønn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Liset Van Dijk, Raymond

G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda. (Netherlands)

138 Identifying Drug-Safety Signals in Electronic Health Records: An Evaluation of Automated Case-Detection Algorithms with Different Sensitivity and Specificity [577]

Zubair Afzal, Jan A Kors, Miriam C Sturkenboom, Martijn J Schuemie. (Netherlands)

139 Standard Method for Assessment of Electronic Health Record (EHR) Data Sources for Pharmacoepidemiology [578]

Stephen OT Agbor, Allise G Kamauu, Aaron WC Kamauu. (United States)

140 Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis [579]

Marloes T Bazelier, Frank de Vries, Peter Vestergaard, Ron MC Herings, Arlene M Gallagher, Hubert GM Leufkens, Tjeerd-Pieter van Staa. (Netherlands)

141 Validity of the Duration of Inhaled Corticosteroid Prescription and the Number of Allowed Refills Recorded in Québec Databases [581]

Lucie Blais, Anne Vilain, Fatima-Zohra Kettani, Amélie Forget, Geneviève Lalonde, Marie-France Beauchesne, Francine Ducharme, Catherine Lemièrre. (Canada)

142 A New Method To Get Fast Patient Reported Outcomes Data from Primary Care in the UK for Patients with Atrial Fibrillation (AF) in the Health Improvement Network (THIN) [582]

Michelle Johnson, Delphine Vial, Mary Thompson, Claire Cockbain, Simon Hogan, Alison Bourke. (United Kingdom)

143 Methods to Link a U.S Arthritis Cohort with Medicare Administrative Claims Data [583]

Lang Chen, Timothy Beukelman, Aseem Bharat, Fenglong Xie, Kenneth G Saag, Elizabeth S Delzell, Jeffrey R Curtis. (United States)

144 Antiepileptic Drug Use in Seven Electronic Health Record Databases in Europe: A Methodological Comparison [585]

Mark CH De Groot, Markus Schuerch, Frank De Vries, Ulrik Hesse, Belén Oliva, Consuelo Huerta Alvarez, Miguel Gil, Gema Requena, Francisco Abajo, Ana Afonso, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel. (Netherlands)

145 Comparison of Seven Electronic Healthcare Databases in EU Countries Using a Standardized Methodology; a Descriptive Study on the Exposure to Calcium-Channel Blockers (CCBs) [586]

Mark CH de Groot, Rianne Van den Ham, Marieke De Bruin, Consuelo Huerta Alvarez, Miguel Gil, Ana Afonso, Gema Requena, Ulrik Hesse, Pernille Falberg Rønn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda. (Netherlands)

146 Estimating Time-Specific Propensity Scores: A Case Study of the Effectiveness of Inhaled Long-Acting Beta-Agonists on Asthma Exacerbations [587]

Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk, Glen T Schumock, Todd A Lee. (Thailand)

147 Development and Validation of a Claims-Based Algorithm To Identify Urinary Retention in Patients Receiving Antiepileptic Drugs [588]

Mei Sheng Duh, Lianna Ishihara, Wendy Cheng, Scott C Quinlan, Yueqin Zhao, Michael Irizarry. (United States)

148 Determining Multiple Sclerosis Subtype from Electronic Medical Records [589]

Scott L DuVall, Jorie Butler, Joanne LaFleur, Aaron WC Kamauu, Markus Schuerch, Nadia Foskett, Richard E Nelson. (United States)

149 Characterization of Patients with ANCA-Associated Vasculitis by Subtype in the Veterans Affairs Database [590]

Scott L DuVall, Aaron WC Kamauu, Stephen OT Agbor, Tmirah Haselkorn, Pavel Napalkov, Iain D Tatt, Curry L Koening. (United States)

150 Analyzing Database Studies with Many Outcomes or Co-Morbidities: Using SAS® to Dynamically Generate Analytic Programs from Case Definitions Stored in Excel® [591]

Kathy Hardis Fraeman, Dena Ramey, Vinay Mehta, Stephan Lanes. (United States)

151 Study Designs in Pharmacoepidemiologic Studies on Electronic Healthcare Databases: A Systematic Review [592]

Nathalie Gault, Stéphanie Foulon, Sylvie Guillo, Florence Tubach. (France)

152 Potential for Early Pharmacoepidemiologic Studies and Monitoring Intake of a Biologic Treatment Using an Electronic Health Records Database Prior to Assigned J-Code [593]

Aaron WC Kamauu, Stephen Agbor, Emily Dastrup, Scott L DuVall, Debra Maldonato, Pavel Napalkov. (United States)

153 Utilization of New Diagnosis Codes for Basal Cell Carcinoma in 2 Large Nationwide EHR Databases [594]

Aaron WC Kamauu, Emily Dastrup, Yeun Mi Yim, Scott L DuVall. (United States)

154 Development and Validation of an Acute Liver Failure (ALF) Risk Prediction Model for Patients with Drug-Induced Hepatitis (DIH) [597]

Vincent Lo Re III, Kevin Haynes, James D Lewis, Dena M Carbonari, Kimberly BF Leidl, Kimberly A Forde, David Goldberg, Melissa S Nezamzadeh, K Rajender Reddy, Jason Roy, Daohang Sha, Amy R Marks, Jolanda De Boer, Brian L Strom, Douglas A Corley. (United States)

Tuesday, August 27
POSTER SESSION B

- 155 Validity of Diagnostic Codes To Identify Cases of Severe Acute Liver Injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database [598]**
Vincent Lo Re III, Kevin Haynes, David Goldberg, Kimberly A Forde, Dena M Carbonari, Kimberly BF Leidl, Sean Hennessy, Rajender Reddy, Pamala A Pawloski, Gregory W Daniel, T Craig Cheetham, Aarthi Iyer, Kara O Coughlin, Sengwee Toh, Denise M Boudreau, William O Cooper, Nandini Selvam, Mano S Selvan, Jeffrey J VanWormer, Mark I Avigan, Monika Houstoun, Gwen L Zornberg, Judith A Racosin, Azadeh Shoabi. (United States)
- 156 Developing Acute Coronary Syndrome Disease Cohorts Using Primary and Secondary Care Database Linkages [599]**
Robert N Lubwama, Cathy A Pinto. (United States)
- 157 Distinguishing Incident and Prevalent Diabetes in an Electronic Medical Record Database [600]**
Ronac Mamtani, Brian S Finkelman, Kevin Haynes, Frank I Scott, James D Lewis. (United States)
- 158 A Novel Process for the Identification, Development and Assessment of Database Coding Algorithms for 5 Psychiatric Conditions [601]**
Vinay Mehta, Melissa Whipple, Natalie Jones, Juliana Lewis, Edward Bortnichak, Matthew Reynolds. (United States)
- 159 A Novel Process for the Identification, Development and Assessment of Database Coding Algorithms for 6 Cardiovascular Conditions [602]**
Vinay Mehta, Melissa Whipple, Natalie Jones, Juliana Lewis, Edward Bortnichak, Matthew Reynolds. (United States)
- 160 Identifying Causes of Death in a Large Cohort of Asthma Patients [603]**
Kirk D Midkiff, Catherine Johannes, Patricia Tennis, Brian Calingaert, Lisa J McQuay, David Harris, Elizabeth B Andrews. (United States)
- 161 Decision Rules for Microbiologically-Evaluable Complicated Urinary Tract Infection in an Electronic Medical Record-Linked Administrative Database [604]**
Fanny Mitrani-Gold, Nittaya Suppapanya, Linda M Mundy. (United States)
- 162 An Assessment of How the Outputs from Signal Detection Can Be Affected by Variation of Database Profile by Analysing Adverse Events Reports of FDA and PMDA Received in 2010 [605]**
Kaori Nomura, Kunihiko Takahashi, Yasushi Hinomura, Genta Kawaguchi, Yasuyuki Matsushita, Hiroko Marui, Tatsuhiko Anzai, Masayuki Hashiguchi, Mayumi Mochizuki. (Japan)
- 163 Validation of a Multiple Myeloma Algorithm in Administrative Data [606]**
Susan Oliveria, Nancy Brandenburg, Syd Phillips, Karen Wells, Kimberley J Woodcroft, Marianne Ulcickas Yood. (United States)
- 164 Multiple Imputation of Missing Data in Longitudinal Electronic Health Records [607]**
Irene Petersen, Catherine Welch, Jonathan Bartlett, Richard Morris, Kate Walters, Irwin Nazareth, Louise Marston, Ian White, James Carpenter. (United Kingdom)
- 165 Projection Methods Using Oncology Electronic Health Records To Produce Nationally Representative Estimates [608]**
David Quach, Alexander Liede, Serapio Byekwaso, Daria Eremina, Bruce S Kossar, Li Zhou, Jane M Quigley, Joel Kallich, John Adams, Paul Smith. (United States)
- 166 The Identification of Incident Cancers in UK Primary Care Databases: A Systematic Review [609]**
Michael E Rañopa, Ian Douglas, Tjeerd van Staa, Liam Smeeth, Krishnan Bhaskaran. (United Kingdom)
- 167 A Remote Research Environment for Collaborative Drug Safety Studies: The OCTOPUS Infrastructure [610]**
Peter R Rijnbeek, Johan van der Lei, Miriam CJM Sturkenboom. (Netherlands)
- 168 Time Trends in Prevalence of Inhaled Long-Acting beta-2-Adrenoceptor Agonist Prescribing – A Comparison of Seven European Electronic Health Record Databases [611]**
Marietta Rottenkolber, Eef Voogd, Liset van Dijk, Paola Primatesta, Raymond G Schlienger, Mark CH de Groot, Estel Plana Hortonedá, Yolanda Alvarez, Julie Durand, Jim Slattery, Ana S Afonso, Gema Requena, Miguel Gil, Consuelo Huerta, Arturo Alvarez, Francisco de Abajo, Ulrik Hesse, Rainald Fischer, Joerg Hasford, Roman Gerlach, Martin Tauscher, Robert Reynolds, Olaf H Klungel, Sven Schmiedl. (Germany)
- 169 A Detection Algorithm for Statin-Induced Myopathy Using Electronic Medical Records [612]**
Kimie Sai, Tadaaki Hanatani, Yuichiro Azuma, Katsunori Segawa, Masahiro Tohkin, Hideaki Omatsu, Hiroo Makimoto, Midori Hirai, Yoshiro Saito. (Japan)
- 170 Test Data in General Practice Are Not Missing at Random – Can We Identify When They Are? [613]**
Cormac J Sammon, Alison L Nightingale, Anne Miller, Kamal R Mahtani, Tim A Holt, Neil McHugh, Raashid A Luqmani, Corinne S de Vries. (United Kingdom)
- 171 Harmonisation of Event Definitions across Electronic Healthcare Databases; Pancreatic and Bladder Cancer as a Case Study [614]**
Cormac J Sammon, Georgia De Berardis, Antonio Nicolucci, Irene Bezemer, Gema Requena, Miguel Gil, Elisa Martin, Ingrid Leal, Gwen MC Masclee, Giampiero Mazzaglia, Peter Rijnbeek, Silvana Romio, Niklas Schmedt, Lorenza Scotti, John D Seeger, Mark Smits, Cristina Aras-Lorenzo, Miriam CJM Sturkenboom, Corinne de Vries. (United Kingdom)
- 172 Validation of Mortality Information in the German Pharmacoepidemiological Research Database (GePaRD) [615]**
Christoph Ohlmeier, Niklas Schmedt, Kathrin Hillebrand, Ingo Langner, Rafael Tadeusz Mikolajczyk, Edeltraut Garbe. (Germany)
- 173 Harmonization of Outcome Extraction for Ischemic and Hemorrhagic Stroke across Data Sources in the SAFEGUARD Project [616]**
Niklas Schmedt, Miguel Gil, Elisa Martin, Gema Requena, Irene Bezemer, Giorgia De Berardis, Corine de Vries, Ingrid Leal, Gwen Masclee, Giampiero Mazzaglia, Peter Rijnbeek, Silvana Romio, Cormac Sammon, Lorenza Scotti, John Seeger, Mark Smits, Tania Schink, Christina Varas-Lorenzo, Miriam Sturkenboom, Edeltraut Garbe. (Germany)
- 174 Identification of Seizures among Adults and Children Following Influenza Vaccination Using Health Insurance Claims Data [617]**
Veena Thyagarajan, Sue Su, Julianne Gee, Jonathan Duffy, Natalie L McCarthy, K Arnold Chan, Eric Weintraub, Nancy D Lin. (United States)
- 175 When Follow-Up Time Cannot Be Assigned: Chronic Kidney Disease and It's Diagnosis [618]**
Jan C van Blijderveen, Sabine M Straus, Miriam C Sturkenboom, Bruno C Stricker, Katia M Verhamme. (Netherlands)
- 176 Spending with Infliximab Versus Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis Treatment in SUS, from 2003 to 2006 [619]**
Juliana O Costa, Augusto AG Júnio, Alessandra M Almeida, Mariangela L Cherciglija, Eli Iola G Andrade, Francisco A Acurcio/ Research Group in Pharmacoepidemiology. (Brazil)
- 177 Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study [620]**
Tony Antoniou, Hong Zheng, Samantha Singh, David N Juurlink, Muhammad M Mamdani, Tara Gomes. (Canada)
- 178 Assessing the Completeness and Quality of Saudi Adverse Event Reporting System (SAERS) [621]**
Wa'ad H Alkathiri, Thamir M Alshammari, Hisham S Aljadhey. (Saudi Arabia)
- 179 Strengthening Pharmacovigilance Capabilities in Canada by Using MedDRA Coding and Medical Case Review in Parallel To Classify Reports of Adverse Events Following Immunization Received by the Public Health Agency of Canada [622]**
Julie Laflièche, Helen Anyoti, Barbara Law. (Canada)
- 180 Evaluation of a Standardised MedDRA Query (SMQ) in Administrative and Electronic Medical Record (EMR) Databases [623]**
Brian Dreyfus, Jasmine Marwaha, Allison Lee. (United States)

Tuesday, August 27
POSTER SESSION B

- 181 Risk Identification in Healthcare Records - Comparison to Epidemiological Studies [624]**
 I Ralph Edwards, Ghazaleh Karimi, Tomas Bergvall, Ola Caster, Alex Asiimwe, Kristina Star, Fatima Bhayat, Montse Soriano-Gabarro, Bharat Thakrar, Mary Thompson, Andrew Bate, G Niklas Norén. (Sweden)
- 182 Safety Signal Surveillance Study of Adverse Events of Special Interest for Intradermal Influenza Vaccine Using THIN Database [625]**
 Shujun Gao, Catherine A Panozzo, Larissa Mege, Marie Miossec, Alena Khromava. (United States)
- 184 Positive Predictive Value of ICD-10 Discharge Diagnoses of Infection among Cancer Patients in Denmark [628]**
 Louise Holland-Bill, Hairong Xu, Henrik T Sorensen, John Acquavella, Claus Sværke, Henrik Gammelager, Vera Ehrenstein. (Denmark)
- 185 Incidence of Opioid Intoxications in Patients with or without Alcohol Related Disorders Treated with High-Potency Opioid Analgesics in 2004-2009 [629]**
 Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)
- 186 Quantitative Analysis of Gender Based Risk in Macrolide-Related QT Prolongation and Cardiovascular Events [630]**
 Jung E Lee, Samina Qureshi. (United States)
- 187 Influence of Computing Power for Time-Dependent Analysis in Large Cohorts Using SAS [631]**
 Lewis McConnachie, David A Rorie, Rob Flynn, Tom M MacDonald, Isla S Mackenzie, Adrian Hapca, Jonathan Monk, Aaron Hoolachan. (United Kingdom)
- 188 Adverse Drug Reaction Reports of Patients and Healthcare Professionals; How Different Are They? [632]**
 Leàn Rolfes, Florence van Hunsel, Eugène van Puijtenbroek, Kees van Grootheest. (Netherlands)
- 189 Hallucinations: A Case/Noncase Study in the French Pharmacovigilance Database [633]**
 Malak Abou Taam, Paul De Boissieu, Sylvain Dukic, Emmanuelle Herlem, Thierry Trenque. (France)
- 190 Leveraging Multiple EHR Databases in Parallel as an Innovative Means for Active Postmarketing Hepatotoxicity Monitoring in Oncology Patients [634]**
 Sumitra Shantakumar, Susan A Hall, Beth Nordstrom, Kristen Snow, Elizabeth Lawler, Irene Bezemer, Jeanette J Nelson. (United States)
- 191 Incidence of Cardiovascular Events in the Real World Population of Cancer Patients with Solid Tumors [635]**
 Jonathan G Zaroff, Douglas A Corley, Wei K Zhao, Lina Titievsky. (United States)
- 192 Cause of Death Recording in the Health Improvement Network (THIN) UK Data among the Afloat Study Population (n=56508) [636]**
 Michelle Johnson, Mary Thompson, Piers Mook, Simon Hogan, Alison Bourke. (United Kingdom)

- 193 Data Elements in Inpatient Databases to Enhance Safety & Health Outcomes Research [637]**
 Anokhi J Kapasi, Sharmila A Kamani, Bao Nguyen-Khoa, Judith K Jones. (United States)
- 194 Prevalence, Selected Co-Morbidities and Systemic Therapies in a U.S. Population-Based Cutaneous Psoriasis Cohort [638]**
 Hoa V Le, Chi T Truong, Julie Priest, Carlyne Averell, Joe Eastman, Martin Crane. (United States)
- 195 The Risk of Tetrazepam To Induce Severe Cutaneous Adverse Reactions [639]**
 Maja Mockenhaupt, Peggy Sekula, Benedicte Lebrun-Vignes, Jean-Claude Roujeau. (Germany)
- 196 Total Mortality Rates across Multiple Databases: Benchmarking Results from a Distributed Data Network - The SAFEGUARD Project [640]**
 John D Seeger, Silvana Romio, Cristina Varas-Lorenzo, Lorenza Scotti, Andrea Arfè, Antonella Zambon, Miguel Gil, Gema Requena, Irene Bezemer, Georgia De Berardis, Corinne DeVries, Ingrid Leal, Gwen Masclee, Gianluca Trifiró, Peter Rijnbeek, Cormac Sammon, Niklas Schmedt, Mark Smits, Giovanni Corrao, Miriam Sturkenboom. (United States)

Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG

- 197 Evaluation of the Effect of SNPs in CYP3A4 and CYP4F2 on the Stable Phenprocoumon and Acenocoumarol Maintenance Dose [654]**
 Rianne van Schie, Judith Wessels, Amin Aousar, Talitha Verhoef, Tom Schalekamp, Saskia le Cessie, Felix van der Meer, Frits Rosendaal, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 198 Pharmacogenomics in Primary Care: Expanding Our Understanding with Deliberations [643]**
 Gillian Bartlett, Cristina Longo, Annyck Besso, Brenda MacGibbon, Martin Dawes. (Canada)
- 199 CARING: Tumour Characteristics of Diabetic and Non-Diabetic Breast Cancer Patients [644]**
 Heleen K Bronsveld, Peter Vestergaard, Vibeke Jensen, Jakob Starup Linde, Sten Cornelissen, Peer Christensen, Marie L De Bruin, Marjanka K Schmidt. (Netherlands)
- 200 Interactions of Human Papillomavirus and Host Genetic Polymorphisms in Carcinogenesis: A Systematic Review and Meta-Analysis [646]**
 Steven Habbous, Vincent Pang, Lawson Eng, Eitan Amir, Geoffrey Liu. (Canada)
- 201 Breast and Colorectal Cancer Patients Decision Making for Pharmacogenomic Diagnostics [647]**
 Amalia M Issa, Waqas Tufail, Nelson Atehortua, Jose Tenorio. (United States)
- 202 Racial Differences Affect Patients Willingness in Providing Additional Biospecimens for Pharmacogenomic Testing [649]**
 Tenneille T Loo, Sinead Cuffe, Henrique Hon, Petra Martin, M Catherine Brown, Shabbir Alibhai, Xin Qiu, Wei Xu, Geoffrey Liu. (Canada)

- 203 Effect of BRM Promoter Polymorphisms on Survival Outcomes of Platinum-Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients [651]**
 Sinead Cuffe, Lu Cheng, Abul Kalam Azad, Yonathan Brhane, Dangxiao Cheng, Zhuo Chen, Xiaoping Qiu, Kevin Boyd, Wei Xu, Frances A Shepherd, Ming-Sound Tsao, David Reisman, Geoffrey Liu. (Canada)
- 204 Polymorphisms of Organic Cation Transporter1 (OCT1) in Indonesian Cancer Patients [652]**
 Dyah Aryani Perwitasari, Jarir Atthohari. (Indonesia)
- 205 The Opportunities and Challenges of Generating Evidence on Medical Device Associated Biomarkers and Implementing the Biomarker-Based Regulatory Research Applications [653]**
 Yelizaveta Torosyan, Danica Marinac-Dabic. (United States)
- 206 Influence of Genetic and Non-Genetic Factors on the Plasma Concentrations of the Clopidogrel Metabolite (SR26334) among Chinese Patients [656]**
 Haoming Zhou, Shu Meng, Jun Zhao, Junfen Xin, Weimin Cai. (China)
- 207 Beat-to-Beat Variability of the QT Interval: A Systematic Review [658]**
 Maartje N Niemeijer, Marten E van den Berg, Mark Eijgelsheim, Jan A Kors, Bruno H Stricker, Peter Rijnbeek. (Netherlands)

Pediatrics SIG

- 208 Latrogenic Aluminum and General Intelligence of Moroccan Children [659]**
 F-Z Azzaoui, M El Hioui, S Boulbaroud, A Ahami. (Morocco)
- 209 Exploration of Defined Daily Dose and Days of Therapy in Paediatrics and ob-gyn – A Descriptive Analysis of Antifungals [660]**
 Justine Guillot, Hélène Roy, Denis Lebel, Philippe Ovetchkine, Jean-François Bussièrès. (Canada)
- 210 Comorbid Conditions and Drug Utilization of Pediatric-Onset Multiple Sclerosis Patients in a Large US Health-Claims Database [696]**
 Made Wenten, Gary Bloomgren, Jin Wang, Anne Dilley. (United States)
- 211 Exploration of Defined Daily Dose and Days of Therapy in Paediatrics and ob-gyn – A Descriptive Analysis of Antivirals [661]**
 Justine Guillot, Hélène Roy, Philippe Ovetchkine, Denis Lebel, Jean-Francois Bussièrès. (Canada)
- 212 Obesity and Metabolic Abnormalities in Antipsychotic Exposed Youth [663]**
 Robert B Christian, Asheley C Skinner, Kathleen Moran, Joel F Farley, Jerry Mckee, Trista Pfeiffenberg, Troy Trygstad, Steve Wegner, Brian C Sheitman. (United States)

Tuesday, August 27
POSTER SESSION B

- 213 Analgesic and Psychiatric Co-Medication in Commercially Insured Pediatric Inflammatory Bowel Disease Patients [664]**
 Jessie P Buckley, Michael D Kappelman, Jeffery K Allen, Bhavani Muppidi, Susan A VanMeter, Suzanne F Cook. (United States)
- 214 Increasing Utilization of Proton Pump Inhibitors in Children: A Cohort Study in 3 European Countries [666]**
 Sandra de Bie, Katia MC Verhamme, Miguel Gil Garcia, Gino Picelli, Sabine MJM Straus, Belen Oliva, Mariagrazia Felisi, Bruno HC Stricker, Francisco J de Abajo, Miriam CJM Sturkenboom. (Netherlands)
- 215 Pediatric Pharmacoepidemiology Safety Study with Long-Term Use of Sertraline: The SPRITES Study [667]**
 Cynthia de Luise, Francesca Kolitsopoulos, Alejandra E Nieto, John F Curry, John S March. (United States)
- 216 Using PMSI Database To Identify Adverse Drug Reactions in a Pediatric University Hospital [668]**
 Genevieve Durrieu, Arnaud Batz, Emmanuelle Bondon-Guitton, Vanessa Rousseau, Leila Chebane, Dominique Petiot, Jean-Louis Montastruc. (France)
- 217 Teething Symptoms and Their Evolution over Time: Data Collected from Parents [669]**
 Soh la Elkebir, Laurence Terzan, Remi Gauchoux, Anne-Laure Fayard. (France)
- 218 Treatment of Teething Symptoms: Evaluation of Parent's Compliance to Pediatricians Prescriptions [670]**
 Soh la Elkebir, Laurence Terzan, Remi Gauchoux, Anne-Laure Fayard. (France)
- 219 Prescription Patterns and Treatment Adherence of Asthma Controller Therapies in Children in a Dutch Primary Care Database [671]**
 Marjolein Engelkes, Hettie M Janssens, Zubair Afzal, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)
- 220 Prevalence and Patterns of Anti-Infective Medication Use in Children with Type 1 Diabetes Mellitus [672]**
 Soulmaz Fazeli Farsani, Patrick C Souverein, Maria MJ van der Vorst, Catherijne AJ Knibbe, Antonius de Boer. (Netherlands)
- 221 Medication Use and Disease History as Risk Factors for the Clinical Manifestation of Type 1 Diabetes Mellitus [673]**
 Soulmaz Fazeli Farsani, Patrick C Souverein, Maria MJ van der Vorst, Catherijne AJ Knibbe, Antonius de Boer. (Netherlands)
- 222 Demographic and Clinical Characteristics Prior to Clozapine Initiation in Early Onset Schizophrenia: A Study Based on the Danish Population-Based Registers [674]**
 Stephen Papachristou, Carolina Schneider, Christiane Gasse, Theresa Wimberley, Sophia Frangou. (Denmark)
- 223 Maternal Smoking in Early Pregnancy Increases Risk of Childhood Overweight [675]**
 Luke E Grzeskowiak, Nicolette A Hodyl, Michael J Stark, Janna L Morrison, Vicki L Clifton. (Australia)
- 224 2nd Immunization Against Measles, Mumps, Rubella with MMRV, MMR or MMR+V [676]**
 Sabrina Hense, Tania Schink, Edeltraut Garbe. (Germany)
- 225 Trends in Prevalence of Antibacterial Drug Use among Dutch Children from 2005 until 2010 [677]**
 Stephan GL Joosten, Leanne MA Houweling, Fernie JA Penning-van Beest. (Netherlands)
- 226 Characteristics and Determinants of Palivizumab Use in the Netherlands [678]**
 Leanne MA Houweling, Fernie JA Penning-van Beest, Irene D Bezemer, Richard A van Lingen, Ron MC Herings. (Netherlands)
- 227 Trends in Prevalence of Drug Use among Dutch Children from 2005 until 2010 [679]**
 Stephan GL Joosten, Leanne MA Houweling, Fernie JA Penning-van Beest. (Netherlands)
- 228 Prevalence of Childhood Asthma and Asthma-Related Health Services Utilization in the Province of British Columbia, Canada [680]**
 Ricardo Jimenez, TingTing Zhang, Hao Luo, Ran Goldman, Anne Smith, Bruce Carleton. (Canada)
- 229 Misuse of Short Courses of Oral Glucocorticoids in Children: A Prospective Observational Study [682]**
 Marie-Laure Laroche, Emily Bennett, Adelilah Tahir, Vincent Guignonis, Louis Merle. (France)
- 230 Distribution and Development of Co-Morbidities in Pediatric Patients with ADHD [683]**
 Xinyue Liu, Paul Kubilis, Dandan Xu, Regina Bussing, Almut G Winterstein. (United States)
- 231 Influence of Drug Prescription Status in Pediatric Adverse Drug Reaction: Review of Spontaneous Reports Registered to the Pharmacovigilance by a Regional Pharmacovigilance Center [684]**
 Mathieu Maupiler, Charlotte Bezzina, Vanessa Rousseau, Leila Chebane, Emmanuelle Bondon-Guitton, Genevieve Durrieu, Jean Louis Montastruc. (France)
- 232 Antipsychotic Use for Youth with ADHD and Psychiatric Comorbidities [686]**
 Xinyi Ng, Sharmila Das, Annie Guan, Susan dosReis. (United States)
- 233 Medication Administration Errors among Paediatric Nurses in Lagos Public Hospitals: An Opinion Survey [687]**
 Kazeem A Oshikoya, Ibrahim A Oreagba, Olayinka O Ogunleye, Idowu O Senbanjo, GL MacEbong, Sunday O Olayemi. (Nigeria)
- 234 Creating a Reference Set for Comparing Data Mining Methods and Evaluating Database Performance in Children – The GRiP Project [688]**
 Osemeke Osokogu, Federica Fregonese, Daniel Weibel, Katia Verhamme, Mariana Catapano, Sandra De Bie, Miriam Sturkenboom, Carmen Ferrajolo, Preciosa Coloma, Geert 't Jong, Martijn Schuemie, Ian Wong, Yingfen Hsia, Madlen Gazarian, Hide Nakamura. (Netherlands)
- 235 Use of SSRIs among Children: A Danish Drug Use Study [689]**
 Anton Potteg rd, Helga Zo ga, Jesper Hallas, Per Damkier. (Denmark)
- 236 Relative Age in Class and Stimulant Drug Utilization for ADHD [690]**
 Anton Potteg rd, Jesper Hallas, Sonia Hern ndez-D az, Helga Zo ga. (Denmark)
- 237 National Trends in Psychotropic Medications Prescribed for Pediatric Bipolar Disorder with and without Comorbid Behavioral Disorders, 1999-2010 [691]**
 Thiyagu Rajakannan, Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 238 Pediatric Exclusivity: Evolving Legislation and Novel Complexities within Pediatric Therapeutic Development [692]**
 Donna R Rivera, Abraham G Hartzema. (United States)
- 239 Automated Information Retrieval for Constructing Evidence-Based Pediatric Formularies [693]**
 Bharat Singh, Gina Ayala, Peter R Rijnbeek, Erik M van Mulligen, Jan A Kors, Miriam CJM Sturkenboom. (Netherlands)
- 240 Results from a Novel and Proactive Program To Evaluate the Safety of Celecoxib in Juvenile Idiopathic Arthritis (JIA) Patients [695]**
 Rachel E Sobel, Staci Abramsky, Carol A Wallace, Sarah Ringold, Audrey Hendrickson, Daniel J Lovell, Edward H Giannini, James Young, Sharon Mallen. (United States)
- 241 Evaluation of Long-Term Safety of Latanoprost in Pediatric Populations: Design and Rationale of an Ongoing Non-Interventional Cohort Study [697]**
 Wanning Xu, Kui Huang, Marla Sultan, Min Zhang. (United States)
- 242 Pediatric Information in Cough/Cold Medication Product Labeling [698]**
 Boon Hou Chua, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

Poster Walk - Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG

- 243 Development and Optimization Process of Benefit/Risk Balance Assessment (BRBA) Model of Medicine for KFDA [493]**
 Jihye Ha, Sung Young Lee, Ji Eun Kang, Han Sung Na, Myeon Woo Chung. (Republic of Korea)

Tuesday, August 27
POSTER SESSION B

- 244 Does Media Attention Affect Impact of DHPs in the Netherlands? [500]**
 Peter GM Mol, Valerie Damoiseaux, Katrin Reber, Sigrid Piening, Jaap Wieringa, Sabine MJM Straus, Flora M Haaijer-Ruskamp. (Netherlands)
- 245 Balancing Individual Benefits and Risks of Warfarin in Patients with Atrial Fibrillation [504]**
 Rianne van den Ham, Olaf H Klungel, Hubert GM Leufkens, Tjeerd P van Staa. (Netherlands)
- 246 A Systematic Review of Randomized Controlled Trials of New Oral Anticoagulants: The Search for a Net Clinical Benefit [505]**
 Martin Viau, Raana Haj Najafi, Jason R Guertin, Jacques LeLorier, Madeleine Durand. (Canada)
- 247 Information on QTc-Interval Prolongation in the Summary of Product Characteristics [506]**
 Miriam J Warnier, Frank A Holtkamp, Frans H Rutten, Arno W Hoes, Anthonius de Boer, Peter GM Mol, Marie L De Bruin. (Netherlands)
- 248 Using Multi-Criteria Decision Analysis for Quantitative Benefit Risk Assessment of Afibercept as a Second Line Treatment in Adults with Metastatic Colorectal Cancer [507]**
 Jasmanda Wu, Lawrence Phillips, Mengyang Wang, Wanju Dai, Sheikh Usman Iqbal, Manu Sondhi, Christopher Kripas, Pankaj Bhargava, Amy Freedman, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 249 Medication Guide Reading Behaviors and Attitudes among Patients with Migraine, Asthma, or COPD [523]**
 Kristen B Bibeau, Rachael L DiSantostefano. (United States)
- 250 Pregnancy and Lactation Labeling Information in Cough and Cold Related Medications [530]**
 Si Mei Shermaine Sue, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

Poster Walk - Database SIG

- 251 Incidence of, and Risk Factors for Herpes Zoster in the HAART Era: An Analysis of the CHORUS Cohort [542]**
 Adrienne P Guignard, François Haguined, Samantha St. Laurent, Vani Vannappagari. (Belgium)
- 252 Use of Disulfiram and Risk of Cancer: A Population-Based Case-Control Study [562]**
 Anton Pottegård, Søren Friis, Lau C Thygesen, Jesper Hallas, Gro Askgaard. (Denmark)
- 253 Harmonization of Outcome Extraction for Heart Failure across Data Sources in the SAFEGUARD Project [563]**
 Lorenza Scotti, Andrea Arfè, Antonella Zambon, Silvana Romio, Niklas Schmedt, Giorgia De Berardis, Cormac Sammon, Miguel Gil, Elisa Martin, Gema Requena, Corine de Vries, John D Seeger, Giampiero Mazzaglia, Irene Bezemer, Cristina Varas-Lorenzo, Mark Smits, Peter Rijnbeek, Miriam Sturkenboom, Giovanni Corrao. (Italy)

- 254 Using Natural Language Processing To Identify US Veterans with Binge Eating Disorder [580]**
 Brandon K Bellows, Scott L Duvall, Thomas Ginter, Aaron WC Kamauu, Dylan Supina, Paul Hodgkins, Haim Erder, Joanne LaFleur. (United States)
- 255 Multiple Database Approach for Study of Associations between Frequently Used Drugs and Community-Acquired Pneumonia [584]**
 Mark CH de Groot, Olaf H Klungel, Hubert GM Leufkens, Liset Van Dijk, Diederick E Grobbee, Ewoudt MW Van de Garde. (Netherlands)
- 256 Potentially Missing Prescription Medication Claims in Administrative Databases: Angioedema Prior to New Angiotensin Receptor Blocker Use [595]**
 J Bradley Layton, Mugdha Gokhale, Til Stürmer, M Alan Brookhart. (United States)
- 257 Sensitivity Analysis of Methods for Active Surveillance of Acute Myocardial Infarction Using Electronic Databases [596]**
 Xiaochun Li, Cynthia J Girman, Susan Ofner, Changyu Shen, Kimberly G Brodovitz, Linas Simonaitis, Nancy Santanello. (United States)
- 258 Development of an Algorithm for Detecting Heparin-Induced Thrombocytopenia and Assessment of the Risk Factors Using a Medical Information Database [627]**
 Tadaaki Hanatani, Kimie Sai, Masahiro Tohkin, Katsunori Segawa, Michio Kimura, Katsuhito Hori, Junichi Kawakami, Yoshiro Saito. (Japan)

Poster Walk - Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG

- 259 Hepatitis C Virus Genotype Coinfection and Distribution in Different Regions of Mexico [641]**
 Ricardo Jimenez, Adriana Loza, Kirvis J Torres, Ricardo Montiel, Laura Cisneros, Vicente Madrid. (Canada)
- 260 Serum Phosphate Variability and Phosphate Binder Usage in Patients New to Hemodialysis [642]**
 Kimberly Farrand, J Brian Copley, Jamie Heise, Moshe Fridman, Michael Keith, Arthur Silverberg. (United States)
- 261 Genetic Association between Variants in Genes for sPLA2 and Cardiovascular Biomarkers [645]**
 Bo Ding, Eva Hurt-Camejo, Audrey Y Chu, Daniel I Chasman, Paul M Ridker, Fredrik Nyberg. (Sweden)
- 262 Cholesteryl Ester Transfer Protein (CETP) Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events [648]**
 Maarten Leusink, N Charlotte Onland, Folkert W Asselbergs, Bo Ding, Salma Kotti, Natalie R van Zuydam, Audrey C Papp, Nicolas Danchin, Louise Donnelly, Andrew D Morris, Daniel I Chasman, Olaf H Klungel, Paul M Ridker, Wiek H van Gilst, Tabassome Simon, Fredrik Nyberg, Colin NA Palmer, Wolfgang Sadee, Pim van der Harst, Paul de Bakker, Anthonius de Boer, Celine Verstuyft, Anke-Hilse Maitland-van der Zee. (Netherlands)

- 263 Patient Willingness To Provide Different Types of Biological Samples for Pharmacogenomic Testing [650]**
 Tenneille T Loo, Sinead Cuffe, Henrike Hon, Petra Martin, M Catherine Brown, Shabbir Alibhai, Xin Qiu, Wei Xu, Geoffrey Liu. (Canada)
- 264 Associations between Overall Survival and Response to Standard of Care and Biomarker Status in Ovarian Cancer Patients Using an Observational Tumor-Linked Database [655]**
 Mellissa Yong, Michael Nebozhyn, Reshma Rangwala, Kimberly Wilson, Timothy Yeatman, Agnes Baffoe-Bonnie, Guochun Xie, Andrey Loboda, Mark Ayers, Theresa Zhang, Daniel Sullivan, James Hardwick. (United States)
- 265 Cost-Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation [657]**
 Talitha I Verhoef, William K Redekop, David L Veenstra, Rahber Thariani, Peter A Beltman, Rianne MF van Schie, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)

Poster Walk - Pediatrics SIG

- 266 Trends in Oral Antidiabetic Medication Use among Children and Adolescents: 2003-2010 [662]**
 Mona Cai, M Alan Brookhart. (United States)
- 267 Description of Psychoactive Drug Utilization in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec [665]**
 Caroline Croteau, Laurent Mottron, Marc Dorais, Sylvie Perreault. (Canada)
- 268 Drug-Induced Adverse Reactions Via Breast-feeding: A Study in the French Pharmacovigilance Database [681]**
 Isabelle Lacroix, Caroline Soussan, Ghislaine Portolan, Jean-Louis Montastruc and the French Association of Regional Pharmacovigilance Centres. (France)
- 269 Analysis of Method To Capture Adverse Events in Neonates and Children in Tertiary Care Pediatric Hospitals [685]**
 Ann W McMahon, Pamela Weinel, Gerold T Wharton, Barbara Abrams, Cecilia P Damilano, Diva DeLeon, Phuong Lieu, Lilly Yen, Carol K Taketomo, Paul S Thornton, Beena Sood, Edwin Doe, Robin L Baker, William Rodriguez, M Dianne Murphy. (United States)
- 270 Results from a Registry To Monitor the Safety of Celecoxib and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Juvenile Idiopathic Arthritis (JIA) [694]**
 Rachel E Sobel, Daniel J Lovell, Hermine I Brunner, Jennifer E Weiss, Paula W Morris, Beth S Gottlieb, Elizabeth C Chalom, Lawrence K Jung, Karen B Onel, Lisa Petiniot, Donald P Goldsmith, Kabita Nanda, Michael Shishov, Staci Abramsky, James Young, Edward H Giannini. (United States)

▶ **END SESSION B**

Biologics, including Vaccines

- 1 **An Algorithm To Predict Biologic DMARD Use in the THIN Database [778]**
 Bing Cai, Qing Liu, Jamie Geier, Andrew Bate. (United States)
- 2 **Narcolepsy and H1N1 Vaccination in France: A Case-Control Sub-Analysis Focusing on the Risk of Narcolepsy with Cataplexy [779]**
 Yves Dauvilliers, Isabelle Arnulff, Michel Lecendreux, Abdelilah Abouelfah, Basma Ambrosino, Sophie Micon, Severine Lignot, Christel Saussier, Antoine Pariente. (France)

Burden of Disease/Epidemiology of Illness

- 5 **Trends in the Antimicrobial Susceptibility of Bacteremias over the past Decade: A Regional Antibiogram of the ESKAPE Pathogens [782]**
 Ajinkya M Pawar, Kerry L LaPlante, Aisling R Caffrey. (United States)
- 6 **Antibiotic Resistance and Differences by Culture Site in Staphylococcus aureus [783]**
 Duncan P Stillier, Ajinkya M Pawar, Kerry L LaPlante, Aisling R Caffrey. (United States)
- 7 **Identification and Treatment of Recurrent Ovarian Cancer in a Large Administrative Claims Database [784]**
 Victoria M Chia, Jan Lethen, Lori Cyprien, Michael Kelsh. (United States)
- 8 **Management of Depression in Taiwan: Unmet Needs in Advanced Pancreatic Cancer Patients? [785]**
 Hsu-Chih Chien, Yan-Shen Shan, Chia-Jui Yen, Yea-Hue Kao Yang. (Taiwan)
- 9 **Developing a Model for Type 2 Diabetes Mellitus Medication Use Prevalence at Local Level [786]**
 Aletta Dijkstra, Fanny Janssen, Jens Bos, René Lub, Leo JG van Wissen, Eelko Hak. (Netherlands)
- 10 **Depression and Anxiety Diagnoses and Treatment in Hemophilia Patients: A US Claims Database Study [787]**
 Anne Dilley, Nydjie Payas, Jin Wang, Lynda M Cristiano. (United States)
- 11 **Baclofen for Alcohol Dependence in France: Incidence of Treated Patients and Patterns of Prescribing [788]**
 Julie Dupouy, Jean-Pascal Fournier, Emilie Jouanjus, Jean-Christophe Poutrain, Stéphane Oustric, Maryse Lapeyre-Mestre. (France)
- 12 **Background Rates of Anaphylaxis in General and Allergic Populations [789]**
 Daina B Esposito, Linda Nelsen, Debra F Eisenberg, April Grant, Jennifer CL Hawes, Crystal N Holick, Xuehua Ke, Rakesh Luthra, Jennifer Maloney, Vinay Mehta, Daniel Mines. (United States)

- 13 **Parkinson's Disease and Risk of Retinal Degeneration [790]**
 Joan Fortuny, Estel Plana. (Spain)
- 14 **Incidence Rates of Pneumonia in Solid Tumor Cancer Patients in the UK [791]**
 Victor M Gastanaga, Charles E Wentworth, Oswald L Bracco, Alexander Liedt. (United States)
- 15 **Contextualization of Safety Endpoints in a Rheumatoid Arthritis (RA) Development Program: Collaboration with the Consortium of Rheumatology of North American Registry (CORONA) [792]**
 Jamie L Geier, Kate Saunders, George Reed. (United States)
- 16 **Sickle Cell Disease Prevalence in a Large US Administrative Claims Database [793]**
 Elsie L Grace, Alex Asimwe, Meghan Jones, James A Michael. (United States)
- 17 **Statin Therapy Is Associated with Decreased Risk of First Intracerebral Hemorrhage and Reduced 30-Day Fatality: Results of a Nationwide Observational Study Including 7696 Cases and 14 670 Controls [794]**
 Karin M Henriksson, Marie Eriksson, Signild Åsberg. (Sweden)
- 18 **Demographics of the Patient Population Recruited into the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [795]**
 Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 19 **Prevalence of Treated Gout in Scotland, England and Denmark and Summary of Recruitment into the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [796]**
 Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 20 **Healthcare Utilization and Treatment Patterns for Patients (pts) with Gastric Cancer (GC) in China [797]**
 Jeff Jianfei, Wenmin Du, Laura Chu, Xiaopei Wang, Jane Prumer. (United States)
- 21 **Risk of Seizures among Patients with Schizophrenia as Compared to the General Population in the Clinical Practice Research Datalink (CPRD) [798]**
 Meghan Jones, Jonathan Swain, Frank DeLisle, Ludmila Kryzhanovskaya, Bruce J Kinon. (United States)
- 22 **CARING: Does Subgroup Analysis by Gender Modify the Potential Association between Diabetes Mellitus and Cancer?- A Meta-Analysis [799]**
 Jakob Starup-Linde, Peter Vestergaard, Oystein Karlstad, Stine A Eriksen, Heleen K Bronsveld, Paul JHL Peeters, Frank De Vries, Marie L De Bruin. (Norway)

- 23 **CARING: Diabetes Mellitus and Risk of Cancer - A Systematic Review and Meta-Analysis [800]**
 Jakob Starup-Linde, Peter Vestergaard, Oystein Karlstad, Stine A Eriksen, Heleen K Bronsveld, Frank De Vries, Anthonius De Boer, Marie L De Bruin. (Norway)
- 24 **Burden of Human Respiratory Syncytial Virus (RSV) Infection [801]**
 Harshila Patel, Hanane Khoury, Myra Widjojatmodjo, Ida Kolte, Antoine El Khoury. (Canada)
- 25 **Out-of-Pocket Prescription Drug Expenditures among the Korean Elderly: Who Is Vulnerable to Cost Burden? [802]**
 Eun-Ja Park, Hyun Soon Sohn, Jin-Won Kwon. (Republic of Korea)
- 26 **Long-Term Follow Up of Concomitant Medication Use in Type 2 Diabetes Patients: A Cohort Study [803]**
 Egbert JF Lamberts, Jacqueline G Hugtenburg, Giel Nijpels, Marcel L Bouvy, Patrick C Souverein. (Netherlands)
- 27 **Case-Mix in General Practice in Italy: Score Development and Validation [804]**
 Francesco Lapi, Elisa Bianchini, Iacopo Cricelli, Federico Spandonaro, Claudio Cricelli. (Italy)
- 28 **An Efficient Way To Estimate Disease Prevalence Rates by Extrapolation of Data from Several Small Studies [805]**
 Nikolay V Matveev, Jeffrey Vietri. (Russian Federation)
- 29 **Rheumatoid Arthritis (RA) in Quebec: Baseline Demographics, Co-Morbidity and Physician Use in an Incident Sample of Provincial Drug Plan Beneficiaries [806]**
 Cristiano Moura, Sasha Bernatsky, Marie-Eve Beauchamp, Hassan Behlouli, Debbie Feldman, Gilles Boire, Louis Bessette, Paul R Fortin, Michal Abrahamowicz. (Canada)
- 30 **Multiple Sclerosis Subtypes and Infections Resulting in a Hospitalization in the Veterans Health Administration [807]**
 Richard E Nelson, Yan Xie, Scott L DuVall, Jorie Butler, Aaron WC Kamauu, Markus Schuerch, Nadia Foskett, Joanne LaFleur. (United States)
- 31 **Exacerbation Recurrence Rates in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-Life Study [808]**
 Jetty A Overbeek, Maria-Magdalena Balp, Fernie JA Penning-van Beest, PN Richard Dekhuijzen, Ron MC Herings. (Netherlands)
- 32 **Incidence of Colorectal Cancer in Association with Diagnosed Hypertension [809]**
 Estel Plana, Ying Zhu, Christoph R Meier, Raymond G Schlienger. (Spain)

Wednesday, August 28
POSTER SESSION C

- 34 Trends in Incidence Rates (IR) of Hip/Femur Fractures in 5 European Countries: A Comparison Using Electronic Health Care Records (e-HCR) [811]**
 Gema Requena, Victoria Abbing-Karahagopian, Consuelo Huerta, Marieke L De Bruin, Yolanda Alvarez, Montserrat Miret, Ulrik Hesse, Helga Gardarsdottir, Patrick Souverein, Jim Slattery, Cornelia Schneider, Marietta Rottenkolber, Sven Schmiedl, Miguel Gil, Mark CH De Groot, Andrew Bate, Ana Ruigómez, Luis A García, Saga Johanson, Frank De Vries, Dolores Montero, Raymond Schlienger, Robert Reynolds, Olaf H Klungel, Francisco J De Abajo. (Spain)
- 35 Patient Preferences for Antihypertensive Medications in General Practice [812]**
 Maribel Salas, Martin Rosas, Gustavo Pastelin. (United States)
- 36 Incidence of Giant Cell Arteritis in Clinical Practice Research Datalink and Cumulative Use of Prednisolone in Patients Treated for GCA [813]**
 Hans Petri, Alan Nevitt, Khaled Sarsour, Neil Collinson, Pavel Napalkov. (United States)
- 37 Thromboembolic Events among Older Ovarian Cancer Patients: A SEER-Medicare Analysis [814]**
 Sumitra Shantakumar, Alexandra C Frost, Li Li. (United States)
- 38 The Burden Imposed by Atopic Dermatitis on Families: Creation of a Specific Questionnaire [815]**
 Cecile Meni, Sebastien Branchoux, Charles Taieb. (France)
- 39 Hemangioma Family Burden: Creation of a Specific Questionnaire [816]**
 Olivia Boccara, Sébastien Branchoux, Jean Jacques Voisard, Charles Taieb. (France)
- 40 Burden of Chronic Kidney Disease [817]**
 Jan C van Blijderveen, Sabine M Straus, Miriam C Sturkenboom, Bruno C Stricker, Katia M Verhamme. (Netherlands)
- 41 A Decision Aid for Initiating a Registry Study [818]**
 Priscilla Valentgas, Jaclyn L Bosco, Allison Bryant, Stephen Arcona, Kristijan Kahler, Nancy A Dreyer. (United States)
- 42 Overview of the Clinical and Economic Burden of Prostate Cancer in the U.S. Veteran Population [819]**
 Li Wang, Lu Li, Elyse Fritschel, Onur Baser. (United States)
- 43 Longitudinal Patterns of Complications of Cystic Fibrosis (CF): An Analysis of a Claims Database in the United States [820]**
 Yan Bai, Winifred Werther, Brooke Harrow, Claus Becker, Ami Buikema. (United States)

**Drug Utilization Research/
 Health Services Research**

- 45 Cost and Utilization Trends of Antiemetic Drug in US Using Medicaid Database, 1991-2011 [823]**
 Ziyad S Almalki, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)
- 46 Co-Prescription of Gastroprotective Agents in Patients Taking Non-Selective NSAIDs or COX-2 Selective Inhibitors: A Hospital Based Retrospective Study [824]**
 Jarir At Thobari. (Indonesia)
- 47 Drug Utilization of Patients Admitted with Conditions Wholly Attributable to Alcohol in Friuli Venezia Giulia, Italy [825]**
 Fabio Barbone, Valentina Rosolen, Marco Giordani, Federica Edith Pisa, Francesco Piani. (Italy)
- 48 User and Treatment Characteristics of Oral Contraceptives in the European Union [826]**
 Irene D Bezemer, Katia MC Verhamme, Rosa Gini, Mees BMT Mosseveld, Peter R Rijnbeek, Miriam CJM Sturkenboom, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)
- 49 Characteristics of Selective Serotonin Re-Uptake Inhibitor (SSRI) Initiators 1999-2009 [827]**
 Greta A Bushnell, Til Stürmer, Virginia Pate, Alice White, Sonja Swanson, Deborah Azrael, Matthew Miller. (United States)
- 50 The Medical Management and Expenditure of Dry Eye Syndrome in Taiwan [828]**
 Chia-Hsien Chang, Yea-Huei Kao Yang, Fung-Rong Hu, Po-Ting Yeh, Kwang Ng, Emily Cheng. (Taiwan)
- 51 Prevalence of Aliskiren Use among Patients with Hypertensive Diabetes in Taiwan: A Nationwide Population-Based Study [829]**
 Chi Wen Chiang, Li Chai Chen, Yaw Bin Huang. (Taiwan)
- 52 Characteristics of Incident Statins Users in Maccabi Healthcare Services 2000-2010 [830]**
 Gabriel Chodick, Raanan Raz, Varda Shalev. (Israel)
- 53 Adherence and Persistence with Type 2 Diabetes (T2DM) Medications: Saxagliptin, Sulfonylureas (SU), Thiazolidinediones (TZD), and Glucagon-Like Peptide 1 (GLP-1) Agonists [831]**
 Suellen M Curkendall, Nina Thomas, Kelly F Bell, Katy Pan, Paul Juneau. (United States)
- 54 Metastatic Castration-Resistant Prostate Cancer: Treatment Pathway and Associated Cost in Canada [832]**
 Alice Dragomir, Daniela Dinea, Marie Vanhuysse, Fabio Cury, Armen Aprikian. (Canada)

- 55 Influence of Life-Saving Drugs Use before Acute MI and during Acute MI Phase on Mortality: LISS (Lyubertsy Infarct Survival Study) Registry Data [833]**
 Sergey Yu Martsevich, Natalia P Kutishenko, Liubov Yu Drozdova, Moisey L Ginzburg, Alexander D Deev. (Russian Federation)
- 56 Differences in Use of Pharmacologic Smoking Cessation Aids between Lung and Other Cancer Patients [834]**
 Lawson Eng, Xin Qiu, Prakruthi R Palepu, Henrique Hon, Steven Habbous, Dan Pringle, Chongya Niu, Luke Harland, Mary Mahler, Oleksandr Halysky, M Catherine Brown, Sinead Cuffe, Jennifer M Jones, Shabbir MH Alibhai, Doris Howell, Peter Selby, Wei Xu, Geoffrey Liu. (Canada)
- 57 Patient Activation by DTCA Influences Primary Care Physicians' Prescriptions of Celebrex for Osteoarthritis [835]**
 Michael A Fischer, Jeffrey N Katz, Lisa D Marceau, Felicia L Trachtenberg, Jing Yu, John B McKinlay. (United States)
- 58 Pharmacy-Based Interventions To Reduce Primary Medication Non-Adherence [836]**
 Michael A Fischer, Katsiaryna Bykov, Niteesh K Choudhry, Gregory Brill, Gregory Bopp, Aaron M Wurst, William H Shrank. (United States)
- 59 Experience of Using Gout Flare Prophylaxis in the FAST Trial [837]**
 Robert WV Flynn, Claudine Jennings, Isla S Mackenzie, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 60 Adherence to Cardiovascular Drugs in Urban and Farmers Elders in the 3C and AMI Cohorts [838]**
 Claire Brotons, Fabienne Bazin, Catherine Helmer, Karine Peres, Antoine Pariente, Philippe Robinson, Pernelle Noize, Jean Francois Dartigues, Annie Fourier-Reglat. (France)
- 61 Use of NSAIDs with Increased Risk of Cardiovascular Events in Low and Middle Income Countries [840]**
 Patricia McGettigan, David Henry. (Canada)
- 62 Interactive Medication Reconciliation by Secure Messaging [841]**
 Leonie Heyworth, Justice Clarke, Max Stewart, Tracey Martin, Steven R Simon. (United States)
- 63 A Tablet a Day or a Tablet a Week - Does It Affect Refill Adherence to Bisphosphonates in Sweden? [842]**
 Anna K Jönsson, Linus Schiöler, Eva Lesén, Karolina A Sundell, Anne-Charlotte Mårdby. (Sweden)
- 64 Up-Titration of Allopurinol in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [843]**
 Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)

- 66 **Development of Prescription Quality Indicators among Diabetic Patients in Taiwan [845]**
 Shu-Ting Chen, Li-Chiu Wu, Chia-Hsuin Chang, Mei-Shu Lai. (Taiwan)
- 67 **Comparison of ATC/DDD Utilization Data of Nervous System Medications with Potential for Abuse and/or Dependence in Bulgaria [846]**
 Hristina V Lebanova, Ilko N Getov, Evgeni E Grigurov. (Bulgaria)
- 68 **Methotrexate and Anti-TNF Drug Use in Seniors with New-Onset Rheumatoid Arthritis (RA) in Quebec [847]**
 Cristiano Moura, Sasha Bernatsky, Marie-Eve Beauchamp, Hassan Behloul, Michal Abrahamowicz. (Canada)
- 69 **What Attitudes Could Influence Antibiotic Dispensing without Prescription? [848]**
 Fátima Roque, Sara Soares, Luiza Breitenfeld, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 70 **Assessing Physician Knowledge and Attitudes Regarding Antibiotic Prescribing and Microbial Resistances [849]**
 António Teixeira Rodrigues, Mónica Ferreira, Fátima Roque, Amílcar Falcão, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 71 **Validity and Reliability of a Questionnaire To Assess Knowledge and Attitudes Regarding Antibiotic Prescribing and Resistances [850]**
 António Teixeira Rodrigues, Mónica Ferreira, Fátima Roque, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 72 **Variation in Nursing Home Antipsychotic Use across Psychiatric Consultant Providers [851]**
 Jennifer Tjia, Becky A Briesacher, Kathleen M Mazor, Celeste Lemay, Terry Field, Daniel Peterson, Michelle Pandolfi, Abir O Kanaan, Jennifer L Donovan, Leslie R Harrold, Jerry H Gurwitz. (United States)
- 73 **Do Antidepressant Drug Treatments Increase the Probability of Receiving an Antipsychotic Treatment in General Population? [852]**
 Marie Tournier, Manon André, Héléne Lepouriel, Yoan Gaudron, Bernard Bégau, Héléne Verdoux. (France)
- 75 **Trends in the Use of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs in the General U.S. Population [854]**
 Yingjun Zhou, Denise M Boudreau, Andrew N Freedman. (United States)

Medical Devices

- 76 **Ectopic Pregnancies under IUD Use: Interim Results from the EURAS-IUD Study [855]**
 Klaas Heinemann, Suzanne Reed, Sabine Moehner. (Germany)

Pharmacoeconomics / Outcomes Research in Pharmacology

- 80 **Cost-Effectiveness of Intermittent Preventive Treatment in Pregnancy (IPTp) with Sulfadoxine-Pyrimethamine in the Light Increasing Resistance [859]**
 Obinna Ikechukwu Ekwunife. (Nigeria)
- 81 **Risk of Venous Thromboembolism Complications Associated with Recurrent Venous Thromboembolism [860]**
 Patrick Lefebvre, François Laliberté, Edith Nutescu, Mei Sheng Duh, Joyce C LaMori, Brahim K Bookhart, William H Olson, Katherine Dea, Yvonnick Hossou, Jeff R Schein, Scott Kaatz. (Canada)
- 82 **The Medicines Benefits Package of National Health Insurance Fund in Sudan [NHIF] The Access, Effectiveness and Use [861]**
 Isam Eldin Mohammed Ali Mustafa, Ismail Salim Haroun. (Sudan)
- 83 **Validity and Reliability of Indonesian Version of ST George Respiratory Questionnaire in Tuberculosis Patients [862]**
 Dyah Aryani Perwitasari, Adnan Adnan, Uly Adhi Mulyani, Jarir Athobari, Ad A Kaptein. (Indonesia)

Biologics SIG

- 85 **Association of Anti-TNF- Agents and Fractures in Rheumatoid Arthritis Patients [866]**
 Nam-Kyong Choi, Joongyub Lee, Xue-Mei Jin, Young-Jin Ko, Byung-Joo Park. (Republic of Korea)
- 86 **Occurrence of Hemolytic Reactions (HRs) on the Same Day as Immune Globulin (IG) Product Administrations during 2008-2012 [868]**
 Hozefa A Divan, Mikhail Menis, Gayathri Sridhar, Nandini Selvam, Richard Forshsee, Hector S Izurieta. (United States)
- 87 **Patient Reported Health Outcomes from Well-Controlled Trials of Biologic Therapies: A Systematic Review [869]**
 Daniel M Frenkl, Mikel Strom, John E Ware, Jr. (United States)
- 89 **Evaluation of Protective Effect of TNF- Inhibitors Against Ischemic Stroke in Patients with Rheumatoid Arthritis [872]**
 Joongyub Lee, Nam-Kyong Choi, Xue-Mei Jin, Young-Jin Ko, Byung-Joo Park. (Republic of Korea)
- 90 **Effectiveness of the Pandemic H1N1 Influenza Vaccines in Preventing Hospitalization for Influenza and Pneumonia: A Population-Based Case-Control Study [873]**
 Salaheddin M Mahmud, Songul Bozat-Emre, Laura H Thompson, Lawrence J Elliott, Paul Van Caesele. (Canada)

- 91 **Hospitalization and Skilled Nursing Care Are Predictors of Influenza Vaccination: Evidence of Confounding by Frailty [874]**
 Leah J McGrath, Stephen R Cole, Abhijit V Kshirsagar, Lily Wang, David J Weber, Stürmer, Alan Brookhart. (United States)
- 92 **Risk of Guillain-Barré Syndrome Following Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccination: Self-Controlled Case Series Study in Germany [876]**
 Jürgen Prestel, Peter Volkers, Dirk Mentzer, Helmar C Lehmann, Hans-Peter Hartung, Brigitte Keller-Stanislawski. (Germany)
- 93 **Exacerbation of Herpes Zoster Ophthalmicus (HZO) Following Zoster Vaccine, Live, Attenuated [Oka/Merck]: A Case Series [879]**
 Elaine Taylor, C Légaré, Duc Vu. (Canada)
- 94 **Population Characteristics, Treatment Patterns and Medical Events in Patients with Psoriatic Arthritis [880]**
 Rolin L Wade, Sylvia L Kindermann, Qingjiang Hou. (United States)
- 95 **Identification of Newly Approved Medications Using Non-Specific Drug Codes in Medicare Administrative Claims Data: Tocilizumab as a Case Study [882]**
 Fenglong Xie, Rui Chen, Huifeng Yun, Meredith L Kilgore, James Lewis, Jie Zhang, Nicole C Wright, Elizabeth S Delzell, Jeffrey R Curtis. (United States)
- 96 **Sex-Specific Association between Antidepressant Drug Use and Body Mass Index in Ambulatory Elderly: Results from the Rotterdam Study [883]**
 Raymond Noordam, Nikkie Aarts, Albert Hofman, Bruno H Stricker, Loes E Visser. (Netherlands)
- 97 **Strengthening Vaccine Lot Safety Surveillance [884]**
 Robert P Wise, Anand M Iyer, Douglas A Domalik, Robert T Miday, Patricia A Price-Abbott, Michael D Blum. (United States)
- 98 **Development of Safety Concerns within RMPs after Approval: A Cohort Study of Biologicals [885]**
 NS Vermeer, RG Duijnhoven, SMJM Straus, S Blackburn, WE Hoogendoorn, AK Mantel-Teeuwisse, ACG Egberts, HGM Leufkens, ML De Bruin. (Netherlands)
- 99 **Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis in the U.S. and the Influence of TNF Inhibitors [886]**
 Melissa Mannion, Fenglong Xie, Jeffrey R Curtis, Timothy Beukelman. (United States)
- 100 **Applicability of the Brighton Collaboration Case Definition for Seizure after Immunization in Active and Enhanced Passive Surveillance in Canada [889]**
 Karina A Top, Cora M Constantinescu, Julie Laffeche, Julie A Bettinger, David W Scheifele, Wendy Vaudry, Scott A Halperin, Barbara J Law. (Canada)

**Drug Utilization/
 Health Services Research SIG**

- 101 Life-Style Characteristics of Elderly Persons Who Receive Seasonal Influenza Vaccination [890]**
 Christian F Christiansen, Rikke B Nielsen, Finn B Larsen, Henrik Toft Sørensen, Reimar W Thomsen. (Denmark)
- 102 Impact of Censoring at or Truncating Risk Time of Hospitalizations on the Effect Measure of the Association between Antiepileptic Drugs and Suicide Attempt [891]**
 Aske Astrup, Christiane Gasse, Liselotte Petersen, Henrik Støvring. (Denmark)
- 103 Impact of Regulatory Warnings on Concomitant Use of Oxycodone and Macrolide Antibiotics [927]**
 Richard A Epstein, William V Bobo, Peter R Martin, James A Morrow, Wei Wang, Rameela Chandrasekhar, William O Cooper. (United States)
- 104 Prevalence of Antibiotic Use: A Methodological Comparison across Various European Health Care Data Sources [912]**
 Ruth Brauer, Ana Ruigómez, Gerry Downey, Andrew Bate, Luis Alberto Garcia Rodriguez, Consuelo Huerta, Belen Oliva, Miguel Gil, Francisco de Abajo, Gema Requena, Yolanda Alvarez, Jim Slattery, Mark de Groot, Patrick Souverein, Ulrik Hesse, Marietta Rottenkolber, Sven Schmiedl, Frank de Vries, Maurille Feudjo Tepie, Raymond Schlienger, Liam Smeeth, Ian Douglas, Robert Reynolds, Olaf Klungel. (United Kingdom)
- 105 Clinical Characteristics, Quality Measure Attainment, and Diabetes-Related Healthcare Costs in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Metformin (MET) and Sulfonylurea (SU) [893]**
 Marie-Helene Lafeuille, Jonathan Gravel, Robert A Bailey, Silas Martin, Lawrence Garber, Mei Sheng Duh, Patrick Lefebvre. (Canada)
- 106 Evaluation of the Efficacy and Safety of Bithrapy on Moroccan Patients Treated from Hepatitis C [894]**
 Ghassan Elmalki, Samir Ahid, Yahia Cherrah. (Morocco)
- 107 Correlates of Nonmedical Use of ADHD-Type Stimulants Versus Nonmedical Use of Other Stimulants in a U.S. National Sample [895]**
 Lian-Yu Chen, Christopher N Kaufmann, Caleb Alexander, Ramin Mojtabai, Silvia S Martins. (United States)
- 108 Case Series of Patients with Reported Renal Events in a Prescription Event-Monitoring (PEM) Study of Aliskiren [1017]**
 Claire Doe, Carole Fogg, Deborah Layton, Saad Shakir. (United Kingdom)
- 109 High Use of Opioids in Patients with Dementia [896]**
 Christina Jensen-Dahm, Christiane Gasse, Aske Astrup, Preben Bo Mortensen, Gunhild Waldemar. (Denmark)

- 111 Combination Antihypertensive Therapy in Older Americans [898]**
 Xiaojuan Li, Wendy Camelo-Castillo, Til Stürmer, Christine L Gray, Soko Setoguchi-Iwata, Virginia Pate, Laura C Hanson, Michele Jonsson Funk. (United States)
- 112 Validaton of a Cohort of New Users of Oral Antidiabetic Agents Free of Microvascular Complications in the RAMQ Database [899]**
 Patrice Simard, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Râkel, Sylvie Perreault. (Canada)
- 113 Pharmaco-Epidemiological Study of Treatment Resistant Schizophrenia and Clozapine Treatment [900]**
 Theresa Wimberley, Henrik Støvring, Christiane Gasse. (Denmark)
- 114 Trends of Utilization of and Spending on Anti-Tuberculosis Medications in the United States Medicaid Program from 1991 to 2011 [901]**
 Abdullah K Alahmari, Mohammed F Aldawsari, Heidi R Luder, Patricia R Wigle, Christina ML Kelton, Jeff J Guo. (United States)
- 115 Prescription Patterns of Antihypertensives in a Community-Health Center in Mexico City. A Drug Utilization Study [902]**
 A Alba-Leonel, A Carvajal, F Castillo-Nájera, J Molina-Guarneros. (Mexico)
- 116 Glucocorticoid-Induced Osteoporosis Management: A Systematic Review [903]**
 Jordan M Albaum, Soyoun Youn, Suzanne M Cadarette. (Canada)
- 117 The Prescribing of Simvastatin in the UK - A Drug Utilisation Study in the Clinical Practice Research Datalink (CPRD) [904]**
 Craig Allen, Katherine L Donegan, Andrew Thomson. (United Kingdom)
- 118 Provider Contact and Antidepressant Fills Prior to Suicide Attempt: A Retrospective Case Series of 32,000 Attempters [905]**
 Heather D Anderson, Robert J Valuck. (United States)
- 119 The Effect of Adherence on Treatment Change among HIV/AIDS Patients at the Korle-Bu Teaching Hospital in Ghana [906]**
 Daniel NA Ankrah, Margaret Lartey, Irene Agyepong, Hubert GM Leufkens, Aukje K Mantel-Teeuwisse. (Ghana)
- 120 A Pregabalin Drug Utilization Study Report [907]**
 Kofi Asomaning, Staci Abramsky, Qing Liu, Xiaofeng Zhou, Rachel Sobel, Stephen Watt. (United States)
- 121 Trends in Antibacterial Use in a German Intensive Care Unit (ICU) [908]**
 Ümniye Balaban, Holger A Lindner, Christel Weiß, Thomas Friedrich, Thomas Kirschning, Manfred Thiel, Verena Schneider-Lindner. (Germany)

- 122 Trends in Prevalent and Incident Use of Blood Glucose-Lowering Agents in Norway: No Increase in Incidence 2006-2011 [909]**
 Hanne Strøm, Christian Berg, Randi Selmer, Lars Christian Stene. (Norway)
- 123 Prevalence, Incidence, Treatment Patterns and Mortality in Patients with Acute Coronary Syndrome in France from 2004 to 2009 [910]**
 Julien Bezin, Régis Lassalle, Abdelilah Abouelfath, Caroline Dureau-Pournin, Annie Fourier-Reglat, Nicholas Moore, Cecile Droz-Perroteau. (France)
- 125 Variation in 12-Lead Electrocardiography for Chest Pain Patients Transported in North Carolina by Emergency Medical Service [913]**
 Montika Bush, Lawrence T Glickman, Antonio R Fernandez, J Lee Garvey, Seth W Glickman. (United States)
- 126 Audit of Dabigatran Use at a Canadian Tertiary Care Centre [914]**
 Aleesa Carter, Kori LeBlanc, Amita Woods, Rita Selby, Donna Lowe. (Canada)
- 127 Development of Evidence Based Medication Related Indicators of Potentially Preventable Hospitalisations [915]**
 Gillian E Caughey, Lisa M Kalisch. (Australia)
- 128 Incidence in Use of Carotid Artery Stenting in Taiwan, 2005-2009: A Nationwide Study [916]**
 Hsi-Chieh Chen, Chia-Hsui Chang, Mei-Shu Lai. (Taiwan)
- 129 Medication-Related Problems of Elders in Long-Term Care Facilities in Taipei in Taiwan [917]**
 Pei-Chen Chen, Lih-Chi Chen, Chi-Hung Lin. (Taiwan)
- 130 Pattern of Use and Costs of Osteoporosis Drugs in an Italian Sub-Population: Data from ARNO Observatory [918]**
 Elisa Cinconze, Maurizio Rossini, Elisa Rossi, Marisa De Rosa, Silvano Adami. (Italy)
- 131 Polypharmacy among Medicaid Recipients with Inflammatory Bowel Disease [919]**
 Jessie P Buckley, Michael D Kappelman, Jeffery K Allen, Susan A VanMeter, Suzanne F Cook. (United States)
- 132 Prevalence and Correlates of Polypharmacy among Men and Women with Mental Illness in Brazil: PESSOAS Project [920]**
 Juliana O Costa, Cristiano S Moura, Francisco A Acurcio, Mark DC Guimarães. (Brazil)
- 133 Utilization Patterns of Cabergoline for Prolactin Reduction in Europe Following the Strengthening of Prescribing Information - The SUCRE Study [921]**
 Cynthia de Luise, Gianluca Trifirò, Miriam Sturkenboom, René Schade, Ron Herings, Lars Pederson, Douglas Ross. (United States)

Wednesday, August 28
POSTER SESSION C

- 135 Preliminary Results of the Impact of the Use of Pillbox on the Stabilization of the INR among Patients Initiating Warfarin Treatment from a Prospective Cohort [923]**
Stephanie Dumas, Etienne Rouleau-Mailloux, Marie-Pierre Dubé, Jean-Claude Tardif, Mario Talajic, Sylvie Perreault. (Canada)
- 136 Validity of Self-Reported Regimen of Dose by Patient Initiating Warfarin Treatment: Population-Based Study [924]**
Stephanie Dumas, Etienne Rouleau-Mailloux, Amina Bardhadi, Marie-Pierre Dubé, Jean-Claude Tardif, Mario Talajic, Sylvie Perreault. (Canada)
- 138 Patient's Views on Multi-Dose Dispensed Medicines [926]**
Lena Ring, Carola Bardage, Anders Ekedahl. (Sweden)
- 139 Dispensing Pattern of Blood Glucose-Lowering Drugs in New Diabetic Patients in Real Practice [928]**
Carmen Ferrajolo, Gianluca Trifirò, Francesco Giorgianni, Concetta Rafaniello, Liberata Sportiello, Vincenzo Arcoraci, Giuseppe Pozzuoli, Claudia Pagliaro, Claudio Linguiti, Daniele U Tari, Achille P Caputi, Francesco Rossi, Dario Giugliano, Katherine Esposito, Annalisa Capuano. (Italy)
- 140 Intervention To Reduce Adverse Outcomes among Older Adults Discharged from Skilled Nursing Facilities to Home [929]**
Terry S Field, Jessica Ogarek, Abir O Kanaan, Jennifer L Donovan, Peggy Preusse, Devi Sundaresan, Shawn J Gagne, Lawrence Garber, Jennifer Tjia, Sarah L Cutrona, Jerry H Gurwitz. (United States)
- 141 Continuation Rates of Long-Acting Reversible Contraceptives: A UK Primary Care Study [930]**
Lucía Cea-Soriano, Mari-Ann Wallander, Susan Andersson, Anna Filonenko, Luis Alberto García Rodríguez. (Germany)
- 142 Antiretroviral Outpatient Drug Utilization in Portugal (2007-2012) [931]**
Claudia Furtado. (Portugal)
- 143 Development of Two Patient Decision Aids To Increase Inhaled Corticosteroids Use in Asthma [932]**
Myriam Gagné, France Légaré, Jocelyne Moisan, Louis-Philippe Boulet. (Canada)
- 144 Metabolic Risk and Screening in CMHC Patients Starting SGAs in MO Medicaid [933]**
Lauren D Garfield, Elizabeth Campagna, Ginger E Nicol, Jeffrey F Scherrer, Neeraja Ganeshraj, Joseph Parks, Elaine H Morrato. (United States)
- 145 Medicine Safety Issues from within Hospital Distribution of Medicines [934]**
Alice V Gilbert, Andrew L Gilbert. (Australia)
- 146 Prevalence and Potential Preventability of Adverse Drug Events – A Population-Based Medical Record Study of 4995 Adults [936]**
Katja M Hakkarainen, Karolina Andersson Sundell, Anna K Jönsson, Max Petzold, Staffan Hägg. (Sweden)
- 147 Use of Pharmaceutical and Non-Pharmaceutical Complementary and Alternative Medicine in Cancer Patients [937]**
Oleksandr Halysky, Lawson Eng, Osvaldo Espin-Garcia, Christine Lam, Kyoko Tiessen, Jodie Villeneuve, Rebecca Charow, Ravi M Shani, Chongya Niu, Dan Pringle, Mary Mahler, Shabbir MH Alibhai, Doris Howell, Jennifer M Jones, M Catherine Brown, Wei Xu, Geoffrey Liu. (Canada)
- 148 Use of Prescription Weight-Loss Drugs in the United States, 1993-2011 [938]**
Christian Hampp, Elizabeth M Kang, Vicky Borders-Hemphill. (United States)
- 149 Factors Associated with Utilization of Saxagliptin in the US and UK [939]**
Melissa S Nezamzadeh, Kevin Haynes, Dena M Carbonari, Craig Newcomb, Jason Roy, Serena Cardillo, Kimberly BF Leidl, Jennifer Wood Ives, Stephanie DeVore, Laura Horne, Betina Blak, Daina Esposito, Crystal Holick, Tjeerd Van Staa, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re III, Eileen E Ming, Sean Hennessy, Peter P Reese, K Rajender Reddy, David Margolis, Andrea Apter, Stephen E Kimmel, Cristin P Freeman, Hanieh Razzaghi. (United States)
- 151 Antipsychotic and Antidepressant Use and Mortality among Nursing Home Residents with Alzheimer's Disease and Related Dementias [941]**
Ting-Ying J Huang, Yu-Jung J Wei, Patience Moyo, Ilene H Zuckerman, Judith Lucas, Linda Simoni-Wastila. (United States)
- 152 Prevalence of Use of Benzodiazepines and Related Drugs in Seven European Databases: A Cross-National Descriptive Study from the PROTECT-EU Project [942]**
Consuelo Huerta, Victoria Abbing-Karahagopian, Gema Requena, Belén Oliva, Yolanda Alvarez, Helga Gardarsdóttir, Montserrat Miret, Comelia Schneider, Miguel Gil, Patrick Souverein, Jim Slattery, Mark CH De Groot, Ulrik Hesse, Marietta Rottenkolber, Sven Schmiedl, Dolores Montero, Andrew Bate, Ana Ruigomez, Luis A García, Saga Johanson, Frank De Vries, Raymond G Schlienger, Robert F Reynolds, Olaf H Kungel, Francisco J De Abajo. (Spain)
- 153 Epidemiologic Measures of Drug Use: Antiepileptic Drugs, Benzodiazepines, and Antidepressants in Four European Countries [943]**
Elena Ballarin, Pili Ferrer, Mónica Sabaté, Joan-Ramon Laporte, Joan Fortuny, Marieke Schoonen, Iain Tatt, Joerg Hasford, Luisa Ibáñez. (Spain)
- 154 Educational Intervention and Knowledge Assessment in Patients on Oral Anticoagulant Treatment [944]**
Consuelo Izazola-Conde, Abraham Majluf-Cruz, Juan Mandoki, Juan Molina-Guarmeros. (Mexico)
- 155 Time Series Methods Applied in Drug Utilization Research: A Systematic Review [945]**
Racquel Jandoc, Andrea M Burden, Suzanne M Cadarette. (Canada)
- 156 Drug Use Pattern of Rivaroxaban in Germany [946]**
Kathrin Jobski, Dirk Enders, Ute Amann, Kiliana Suzart-Woischnik, Mari-Ann Wallander, Tania Schink, Edeltraut Garbe. (Germany)
- 158 Urinary Incontinence: A Poorly Recognised Adverse Effect of Medicines [948]**
Lisa M Kalisch Ellett, Nicole L Pratt, John D Barratt, Elizabeth E Roughead. (Australia)
- 159 Trends in the Use of Non-Benzodiazepine Sleep-Aid Medications in the United States, 1996-2010 [949]**
Christopher N Kaufmann, Lian-Yu Chen, Adam P Spira, Sarah L Canham, G Caleb Alexander, Ramin Mojtabai. (United States)
- 160 Sex-Based Differences in the Use of Evidence-Based Treatment for Heart Failure in Québec [950]**
Jeanne Françoise Kayibanda, Catherine Girouard, Eric Demers, Jean-Pierre Grégoire, Jocelyne Moisan. (Canada)
- 161 Optimizing Medication Use among Patients with Advanced Alzheimer Disease in Long-Term Care - A Scoping Review [951]**
Edeltraut Kröger, Marcel Arcand, Johanne Monette, Mabelle Wilchesky, Nathalie Champoux, Philippe Voyer, Michèle Aubin, Pierre Durand, René Verrault. (Canada)
- 162 Patterns of Relapse and Associated Cost Burden in Schizophrenia Patients Receiving Atypical Antipsychotics [952]**
Marie-Helene Lafeuille, Jonathan Gravel, Patrick Lefebvre, John Fasteneau, Erik Muser, Dilesh Doshi, Mei Sheng Dug. (Canada)
- 163 Meta-Analysis of the Efficacy and Safety of Bortezomib (BTZ) Retreatment in Patients (pts) with Multiple Myeloma (MM) [953]**
Kevin B Knopf, Mei Sheng Duh, Marie-Helene Lafeuille, Jonathan Gravel, Patrick Lefebvre, Liviu Niculescu, Abbie Ba-mancini, Esprit Ma, Hongliang Shi, Raymond L Comenzo. (Canada)
- 164 Sociodemographic Correlates of Glucosamine/Chondroitin Use over 4 Years in the National Osteoarthritis Initiative [954]**
Kate L Lapane, Shihing Yang, Tim McAlindon, Charles Eaton. (United States)
- 166 Predictors of Non-Vaccination Against Human Papillomavirus among US Women Aged 18-26: Data from the 2010 National Health Interview Survey [957]**
H Elsa Larson, Aisling Caffrey, Andrea Paiva, Cynthia Willey. (United States)
- 168 Effect of Computerized Clinical Decision Support on Appropriate Laboratory Monitoring of Medications [960]**
Amy Linsky, Lynn Volk, Nivethietha Maniam, Steven R Simon. (United States)

Wednesday, August 28
POSTER SESSION C

- 169 Profiling Chronic Opioid Use for Non-Cancer Pain in the United States [962]**
Robert J LoCasale, David M Kern, Siting Zhou, Soheil Chavoshi, Ozgur Tunceli, Mark Sostek. (United States)
- 170 Does Weight Status Affect Antibiotic Prescribing Patterns? [963]**
Cristina Longo, Gillian Bartlett, Brenda Macgibbon, Nancy Mayo, Ellen Rosenberg, Stella Daskolopoulou. (Canada)
- 171 Profile of Use of Anti-Tumor Necrosis Factor (Anti-TNF) Agents and Disease Modifying Anti Rheumatic Drugs (DMARD) in Ankylosing Spondylitis Patients in a Brazilian Healthcare Database [964]**
Marina AA Machado, Felipe Ferre, Cristiano S Moura, Alessandra M Almeida, Iola G Andrade, Mariângela A Cherchiglia, Augusto A Guerra, Junior, Francisco A Acurio. (Brazil)
- 172 Bladder Antimuscarinics Use in Veterans Affairs Community Living Centers [965]**
Daniela C Moga, Ryan M Carnahan, Brian C Lund, Jane Pendergast, Robert Wallace, James Torner, Yue Li, Elizabeth A Chrischilles. (United States)
- 173 Practice Pattern Changes in Small Dialysis Organizations Following 25% Phase-In v 100% Opt-In to the Dialysis Capitated Payment System [966]**
Keri L Monda, Brian D Bradbury, Robert J Rubin. (United States)
- 174 Usage Patterns of "OTC" Versus "Prescription" NSAIDs in France [967]**
Nicholas Moore, Mai Duong, Abdelilah Abouelfath, Francesco Salvo, Antoine Pariente, Regis Lassalle, Cécile Droz, Patrick Blin. (France)
- 175 The Enigma of Appropriate Antimicrobial Use: A Model Antimicrobial Stewardship Program (ASP) [968]**
Haley J Morrill, Aisling R Caffrey, Melissa M Gaitanis, Patricia A Cristofaro, Tanya Ali, Kerry L LaPlante. (United States)
- 176 Identifying Older Adults with Major Depressive Disorder from Medicare Current Beneficiary Survey Data [969]**
Eunsun Noh, Brian J Quilliam. (United States)
- 177 Patterns of Antibiotic Use and Dose Adjustment in Patients with Chronic Kidney Disease at Kenyatta National Hospital, Kenya [970]**
Mary Atieno Onyango, Faith A Okalebo, George O Osanjo, David G Nyamu. (Kenya)
- 178 Geographic Variation of Chronic Opioid Use in Fibromyalgia [971]**
Jacob T Painter, Jeffery Talbert, Leslie J Crofford. (United States)
- 179 Medical and Mechanical Prophylaxis for Venous Thromboembolism after Total Hip and Knee Replacement [972]**
Elisabetta Patorno, Brian Bateman, Niteesh Choudhry, Joan Landon, Sebastian Schneeweiss. (United States)
- 180 Drug Utilization and Safety Evaluations: Lessons Learned from International Multi-National Retrospective Chart Review Study Applications [973]**
Krista A Payne, Dara Stein, Annette Stemhagen. (Canada)
- 181 Non-Prescription Medicines -The Missing Pieces of the Drug Utilization Puzzle [974]**
Lisa G Pont, Hanane Jomaa, Gerard Stevens, Andrew J McLachlan. (Australia)
- 182 Medication Characteristics and Disparities in the Underuse of Prescription Medications among Chronically Ill Adults in the U.S. [975]**
Dima M Qato, Wendy Cheng. (United States)
- 183 Sulfonylurea Use Associated with Higher Emergency Room Utilization among Elderly Patients with Type 2 Diabetes [976]**
Swapnil Rajpathak, Chunmay Fu, Kimberly Brodovicz, Samuel Engel. (United States)
- 184 Lack of Therapeutic Efficacy on Type 2 Diabetic Patients Treated with Glibenclamide and Metformin in Mexico City [977]**
Mauricio Ramos-Coss, Nidia Rodriguez-Rivera, Juan A Molina-Guarneros, Fernando Castillo-Najera. (Mexico)
- 185 Performance of Three Brands of Drug Interaction Programs for Use in Geriatrics [978]**
Thais M Guedes, Adriano Max M Reis. (Brazil)
- 186 Agreement among Published Explicit Criteria for Inappropriate Medications in Elderly People [979]**
Tárcita P Figueredo, Maria Auxiliadora P Martins, Adriano Max M Reis. (Brazil)
- 187 Evaluation of Drug Interaction Screening Programs in Oncology [980]**
Kirla B Detoni, Maria Auxiliadora P Martins, Adriano Max M Reis. (Brazil)
- 188 INN Mandatory Prescription in Portugal Mainland [981]**
Mafalda Ribeirinho, Óscar Carvalho. (Portugal)
- 189 Antimicrobial Utilization in Hospital and Primary Care in Portugal Mainland [982]**
Mafalda Ribeirinho. (Portugal)
- 190 Prognostic Value of Chronic Anxiety and Depression and Utilization of Anti-Depressant Medication in Patients with Coronary Heart Disease [983]**
Dietrich Rothenbacher, Andrea Kleiner, Ute Mons, Harry Hahmann, Bernd Wüsten, Thomas Becker, Wolfgang Koenig, Hermann Brenner. (Germany)
- 191 Association between Bronchodilator Treatment and Myocardial Infarction in COPD Patients: A Structured Assessment of Systematic Reviews and Meta-Analyses [984]**
Marietta Rottenkolber, Dominik Rottenkolber, Luisa Ibañez, Joerg Hasford, Sven Schmiedl. (Germany)
- 192 Post Fracture Osteoporosis Care in Rheumatoid Arthritis (RA) [985]**
Jean-Pascal Roussy, Louis Bessette, Sasha Bernatsky, Elham Rahme, Jean Lachaine. (Canada)
- 193 Rates of Non-Vertebral Osteoporotic Fractures in Rheumatoid Arthritis (RA) and Impact of Clinical Practice Guidelines for the Management of Osteoporosis [986]**
Jean-Pascal Roussy, Louis Bessette, Sasha Bernatsky, Elham Rahme, Jean Lachaine. (Canada)
- 194 Characteristics of Antipsychotic Dispensations after First Admission to a Long-Term Care Facility (LTCF) in Saskatchewan, Canada [987]**
Nianping Hu, David Blackburn, Yvonne Sevchuck, Gary Teare, Lisa Lix, Verena Schneider-Lindner. (Germany)
- 196 Sales Trends of Rosiglitazone and Pioglitazone after Safety Alert in Portugal (2002-2012) [989]**
Sara Soares, António Teixeira Rodrigues, Tânia Silva, Fátima Roque, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 197 The Effect of a Training-Programme on Intravenous Preparation and Administration Errors in a Vietnamese Hospital [990]**
Katja Taxis, Huong T Nguyen, TD Nguyen, Edwin van den Heuvel, Floor M Haaijer-Ruskamp. (Netherlands)
- 198 Errors in Medication Preparation and Administration in Vietnamese Hospitals [991]**
Katja Taxis, Huong T Nguyen, TD Nguyen, Edwin vd Heuvel, Floor M Haaijer-Ruskamp. (Netherlands)
- 199 Effectiveness of Interventions by Community Pharmacists To Reduce Risk for Gastrointestinal Side Effects in NSAID Users [992]**
Martina Teichert, Fabienne Griens, Edgar Buijs, Michel Wensing, Peter de Smet. (Netherlands)
- 200 Low Persistence with Oral Bisphosphonate Treatment in Portuguese Women with Postmenopausal Osteoporosis [993]**
Carla Torre, José Guerreiro, Zilda Mendes, Ana Miranda, Helena Canhão, Jaime Branco, Manuela Machado, I Ferreira, M Feudjo-Tepie, Joaquim Cristino. (Portugal)
- 201 Comparison of the Antidepressant Treatment Patterns in Younger and Older Adults Using the French Health Insurance Claims Database [994]**
Fanny Etchepare, Thibaut Sanglier, Manon André, Héliène Verdoux, Marie Tournier. (France)
- 203 Trends in Buprenorphine and Methadone Sales and Utilization in the United States, 1997-2012 [996]**
Lydia Turner, Stefan Kruszewski, Ramin Mojtabai, Daniel Webster, Suzanne Nesbit, Randall Stafford, G Caleb Alexander. (United States)
- 204 Quality and Pattern of Use of Psychotherapeutic Agents in a Nigerian Referral Hospital [997]**
Chukwuemeka M Ubaka, Maxwell O Adibe, Sunday O Nduka, Chinwe V Ukwé. (Nigeria)
- 205 Characteristics Associated with Initiation of Intravenous Versus Subcutaneous Injection Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis Patients [998]**
Onur Baser, Li Wang, Lu Li, Lin Xie. (United States)

Wednesday, August 28
POSTER SESSION C

- 206 Comparative Prevalence of Some Antipsychotic-Containing Drug Combinations in Geriatric Inpatients with Hospital-Acquired Pneumonia [999]**
 Jean Frederic Westphal, Cathy Nonnenmacher. (France)
- 207 Benzodiazepine Use in the HIV-Infected Population [1000]**
 Sarah E Wixson, Emily S Brouwer. (United States)
- 208 Assessment of Dronedrone Utilization Using US MarketScan Database [1001]**
 Jasmanda Wu, Jane Thammakhoune, Wanju Dai, Andrew Koren, Stephanie Tcheryny-Lessenot, Shujun Gao, Chuntao Wu, Laurent Auclert, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 209 Time Trends in Assessment of Dronedrone Utilization in the US [1002]**
 Jasmanda Wu, Juhaeri Juhaeri, Jane Thammakhoune, Shujun Gao, Heather Schiappacasse, Gary Wieczorek, Andrew Koren, Laurent Auclert, Patrick Caubel. (United States)
- 211 Trends in the Use of Guideline-Recommended Medication Treatment and In-Hospital Mortality of Patients with Acute Myocardial Infarction in China [1004]**
 Jing Hu, Zheng Shu, Yanming Xie, Siyan Zhan. (China)
- 212 Effects of Changing from Suboptimal to Optimal Asthma Regimens on Asthma-Related Health Services Utilization [1005]**
 TingTing Zhang, Ricardo Jimenez, Hao Luo, Anne Smith, Bruce Carleton. (Canada)
- 213 Age and Sex Patterns of Drug Prescribing in a Defined American Population [1006]**
 Wenjun Zhong, Hilal Maradit-Kremers, Jennifer L St. Sauver, Barbara P Yawn, Jon O Ebbert, Veronique L Roger, Debra J Jacobson, Michaela E McGree, Scott M Brue, Walter A Rocca. (United States)
- 214 Trends in Antidepressant Prescribing: A Population-Based Study [1007]**
 Wenjun Zhong, Hilal Maradit-Kremers, Jennifer L St. Sauver, William V Bobo, Lila J Rutten, Barbara P Yawn, Walter A Rocca. (United States)
- 215 Birth Cohort Confounds Effect Estimates of Guideline Changes on Prevalence of Statin Use in Diabetic Patients [1008]**
 Eelko Hak, Maarten J Bijlsma, Fanny Janssen, Rene Lub, Jens Bos, Dianna de Vries. Netherlands)
- 216 A Chart Review Methodology To Characterize Treatment Patterns and Clinical Outcomes in Patients with Multicentric Castleman's Disease [1009]**
 Marie-Pierre Desrosiers, Noreen Lordan, Matthew W Reynolds, Donald W Robinson, Jr., Krista A Payne. (Canada)
- 217 Using the RIFLE Classification System To Categorise Severity of Adverse Renal Events in a Prescription Event-Monitoring Study [1010]**
 Claire Doe, Deborah Layton, Saad Shakir. (United Kingdom)
- 218 Latent Class Analysis: A New Approach To Characterize Psychotropic Drug Consumption [1011]**
 Fanny Feuillet, Caroline Victorri-Vigneau, Jean-Benoit Hardouin, Jacques Pivette, Anicet Chaslerie, Véronique Sebillé, Pascale Jolliet. (France)
- 219 Assessing Quality in Systematic Reviews of Adverse Effects [1012]**
 Mónica Sabaté, Pili Ferrer, Elena Ballarín, Marietta Rottenkolber, Sven Schmiedl, Marieke Schoonen, Joan Fortuny, Iain Tatt, Joan-Ramon Laporte, Joerg Hasford, Luisa Ibáñez. (Spain)
- 220 The Effect of Misclassification of the Outcome on the Relationship between an Increase in Anticholinergic Drug Burden and Memory Impairment in Older Adults [1013]**
 Mandavi Kashyap, Sylvie Belleville, Benoit Mul-sant, Sarah Hilmer, Cara Tannenbaum. (Canada)
- 221 Comparison of Methods for the Estimation of Drug Prevalence in a Dynamic Cohort [1014]**
 Tania Schink, Edeltraut Garbe. (Germany)
- 222 Utilization and Expenditure Trends for Anti-Allergic Agents in the Medicaid Program [1015]**
 Jing Guo, Jeff J Guo, Christina ML Kelton, Patricia Wigle. (United States)
- 223 Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder (PERFORM): Design and Characteristics of First 1000 Patients [1016]**
 Josep Maria Haro, J Chollet, Jean-Philippe Boulenger, Bengt Jönsson, Martin Knapp, Benoît Rive, Delphine Saragoussi. (France)
- 224 Post-Authorization Surveys To Evaluate Physician Knowledge: Contract Research Organization (CRO) Evaluation Case Study [1018]**
 Alexander Liede, Scott Stryker, Oliver Günther, John F Acquavella, J Michael Sprafka. (United States)
- 226 Endotoxin-Associated Sterile Peritonitis Observational Study (e-STEPS): Safety Findings [1020]**
 Dara Stein, Cory Sise, Matthew Sherwood, Örjan Mortimer. (Canada)
- 227 Using Forensic Toxicology Registers in Combination with Drug Dispensing Databases To Identify Prescription Drug Abuse: The Example of Tramadol [1021]**
 Micaela Tjäderborn, Anna K Jönsson, Staffan Hägg, Johan Ahlner. (Sweden)
- 228 Web Traffic: A New Tool in Pharmacovigilance? [1022]**
 Thierry Trenque, Malak Abou Taam, Paul De Boissieu, Emmanuelle Herlem. (France)
- 229 Quantitative Evaluation of Metformin Safety Warning on Drug Utilization and Clinical Adverse Effect in Taiwan [1023]**
 Jason C Hsu, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 230 Observational Assessment of Safety in Seroquel (OASIS) – Design, Recruitment and Baseline Patient Characteristics [1024]**
 Sarah Clarke, Deborah Layton, Saad Shakir, Joe Reilly, Anthony Hale. (United Kingdom)
- 231 Trends in Utilization of Cabergoline for Neurological Indications in Four European Countries. Do Doctors Comply with Risk Minimization Activities Concerning Heart Valve Fibrosis? A Population-Based Analysis [1025]**
 René Schade, Gianluca Trifirò, Ron Herings, Giampiero Mazzaglia, Lars Pedersen, Miriam Sturkenboom. (Netherlands)
- 232 Why Are the Myelosuppression as Adverse Reactions of Linezolid Often Reported in Japan? [1026]**
 Yukie Yamauchi, Shiro Hinotsu, Shiro Tanaka, Jun Morikawa, Yasunori Ichiba, Koji Kawakami. (Japan)
- 233 Antipsychotic Duration of Use among Medicaid-Insured Preschoolers, Young Children, and Adolescents [1027]**
 Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 234 Interaction of Age and Psychiatric Diagnosis on Antipsychotic Use among Publicly-Insured Youth with ADHD or Disruptive Behavior Disorders [1028]**
 Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 235 Use of Glucagon-Like Peptide 1 Analogues and the Risk of Fracture in Type 2 Diabetes Patients [1029]**
 Johanna HM Driessen, Hein A van Onzenoort, Arief Lal Mohamed, Corinne Klop, Marloes Baze-lier, Kees Neef, Frank de Vries. (Netherlands)
- 238 Utilization of Antipsychotic Medications in the Youth Population of Manitoba [1032]**
 Sarita Jha, Robert G Biscontri, Laurence Y Katz, Shawn Bugden, David M Collins, Silvia Alessi-Severini. (Canada)
- 239 Changes in Antibiotic Prescribing in Infants and Young Children in Denmark, 1999-2011 [1033]**
 Alan Kinlaw, Til Stürmer, Henrik Toft Sørensen, Jennifer L Lund. (United States)
- 240 Incidence of Stimulant Augmentation among Children and Adolescents with Attention/Deficit Hyperactivity Disorder (ADHD) during 2010 [1034]**
 Keith A Betts, Vanja Sikirica, Paul Hodgkins, Ella Du, Zhou Zhou, Haim M Erder, Eric Q Wu. (United States)

Wednesday, August 28
POSTER SESSION C

- 241 Use of Medication among Young People with Intellectual Disability in Quebec [1035]**
Caroline Sirois, Hubert Gascon, Mirella Faubert, Marie-Eve Gagnon. (Canada)
- 242 Use of Medication by Young People with Autism-Spectrum Disorders in Quebec [1036]**
Caroline Sirois, Hubert Gascon, Mirella Faubert, Marie-Eve Gagnon. (Canada)
- 243 Persistent Antipsychotic Treatment and the Impact on Outpatient, Inpatient, and Emergency Department Services for Youth in Foster Care [1037]**
Ming-Hui Tai, Susan dosReis, Bansri Desai, Gloria Reeves, Terry Shaw. (United States)
- 244 Age-Related Emergency Department Reliance (EDR) and Healthcare Resource Utilization in Patients with Sickle Cell Disease (SCD) [1038]**
Morey A Blinder, Francis Vekeman, Medha Sasane, Alex Trahey, Carole Paley, Matthew Magestro, Mei Sheng Duh. (Canada)
- 245 Predictors of Stopping Medication Use in Pregnancy among Women with Chronic Conditions [294]**
Nisha Almeida, Robyn Tamblyn. (Canada)
- 246 Regional Variations in Complex Antipsychotic Medication Regimens in U.S. Foster Care Youth [1040]**
Julie M Zito, Mehmet Burcu, Salma Lemtouni, Daniel J Safer, Ian Schmid, Carol Pamer, Stephen McKean, Chelsea Lam, Dale Slavin. (United States)

Poster Walk - Asian Pharmacoeconomics Network (AsPEN) SIG

- 248 Prescription Audit of Indian Elderly Ambulatory Patients Using WHO Prescribing Indicators [863]**
Mandavi Kashyap, Sanjay D'Cruz, Atul Sachdev, Pramil Tiwari. (Canada)
- 249 Community Pharmacists' Knowledge, Behaviors and Experiences about Adverse Drug Reactions Reporting in Saudi Arabia [865]**
Mansour A Mahmoud, Yazeed Alswaida, Thami Alshammari, Mohamed Azmi Hassali, Hisham Aljadhey. (Saudi Arabia)

Poster Walk - Medical Devices Poster SIG

- 250 An Evaluation of Three Methods To Identify Adverse Event Signals Associated with Marketed Drugs and Devices [1041]**
Dorian Villegas, Wendy Ye, Fred Schneiweiss, Ayela-Uwangué Osas. (United States)
- 251 Long Acting Reversible Contraceptives and Female Sterilization in Medicaid Population, 1999-2009 [1042]**
Colin Anderson-Smits, Allison O'Neill, Julia Corrado, Danica Marinac-Dabic. (United States)

- 252 The Development of the Pelvic Floor Disorder Registry (PFDR) [1043]**
Colin Anderson-Smits, Julia Corrado, Veronica Sansing, Danica Marinac-Dabic. (United States)
- 253 Outcomes after Carotid Artery Stenting in Medicare Beneficiaries, 2005-2009 [1044]**
Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, Andrew T Rothman, Hiraku Kumamaru, Lauren A Williams, Chih-Ying Chen, Jun Liu, John D Seeger, Soko Setoguchi. (United States)
- 254 The Development and Opportunities of a Transcatheter Aortic Valve Replacement Therapy (TVT) Registry [1046]**
Veronica V Sansing, Daniel Canos, Collin Anderson-Smits, Danica Marinac-Dabic. (United States)
- 255 Cohort Profile of Privately Insured Working Adults Undergoing Total Hip Arthroplasty [1047]**
Jonathan Schelfhout. (United States)

Poster Walk - Drug Utilization Research/Health Services Research SIG

- 256 The Effect of the Financial Crisis in the Use of Psychotropics Drugs in Portugal [839]**
Claudia Furtado. (Portugal)
- 257 Clinical Provider Perceptions of Intentional Medication Discontinuation [911]**
Amy Linsky, Steven R Simon, Barbara Bokhour. (United States)
- 258 The Effect of Non-Dihydropyridine Calcium Channel Blocker Therapy among Patients with Supraventricular Tachyarrhythmias Hospitalized for Systolic Heart Failure [935]**
Regina C Grebla, Gregory A Wellenius, Charles B Eaton, Constantine Gatsonis, Wen-Chih Wu. (United States)
- 259 Potentially Inappropriate Medications in the Elderly with Alzheimer's Disease and Related Dementia [955]**
Marie-Laure Laroche, Marion Lassalle, Jean-Pierre Charmes, Jean Doucet, Muriel Rainfray, Régis Gonthier, Amina Lahlou, Emmanuel Alix, Jean-Marc Eyche. (France)
- 260 Factors Associated with Compliance with Inhaled Corticosteroids in Asthma [958]**
Moulikatou A Lawani, Marie-Claude Breton, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
- 261 Long-Acting Beta2-Adrenergic Agonists (LABA) Use in Pediatric and Adolescent Asthma Patients, 2003-2011 [1039]**
Esther H Zhou, Elizabeth M Kang, Sally Seymour, Solomon Iyasu. (United States)

Poster Walk - Biologics SIG

- 262 Impact of Influenza Vaccination on Risk of Myocardial Infarction, Pneumonia, and Death in Elderly Patients Surviving Intensive Care: A Cohort Study [867]**
Christian F Christiansen, Reimar W Thomsen, Morten Schmidt, Lars Pedersen, Martin B Johansen, Henrik Toft Sørensen. (Denmark)
- 263 Risk of Lymphoma in Rheumatoid Arthritis (RA) Patients Treated with Certolizumab Pegol (CZP) Compared to World and US General Populations [870]**
Jennifer D Guo, Amanda Golembesky, Theresa Rosario-Jansen, David P Miller. (United States)
- 264 Feasibility Evaluation for a Rituximab (RTX) Utilization Study To Be Conducted in Infusion Centers [875]**
Manel Pladevall, Laurie Zografos, Iain Tatt, Pavel Napalkov, Elizabeth Andrews, Susana Perez-Gutthann. (Spain)
- 265 Immune Globulins (IGs) and Risk for Thrombotic Adverse Events (TEs) during 2008-2012 Study Period [877]**
Gayathri Sridhar, Mikhail Menis, Hector S Izurieta, Hozefa A Divan, Richard Forshee, Nandini Selvam. (United States)
- 266 Characterization of Patients with Rheumatoid Arthritis Treated with Rituximab or Tocilizumab in Post-Marketing Patient Registries [878]**
Iain D Tatt, Khaled Sarsour, Jamie Robinson, Eric Low, Pavel Napalkov. (Switzerland)
- 267 Comparative Risks of Recurrent Hospitalized Infection Associated with Biologics in RA Patients at High Risk [881]**
Huifeng Yun, Fenglong Xie, Elizabeth S Delzell, Lang Chen, Emily Levitan, James D Lewis, Kenneth G Saag, Timothy Beukelman, Kevin L Winthrop. (United States)
- 268 Autoimmune, Neurologic, and Venous Thromboembolic Adverse Events Following Administration of a Quadrivalent HPV Vaccine to Adolescent Girls in Denmark and Sweden [887]**
Lisen Arnheim-Dahlström, Björn Pasternak, Henrik Svanström, Pär Sparén, Anders Hviid. (Denmark)
- 269 A Novel Approach to Assessing the Real-World Effectiveness of the Human Papillomavirus Vaccine: The Regression Discontinuity Design [888]**
Leah M Smith, Erin C Strumpf, Jay S Kaufman, Linda E Lévesque. (Canada)

▶ **END SESSION C**

ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Monday, August 26				
Back to the Future: Methods in Time (Methods 1)				
1		10:30 am	519 AB	Oral
2		10:45 am	519 AB	Oral
3		11:00 am	519 AB	Oral
4		11:15 am	519 AB	Oral
5		11:30 am	519 AB	Oral
6		11:45 am	519 AB	Oral
Burden of Disease: Profiles and Prospects				
7		10:30 am	524 AB	Oral
8		10:45 am	524 AB	Oral
9		11:00 am	524 AB	Oral
10		11:15 am	524 AB	Oral
11		11:30 am	524 AB	Oral
12		11:45 am	524 AB	Oral
Opioids or NSAIDs: A Painful Choice				
13		10:30 am	520 CF	Oral
14		10:45 am	520 CF	Oral
15		11:00 am	520 CF	Oral
16		11:15 am	520 CF	Oral
17		11:30 am	520 CF	Oral
18		11:45 am	520 CF	Oral
Part Man - Part Machine, A Device Potpourri				
19		10:30 am	518 AB	Oral
20		10:45 am	518 AB	Oral
21		11:00 am	518 AB	Oral
22		11:15 am	518 AB	Oral
23		11:30 am	518 AB	Oral
24		11:45 am	518 AB	Oral
Pregnancy Session 1				
25		10:30 am	520 AD	Oral
26		10:45 am	520 AD	Oral
27		11:00 am	520 AD	Oral
28		11:15 am	520 AD	Oral
29		11:30 am	520 AD	Oral
30		11:45 am	520 AD	Oral
Use Your Heart				
31		10:30 am	520 BE	Oral
32		10:45 am	520 BE	Oral
33		11:00 am	520 BE	Oral
34		11:15 am	520 BE	Oral
35		11:30 am	520 BE	Oral
36		11:45 am	520 BE	Oral
Big Molecules, Big Problems?				
37		1:30 pm	524 AB	Oral
38		1:45 pm	524 AB	Oral
39		2:00 pm	524 AB	Oral
40		2:15 pm	524 AB	Oral
41		2:30 pm	524 AB	Oral
42		2:45 pm	524 AB	Oral

Abstract #	Poster #	Presentation Time	Room	Format
Gene Meets Drug				
43		1:30 pm	520 CF	Oral
44		1:45 pm	520 CF	Oral
45		2:00 pm	520 CF	Oral
46		2:15 pm	520 CF	Oral
47		2:30 pm	520 CF	Oral
48		2:45 pm	520 CF	Oral
Hot Topics in Diabetes: Pancreatitis and Cancer				
49		1:30 pm	520 BE	Oral
50		1:45 pm	520 BE	Oral
51		2:00 pm	520 BE	Oral
52		2:15 pm	520 BE	Oral
53		2:30 pm	520 BE	Oral
54		2:45 pm	520 BE	Oral
Methods in CER				
55		1:30 pm	519 AB	Oral
56		1:45 pm	519 AB	Oral
57		2:00 pm	519 AB	Oral
58		2:15 pm	519 AB	Oral
59		2:30 pm	519 AB	Oral
60		2:45 pm	519 AB	Oral
Respiratory				
61		1:30 pm	518 AB	Oral
62		1:45 pm	518 AB	Oral
63		2:00 pm	518 AB	Oral
64		2:15 pm	518 AB	Oral
65		2:30 pm	518 AB	Oral
66		2:45 pm	518 AB	Oral
Sounding All the Sources				
67		1:30 pm	520 AD	Oral
68		1:45 pm	520 AD	Oral
69		2:00 pm	520 AD	Oral
70		2:15 pm	520 AD	Oral
71		2:30 pm	520 AD	Oral
72		2:45 pm	520 AD	Oral
Benefit-Risk Assessment, Communication and Evaluation (BRACE): Embrace the Challenges and Opportunities (Submitted on Behalf of the BRACE SIG)				
73		5:00 – 6:30 pm	520 BE	Sympos.
Design and Methodological Considerations in Conducting Relative Effectiveness Studies of Newly Launched Products				
74		5:00 – 6:30 pm	520 CF	Sympos.
Drug Response in Diverse Populations: Role of Ethnicity				
75		5:00 – 6:30 pm	518 AB	Sympos.
Harmonizing Methods and Data across Multiple Databases: Beautiful Music or Cacophony?				
76		5:00 – 6:30 pm	517 D	Sympos.
Non-Database Pharmacoepidemiology in Low Resource Settings: Current Status and Unique Opportunities To Advance Methods				
77		5:00 – 6:30 pm	524 AB	Sympos.
Post-Marketing Pharmacoepidemiologic (PE) Database Studies to Assess Drug Safety				
78		5:00 – 6:30 pm	519 AB	Sympos.
Strategies to Enhance Validity in the Design of Comparative Effectiveness Studies				
79		5:00 – 6:30 pm	520 AD	Sympos.

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Monday, August 26 continued				
POSTER SESSION A				
Classical Pharmacoepidemiology				
80	1	8:00 am – 6:00 pm		Poster
81	2	8:00 am – 6:00 pm		Poster
82	3	8:00 am – 6:00 pm		Poster
83	4	8:00 am – 6:00 pm		Poster
84	5	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
85	6	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
86	7	8:00 am – 6:00 pm		Poster
87	8	8:00 am – 6:00 pm		Poster
88	9	8:00 am – 6:00 pm		Poster
89	10	8:00 am – 6:00 pm		Poster
90	11	8:00 am – 6:00 pm		Poster
91	12	8:00 am – 6:00 pm		Poster
93	13	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
94	14	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
95	15	8:00 am – 6:00 pm		Poster
96	16	8:00 am – 6:00 pm		Poster
97	17	8:00 am – 6:00 pm		Poster
98	18	8:00 am – 6:00 pm		Poster
99	19	8:00 am – 6:00 pm		Poster
100	20	8:00 am – 6:00 pm		Poster
102	22	8:00 am – 6:00 pm		Poster
103	23	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
104	24	8:00 am – 6:00 pm		Poster
105	25	8:00 am – 6:00 pm		Poster
106	26	8:00 am – 6:00 pm		Poster
107	27	8:00 am – 6:00 pm		Poster
108	28	8:00 am – 6:00 pm		Poster
109	29	8:00 am – 6:00 pm		Poster
110	30	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
111	31	8:00 am – 6:00 pm		Poster
112	32	8:00 am – 6:00 pm		Poster
113	33	8:00 am – 6:00 pm		Poster
114	34	8:00 am – 6:00 pm		Poster
115	35	8:00 am – 6:00 pm		Poster
116	36	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
117	37	8:00 am – 6:00 pm		Poster
118	38	8:00 am – 6:00 pm		Poster
119	39	8:00 am – 6:00 pm		Poster
120	40	8:00 am – 6:00 pm		Poster
121	41	8:00 am – 6:00 pm		Poster
122	42	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
123	43	8:00 am – 6:00 pm		Poster
124	44	8:00 am – 6:00 pm		Poster
125	45	8:00 am – 6:00 pm		Poster
126	46	8:00 am – 6:00 pm		Poster
127	47	8:00 am – 6:00 pm		Poster
128	48	8:00 am – 6:00 pm		Poster
130	49	8:00 am – 6:00 pm		Poster
131	50	8:00 am – 6:00 pm		Poster
132	51	8:00 am – 6:00 pm		Poster
133	52	8:00 am – 6:00 pm		Poster
134	53	8:00 am – 6:00 pm		Poster
135	54	8:00 am – 6:00 pm		Poster
136	55	8:00 am – 6:00 pm		Poster
137	56	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
138	57	8:00 am – 6:00 pm		Poster
139	58	8:00 am – 6:00 pm		Poster
140	59	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
141	60	8:00 am – 6:00 pm		Poster
Comparative Effectiveness Research				
142	61	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
143	62	8:00 am – 6:00 pm		Poster
144	63	8:00 am – 6:00 pm		Poster
145	64	8:00 am – 6:00 pm		Poster
146	65	8:00 am – 6:00 pm		Poster
Drug Safety in Pregnancy and Lactation				
147	66	8:00 am – 6:00 pm		Poster
148	67	8:00 am – 6:00 pm		Poster
149	68	8:00 am – 6:00 pm		Poster
Other				
150	69	8:00 am – 6:00 pm		Poster
151	70	8:00 am – 6:00 pm		Poster
152	71	8:00 am – 6:00 pm		Poster
153	72	8:00 am – 6:00 pm		Poster
154	73	8:00 am – 6:00 pm		Poster
155	74	8:00 am – 6:00 pm		Poster
156	75	8:00 am – 6:00 pm		Poster
157	76	8:00 am – 6:00 pm		Poster
158	77	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
159	78	8:00 am – 6:00 pm		Poster
160	79	8:00 am – 6:00 pm		Poster
161	80	8:00 am – 6:00 pm		Poster
162	81	8:00 am – 6:00 pm		Poster
163	82	8:00 am – 6:00 pm		Poster
164	83	8:00 am – 6:00 pm		Poster
Pharmacovigilance				
165	84	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
166	85	8:00 am – 6:00 pm		Poster
167	86	8:00 am – 6:00 pm		Poster
168	87	8:00 am – 6:00 pm		Poster
169	88	8:00 am – 6:00 pm		Poster
170	89	8:00 am – 6:00 pm		Poster
171	90	8:00 am – 6:00 pm		Poster
172	91	8:00 am – 6:00 pm		Poster
173	92	8:00 am – 6:00 pm		Poster
174	93	8:00 am – 6:00 pm		Poster
175	94	8:00 am – 6:00 pm		Poster
176	95	8:00 am – 6:00 pm		Poster
177	96	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
178	97	8:00 am – 6:00 pm		Poster
179	98	8:00 am – 6:00 pm		Poster
180	99	8:00 am – 6:00 pm		Poster
181	100	8:00 am – 6:00 pm		Poster
182	101	8:00 am – 6:00 pm		Poster
183	102	8:00 am – 6:00 pm		Poster
184	103	8:00 am – 6:00 pm		Poster
185	104	8:00 am – 6:00 pm		Poster
186	105	8:00 am – 6:00 pm		Poster
187	106	8:00 am – 6:00 pm		Poster
188	107	8:00 am – 6:00 pm		Poster
189	108	8:00 am – 6:00 pm		Poster
190	109	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Monday, August 26 continued				
191	110	8:00 am – 6:00 pm		Poster
192	111	8:00 am – 6:00 pm		Poster
193	112	8:00 am – 6:00 pm		Poster
194	113	8:00 am – 6:00 pm		Poster
195	114	8:00 am – 6:00 pm		Poster
196	115	8:00 am – 6:00 pm		Poster
197	116	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
198	117	8:00 am – 6:00 pm		Poster
199	118	8:00 am – 6:00 pm		Poster
200	119	8:00 am – 6:00 pm		Poster
201	120	8:00 am – 6:00 pm		Poster
202	121	8:00 am – 6:00 pm		Poster
203	122	8:00 am – 6:00 pm		Poster
204	123	8:00 am – 6:00 pm		Poster
205	124	8:00 am – 6:00 pm		Poster
206	125	8:00 am – 6:00 pm		Poster
207	126	8:00 am – 6:00 pm		Poster
208	127	8:00 am – 6:00 pm		Poster
209	128	8:00 am – 6:00 pm		Poster
210	129	8:00 am – 6:00 pm		Poster
211	130	8:00 am – 6:00 pm		Poster
Risk Management / Risk Minimization/Communication				
212	131	8:00 am – 6:00 pm		Poster
213	132	8:00 am – 6:00 pm		Poster
214	133	8:00 am – 6:00 pm		Poster
215	134	8:00 am – 6:00 pm		Poster
216	135	8:00 am – 6:00 pm		Poster
217	136	8:00 am – 6:00 pm		Poster
218	137	8:00 am – 6:00 pm		Poster
219	138	8:00 am – 6:00 pm		Poster
220	139	8:00 am – 6:00 pm		Poster
221	140	8:00 am – 6:00 pm		Poster
Adherence SIG				
244	141	8:00 am – 6:00 pm		Poster
223	142	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
224	143	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
225	144	8:00 am – 6:00 pm		Poster
226	145	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
242	146	8:00 am – 6:00 pm		Poster
227	147	8:00 am – 6:00 pm		Poster
229	148	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
234	149	8:00 am – 6:00 pm		Poster
236	150	8:00 am – 6:00 pm		Poster
237	151	8:00 am – 6:00 pm		Poster
238	152	8:00 am – 6:00 pm		Poster
239	153	8:00 am – 6:00 pm		Poster
241	154	8:00 am – 6:00 pm		Poster
243	155	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
245	156	8:00 am – 6:00 pm		Poster
246	157	8:00 am – 6:00 pm		Poster
247	158	8:00 am – 6:00 pm		Poster
248	159	8:00am – 6:00pm		Poster
Comparative Effectiveness Research (CER)				
249	160	8:00 am – 6:00 pm		Poster
250	161	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
251	162	8:00 am – 6:00 pm		Poster
252	163	8:00 am – 6:00 pm		Poster
253	164	8:00 am – 6:00 pm		Poster
255	165	8:00 am – 6:00 pm		Poster
256	166	8:00 am – 6:00 pm		Poster
258	167	8:00 am – 6:00 pm		Poster
259	168	8:00 am – 6:00 pm		Poster
260	169	8:00 am – 6:00 pm		Poster
261	170	8:00 am – 6:00 pm		Poster
262	171	8:00 am – 6:00 pm		Poster
263	172	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
264	173	8:00AM – 6:00 pm		Poster
265	174	8:00 am – 6:00 pm		Poster
266	175	8:00 am – 6:00 pm		Poster
267	176	8:00 am – 6:00 pm		Poster
268	177	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
270	178	8:00 am – 6:00 pm		Poster
271	179	8:00 am – 6:00 pm		Poster
272	180	8:00 am – 6:00 pm		Poster
273	181	8:00 am – 6:00 pm		Poster
274	182	8:00 am – 6:00 pm		Poster
275	183	8:00 am – 6:00 pm		Poster
277	184	8:00 am – 6:00 pm		Poster
278	185	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
279	186	8:00 am – 6:00 pm		Poster
280	187	8:00 am – 6:00 pm		Poster
281	188	8:00 am – 6:00 pm		Poster
282	189	8:00 am – 6:00 pm		Poster
283	190	8:00 am – 6:00 pm		Poster
285	191	8:00 am – 6:00 pm		Poster
286	192	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
288	193	8:00 am – 6:00 pm		Poster
289	194	8:00 am – 6:00 pm		Poster
Medications in Pregnancy SIG				
290	195	8:00 am – 6:00 pm		Poster
291	196	8:00 am – 6:00 pm		Poster
292	197	8:00 am – 6:00 pm		Poster
293	198	8:00 am – 6:00 pm		Poster
295	199	8:00 am – 6:00 pm		Poster
296	200	8:00 am – 6:00 pm		Poster
297	201	8:00 am – 6:00 pm		Poster
298	202	8:00 am – 6:00 pm		Poster
300	203	8:00 am – 6:00 pm		Poster
302	204	8:00 am – 6:00 pm		Poster
303	205	8:00 am – 6:00 pm		Poster
304	206	8:00 am – 6:00 pm		Poster
305	207	8:00 am – 6:00 pm		Poster
306	208	8:00 am – 6:00 pm		Poster
307	209	8:00 am – 6:00 pm		Poster
309	210	8:00 am – 6:00 pm		Poster
310	211	8:00 am – 6:00 pm		Poster
311	212	8:00 am – 6:00 pm		Poster
312	213	8:00 am – 6:00 pm		Poster
313	214	8:00 am – 6:00 pm		Poster
314	215	8:00 am – 6:00 pm		Poster
315	216	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Monday, August 26 continued				
316	217	8:00 am – 6:00 pm		Poster
317	218	8:00 am – 6:00 pm		Poster
318	219	8:00 am – 6:00 pm		Poster
319	220	8:00 am – 6:00 pm		Poster
320	221	8:00 am – 6:00 pm		Poster
321	222	8:00 am – 6:00 pm		Poster
322	223	8:00 am – 6:00 pm		Poster
323	224	8:00 am – 6:00 pm		Poster
325	225	8:00 am – 6:00 pm		Poster
326	226	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
327	227	8:00 am – 6:00 pm		Poster
328	228	8:00 am – 6:00 pm		Poster
329	229	8:00 am – 6:00 pm		Poster
330	230	8:00 am – 6:00 pm		Poster
331	231	8:00 am – 6:00 pm		Poster
333	232	8:00 am – 6:00 pm		Poster
335	233	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
336	234	8:00 am – 6:00 pm		Poster
337	235	8:00 am – 6:00 pm		Poster
338	236	8:00 am – 6:00 pm		Poster
339	237	8:00 am – 6:00 pm		Poster
340	238	8:00 am – 6:00 pm		Poster
341	239	8:00 am – 6:00 pm		Poster
342	240	8:00 am – 6:00 pm		Poster
343	241	8:00 am – 6:00 pm		Poster
345	242	8:00 am – 6:00 pm		Poster
346	243	8:00 am – 6:00 pm		Poster
347	244	8:00 am – 6:00 pm		Poster
348	245	8:00 am – 6:00 pm		Poster
Adherence SIG Poster Walk Session				
226	246	8:00 am – 6:00 pm		Poster
228	247	8:00 am – 6:00 pm		Poster
232	248	8:00 am – 6:00 pm		Poster
233	249	8:00 am – 6:00 pm		Poster
235	250	8:00 am – 6:00 pm		Poster
238	251	8:00 am – 6:00 pm		Poster
240	252	8:00 am – 6:00 pm		Poster
Comparative Effectiveness Research (CER) SIG Poster Walk Session				
254	253	8:00 am – 6:00 pm		Poster
257	254	8:00 am – 6:00 pm		Poster
268	255	8:00 am – 6:00 pm		Poster
269	256	8:00 am – 6:00 pm		Poster
276	257	8:00 am – 6:00 pm		Poster
284	258	8:00 am – 6:00 pm		Poster
287	259	8:00 am – 6:00 pm		Poster
Medications in Pregnancy SIG Poster Walk Session				
299	260	8:00 am – 6:00 pm		Poster
301	261	8:00 am – 6:00 pm		Poster
308	262	8:00 am – 6:00 pm		Poster
324	263	8:00 am – 6:00 pm		Poster
332	264	8:00 am – 6:00 pm		Poster
334	265	8:00 am – 6:00 pm		Poster
344	266	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Tuesday, August 27				
Brain, Skin and Bones in Relation to CNS Drugs				
349		8:00 am	520 CF	Oral
350		8:15 am	520 CF	Oral
351		8:30 am	520 CF	Oral
352		8:45 am	520 CF	Oral
353		9:00 am	520 CF	Oral
354		9:15 am	520 CF	Oral
Money Matters				
355		8:00 am	518 AB	Oral
356		8:15 am	518 AB	Oral
357		8:30 am	518 AB	Oral
358		8:45 am	518 AB	Oral
359		9:00 am	518 AB	Oral
360		9:15 am	518 AB	Oral
Pediatrics				
361		8:00 am	520 AD	Oral
362		8:15 am	520 AD	Oral
363		8:30 am	520 AD	Oral
364		8:45 am	520 AD	Oral
365		9:00 am	520 AD	Oral
366		9:15 am	520 AD	Oral
PS, I Love You (Methods 2)				
367		8:00 am	519 AB	Oral
368		8:15 am	519 AB	Oral
369		8:30 am	519 AB	Oral
370		8:45 am	519 AB	Oral
371		9:00 am	519 AB	Oral
372		9:15 am	519 AB	Oral
That's Interesting...				
373		8:00 am	524 AB	Oral
374		8:15 am	524 AB	Oral
375		8:30 am	524 AB	Oral
376		8:45 am	524 AB	Oral
377		9:00 am	524 AB	Oral
378		9:15 am	524 AB	Oral
Up and Down the GI Tract				
379		8:00 am	520 BE	Oral
380		8:15 am	520 BE	Oral
381		8:30 am	520 BE	Oral
382		8:45 am	520 BE	Oral
383		9:00 am	520 BE	Oral
384		9:15 am	520 BE	Oral
Methods 3				
385		10:00 am	519 AB	Oral
386		10:15 am	519 AB	Oral
387		10:30 am	519 AB	Oral
388		10:45 am	519 AB	Oral
389		11:00 am	519 AB	Oral
390		11:15 am	519 AB	Oral
Potential Bias in Cardiovascular Studies				
391		10:00 am	520 BE	Oral
392		10:15 am	520 BE	Oral
393		10:30 am	520 BE	Oral
394		10:45 am	520 BE	Oral
395		11:00 am	520 BE	Oral
396		11:15 am	520 BE	Oral

ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Tuesday, August 27 continued				
Pregnancy Potpourri				
397		10:00 am	520 CF	Oral
398		10:15 am	520 CF	Oral
399		10:30 am	520 CF	Oral
400		10:45 am	520 CF	Oral
401		11:00 am	520 CF	Oral
402		11:15 am	520 CF	Oral
Psychotropics on Your Mind				
403		10:00 am	518 AB	Oral
404		10:15 am	518 AB	Oral
405		10:30 am	518 AB	Oral
406		10:45 am	518 AB	Oral
450		11:00 am	518 AB	Oral
408		11:15 am	518 AB	Oral
Sweet Spot on CER				
409		10:00 am	520 AD	Oral
410		10:15 am	520 AD	Oral
411		10:30 am	520 AD	Oral
412		10:45 am	520 AD	Oral
413		11:00 am	520 AD	Oral
414		11:15 am	520 AD	Oral
Vaccines: Benefits, Risks; Reducing the Unknowns				
415		10:00 am	524 AB	Oral
416		10:15 am	524 AB	Oral
417		10:30 am	524 AB	Oral
418		10:45 am	524 AB	Oral
419		11:00 am	524 AB	Oral
420		11:15 am	524 AB	Oral
Plenary Session: Edlavitch Award				
421		2:30 – 4:00 pm	517 D	Plenary
Advanced Topics on Database Algorithm Development and Validation				
422		4:30 – 6:00 pm	517 D	Sympos.
Best Practices and Areas of Future Research in the Development of Educational Material To Communicate Risk to Patients and Clinicians				
423		4:30 – 6:00 pm	518 AB	Sympos.
Impact of the Choice of Reference Set on Performance Testing of Signal Detection Methods				
424		4:30 – 6:00 pm	524AB	Sympos.
Importance of Sensitivity Analyses for Design Decisions in Comparative Effectiveness Research				
425		4:30 – 6:00 pm	520 AD	Sympos.
Looking for Efficient Solutions To Optimize Adherence to Drug Treatment: The Clinical, Health Services Research and Economics Perspectives				
426		4:30 – 6:00 pm	520 BE	Sympos.
New Approaches To Account for Selection Bias and Confounding by Frail Health Status				
427		4:30 – 6:00 pm	520 CF	Sympos.
Welcoming Advanced Methods into the World of Pregnancy Research				
428		4:30 – 6:00 pm	519 AB	Sympos.
POSTER SESSION B				
Benefit Risk Assessment and Risk Communication				
429	1	8:00 am – 6:00 pm		Poster
430	2	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
431	3	8:00 am – 6:00 pm		Poster
432	4	8:00 am – 6:00 pm		Poster
433	5	8:00 am – 6:00 pm		Poster
434	6	8:00 am – 6:00 pm		Poster
Methods				
435	7	8:00 am – 6:00 pm		Poster
436	8	8:00 am – 6:00 pm		Poster
437	9	8:00 am – 6:00 pm		Poster
438	10	8:00 am – 6:00 pm		Poster
439	11	8:00 am – 6:00 pm		Poster
440	12	8:00 am – 6:00 pm		Poster
441	13	8:00 am – 6:00 pm		Poster
442	14	8:00 am – 6:00 pm		Poster
443	15	8:00 am – 6:00 pm		Poster
444	16	8:00 am – 6:00 pm		Poster
445	17	8:00 am – 6:00 pm		Poster
446	18	8:00 am – 6:00 pm		Poster
447	19	8:00 am – 6:00 pm		Poster
448	20	8:00 am – 6:00 pm		Poster
449	21	8:00 am – 6:00 pm		Poster
407	22	8:00 am – 6:00 pm		Poster
451	23	8:00 am – 6:00 pm		Poster
452	24	8:00 am – 6:00 pm		Poster
453	25	8:00 am – 6:00 pm		Poster
454	26	8:00 am – 6:00 pm		Poster
455	27	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
456	28	8:00 am – 6:00 pm		Poster
457	29	8:00 am – 6:00 pm		Poster
458	30	8:00 am – 6:00 pm		Poster
459	31	8:00 am – 6:00 pm		Poster
460	32	8:00 am – 6:00 pm		Poster
461	33	8:00 am – 6:00 pm		Poster
462	34	8:00 am – 6:00 pm		Poster
463	35	8:00 am – 6:00 pm		Poster
464	36	8:00 am – 6:00 pm		Poster
465	37	8:00 am – 6:00 pm		Poster
466	38	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
467	39	8:00 am – 6:00 pm		Poster
468	40	8:00 am – 6:00 pm		Poster
469	41	8:00 am – 6:00 pm		Poster
470	42	8:00 am – 6:00 pm		Poster
471	43	8:00 am – 6:00 pm		Poster
472	44	8:00 am – 6:00 pm		Poster
473	45	8:00 am – 6:00 pm		Poster
474	46	8:00 am – 6:00 pm		Poster
475	47	8:00 am – 6:00 pm		Poster
476	48	8:00 am – 6:00 pm		Poster
477	49	8:00 am – 6:00 pm		Poster
478	50	8:00 am – 6:00 pm		Poster
479	51	8:00 am – 6:00 pm		Poster
Pediatrics				
480	52	8:00 am – 6:00 pm		Poster
481	53	8:00 am – 6:00 pm		Poster
482	54	8:00 am – 6:00 pm		Poster
483	55	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
484	56	8:00 am – 6:00 pm		Poster
485	57	8:00 am – 6:00 pm		Poster
486	58	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Tuesday, August 27 continued				
487	59	8:00 am – 6:00 pm		Poster
488	60	8:00 am – 6:00 pm		Poster
Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG				
489	61	8:00 am – 6:00 pm		Poster
490	62	8:00 am – 6:00 pm		Poster
491	63	8:00 am – 6:00 pm		Poster
492	64	8:00 am – 6:00 pm		Poster
494	65	8:00 am – 6:00 pm		Poster
495	66	8:00 am – 6:00 pm		Poster
496	67	8:00 am – 6:00 pm		Poster
497	68	8:00 am – 6:00 pm		Poster
498	69	8:00 am – 6:00 pm		Poster
499	70	8:00 am – 6:00 pm		Poster
501	71	8:00 am – 6:00 pm		Poster
502	72	8:00 am – 6:00 pm		Poster
503	73	8:00 am – 6:00 pm		Poster
508	74	8:00 am – 6:00 pm		Poster
509	75	8:00 am – 6:00 pm		Poster
510	76	8:00 am – 6:00 pm		Poster
511	77	8:00 am – 6:00 pm		Poster
512	78	8:00 am – 6:00 pm		Poster
513	79	8:00 am – 6:00 pm		Poster
514	80	8:00 am – 6:00 pm		Poster
515	81	8:00 am – 6:00 pm		Poster
516	82	8:00 am – 6:00 pm		Poster
517	83	8:00 am – 6:00 pm		Poster
518	84	8:00 am – 6:00 pm		Poster
519	85	8:00 am – 6:00 pm		Poster
520	86	8:00 am – 6:00 pm		Poster
521	87	8:00 am – 6:00 pm		Poster
522	88	8:00 am – 6:00 pm		Poster
524	89	8:00 am – 6:00 pm		Poster
525	90	8:00 am – 6:00 pm		Poster
526	91	8:00 am – 6:00 pm		Poster
527	92	8:00 am – 6:00 pm		Poster
528	93	8:00 am – 6:00 pm		Poster
529	94	8:00 am – 6:00 pm		Poster
531	95	8:00 am – 6:00 pm		Poster
Database SIG				
532	96	8:00 am – 6:00 pm		Poster
533	97	8:00 am – 6:00 pm		Poster
534	98	8:00 am – 6:00 pm		Poster
535	99	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
536	100	8:00 am – 6:00 pm		Poster
537	101	8:00 am – 6:00 pm		Poster
538	102	8:00 am – 6:00 pm		Poster
539	103	8:00 am – 6:00 pm		Poster
540	104	8:00 am – 6:00 pm		Poster
541	105	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
543	106	8:00 am – 6:00 pm		Poster
544	107	8:00 am – 6:00 pm		Poster
545	108	8:00 am – 6:00 pm		Poster
546	109	8:00 am – 6:00 pm		Poster
547	110	8:00 am – 6:00 pm		Poster
548	111	8:00 am – 6:00 pm		Poster
549	112	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
550	113	8:00 am – 6:00 pm		Poster
551	114	8:00 am – 6:00 pm		Poster
552	115	8:00 am – 6:00 pm		Poster
553	116	8:00 am – 6:00 pm		Poster
554	117	8:00 am – 6:00 pm		Poster
555	118	8:00 am – 6:00 pm		Poster
556	119	8:00 am – 6:00 pm		Poster
557	120	8:00 am – 6:00 pm		Poster
558	121	8:00 am – 6:00 pm		Poster
559	122	8:00 am – 6:00 pm		Poster
560	123	8:00 am – 6:00 pm		Poster
561	124	8:00 am – 6:00 pm		Poster
564	125	8:00 am – 6:00 pm		Poster
565	126	8:00 am – 6:00 pm		Poster
566	127	8:00 am – 6:00 pm		Poster
567	128	8:00 am – 6:00 pm		Poster
568	129	8:00 am – 6:00 pm		Poster
569	130	8:00 am – 6:00 pm		Poster
570	131	8:00 am – 6:00 pm		Poster
571	132	8:00 am – 6:00 pm		Poster
572	133	8:00 am – 6:00 pm		Poster
573	134	8:00 am – 6:00 pm		Poster
574	135	8:00 am – 6:00 pm		Poster
575	136	8:00 am – 6:00 pm		Poster
576	137	8:00 am – 6:00 pm		Poster
577	138	8:00 am – 6:00 pm		Poster
578	139	8:00 am – 6:00 pm		Poster
579	140	8:00 am – 6:00 pm		Poster
581	141	8:00 am – 6:00 pm		Poster
582	142	8:00 am – 6:00 pm		Poster
583	143	8:00 am – 6:00 pm		Poster
585	144	8:00 am – 6:00 pm		Poster
586	145	8:00 am – 6:00 pm		Poster
587	146	8:00 am – 6:00 pm		Poster
588	147	8:00 am – 6:00 pm		Poster
589	148	8:00 am – 6:00 pm		Poster
590	149	8:00 am – 6:00 pm		Poster
591	150	8:00 am – 6:00 pm		Poster
592	151	8:00 am – 6:00 pm		Poster
593	152	8:00 am – 6:00 pm		Poster
594	153	8:00 am – 6:00 pm		Poster
597	154	8:00 am – 6:00 pm		Poster
598	155	8:00 am – 6:00 pm		Poster
599	156	8:00 am – 6:00 pm		Poster
600	157	8:00 am – 6:00 pm		Poster
601	158	8:00 am – 6:00 pm		Poster
602	159	8:00 am – 6:00 pm		Poster
603	160	8:00 am – 6:00 pm		Poster
604	161	8:00 am – 6:00 pm		Poster
605	162	8:00 am – 6:00 pm		Poster
606	163	8:00 am – 6:00 pm		Poster
607	164	8:00 am – 6:00 pm		Poster
608	165	8:00 am – 6:00 pm		Poster
609	166	8:00 am – 6:00 pm		Poster
610	167	8:00 am – 6:00 pm		Poster
611	168	8:00 am – 6:00 pm		Poster
612	169	8:00 am – 6:00 pm		Poster
613	170	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Tuesday, August 27 continued				
614	171	8:00 am – 6:00 pm		Poster
615	172	8:00 am – 6:00 pm		Poster
616	173	8:00 am – 6:00 pm		Poster
617	174	8:00 am – 6:00 pm		Poster
618	175	8:00 am – 6:00 pm		Poster
619	176	8:00 am – 6:00 pm		Poster
620	177	8:00 am – 6:00 pm		Poster
621	178	8:00 am – 6:00 pm		Poster
622	179	8:00 am – 6:00 pm		Poster
623	180	8:00 am – 6:00 pm		Poster
624	181	8:00 am – 6:00 pm		Poster
625	182	8:00 am – 6:00 pm		Poster
626	183	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
628	184	8:00 am – 6:00 pm		Poster
629	185	8:00 am – 6:00 pm		Poster
630	186	8:00 am – 6:00 pm		Poster
631	187	8:00 am – 6:00 pm		Poster
632	188	8:00 am – 6:00 pm		Poster
633	189	8:00 am – 6:00 pm		Poster
634	190	8:00 am – 6:00 pm		Poster
635	191	8:00 am – 6:00 pm		Poster
636	192	8:00 am – 6:00 pm		Poster
637	193	8:00 am – 6:00 pm		Poster
638	194	8:00 am – 6:00 pm		Poster
639	195	8:00 am – 6:00 pm		Poster
640	196	8:00 am – 6:00 pm		Poster
Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG				
654	197	8:00 am – 6:00 pm		Poster
643	198	8:00 am – 6:00 pm		Poster
644	199	8:00 am – 6:00 pm		Poster
646	200	8:00 am – 6:00 pm		Poster
647	201	8:00 am – 6:00 pm		Poster
649	202	8:00 am – 6:00 pm		Poster
651	203	8:00 am – 6:00 pm		Poster
652	204	8:00 am – 6:00 pm		Poster
653	205	8:00 am – 6:00 pm		Poster
656	206	8:00 am – 6:00 pm		Poster
658	207	8:00 am – 6:00 pm		Poster
Pediatrics SIG				
659	208	8:00am – 6:00pm		Poster
660	209	8:00am – 6:00 pm		Poster
696	210	8:00am – 6:00 pm		Poster
661	211	8:00am – 6:00 pm		Poster
663	212	8:00am – 6:00 pm		Poster
664	213	8:00am – 6:00 pm		Poster
666	214	8:00am – 6:00 pm		Poster
667	215	8:00am – 6:00 pm		Poster
668	216	8:00am – 6:00 pm		Poster
669	217	8:00am – 6:00 pm		Poster
670	218	8:00am – 6:00 pm		Poster
671	219	8:00am – 6:00 pm		Poster
672	220	8:00am – 6:00 pm		Poster
673	221	8:00am – 6:00 pm		Poster
674	222	8:00am – 6:00 pm		Poster
675	223	8:00am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
676	224	8:00am – 6:00 pm		Poster
677	225	8:00am – 6:00 pm		Poster
678	226	8:00am – 6:00 pm		Poster
679	227	8:00am – 6:00 pm		Poster
680	228	8:00am – 6:00 pm		Poster
682	229	8:00am – 6:00 pm		Poster
683	230	8:00am – 6:00 pm		Poster
684	231	8:00am – 6:00 pm		Poster
686	232	8:00am – 6:00 pm		Poster
687	233	8:00am – 6:00 pm		Poster
688	234	8:00am – 6:00 pm		Poster
689	235	8:00am – 6:00 pm		Poster
690	236	8:00am – 6:00 pm		Poster
691	237	8:00am – 6:00 pm		Poster
692	238	8:00am – 6:00 pm		Poster
693	239	8:00am – 6:00 pm		Poster
695	240	8:00am – 6:00 pm		Poster
697	241	8:00am – 6:00 pm		Poster
698	242	8:00am – 6:00 pm		Poster
Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG Poster Walk Session				
493	243	8:00 am – 6:00 pm		Poster
500	244	8:00 am – 6:00 pm		Poster
504	245	8:00 am – 6:00 pm		Poster
505	246	8:00 am – 6:00 pm		Poster
506	247	8:00 am – 6:00 pm		Poster
507	248	8:00 am – 6:00 pm		Poster
523	249	8:00 am – 6:00 pm		Poster
530	250	8:00 am – 6:00 pm		Poster
Database SIG Poster Walk Session				
542	251	8:00 am – 6:00 pm		Poster
562	252	8:00 am – 6:00 pm		Poster
563	253	8:00 am – 6:00 pm		Poster
580	254	8:00 am – 6:00 pm		Poster
584	255	8:00 am – 6:00 pm		Poster
595	256	8:00 am – 6:00 pm		Poster
596	257	8:00 am – 6:00 pm		Poster
627	258	8:00 am – 6:00 pm		Poster
Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG Poster Walk Session				
641	259	8:00 am – 6:00 pm		Poster
642	260	8:00 am – 6:00 pm		Poster
645	261	8:00 am – 6:00 pm		Poster
648	262	8:00 am – 6:00 pm		Poster
650	263	8:00 am – 6:00 pm		Poster
655	264	8:00 am – 6:00 pm		Poster
657	265	8:00 am – 6:00 pm		Poster
Pediatrics SIG Poster Walk Session				
662	266	8:00 am – 6:00 pm		Poster
665	267	8:00 am – 6:00 pm		Poster
681	268	8:00 am – 6:00 pm		Poster
685	269	8:00 am – 6:00 pm		Poster
694	270	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Wednesday, August 28				
Around the World in 90 Minutes				
699		8:30 am	518 AB	Oral
700		8:45 am	518 AB	Oral
701		9:00 am	518 AB	Oral
702		9:15 am	518 AB	Oral
703		9:30 am	518 AB	Oral
704		9:45 am	518 AB	Oral
Chicken and Egg: Common Drugs, Cancer Risk and Outcome				
705		8:30 am	524 AB	Oral
706		8:45 am	524 AB	Oral
707		9:00 am	524 AB	Oral
708		9:15 am	524 AB	Oral
709		9:30 am	524 AB	Oral
710		9:45 am	524 AB	Oral
Effective Choices (CER)				
711		8:30 am	519 AB	Oral
712		8:45 am	519 AB	Oral
713		9:00 am	519 AB	Oral
714		9:15 am	519 AB	Oral
715		9:30 am	519 AB	Oral
716		9:45 am	519 AB	Oral
Risky Business				
717		8:30 am	520 BE	Oral
718		8:45 am	520 BE	Oral
719		9:00 am	520 BE	Oral
720		9:15 am	520 BE	Oral
721		9:30 am	520 BE	Oral
722		9:45 am	520 BE	Oral
Sexy Hormones				
723		8:30 am	520 AD	Oral
724		8:45 am	520 AD	Oral
725		9:00 am	520 AD	Oral
726		9:15 am	520 AD	Oral
727		9:30 am	520 AD	Oral
728		9:45 am	520 AD	Oral
The Down Side of Pregnancy				
729		8:30 am	520 CF	Oral
730		8:45 am	520 CF	Oral
731		9:00 am	520 CF	Oral
732		9:15 am	520 CF	Oral
733		9:30 am	520 CF	Oral
734		9:45 am	520 CF	Oral
ARITMO Final Results: Prediction of the Arrhythmogenic Risk of Antihistamines, Antipsychotics and Anti-Infectives by Integration of Translational Evidence				
735		10:30 am – 12 pm	520 CF	Sympos.
Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources				
736		10:30 am – 12 pm	518 AB	Sympos.
Confounding's Ugly Little Sister: Measurement Bias in Pharmacoepidemiology				
737		10:30 am – 12 pm	517 D	Sympos.
Improving Consistency in Findings from Pharmacoepidemiological Studies: The IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Project				
738		10:30 am – 12 pm	520 BE	Sympos.

Abstract #	Poster #	Presentation Time	Room	Format
Improving the Science of Regulatory Decision-Making – Advances in 2012/2013				
739		10:30 am – 12 pm	520 AD	Sympos.
Interpreting and Communicating Risk of Medications in Pregnancy, Using SSRIs as an Example				
740		10:30 am – 12 pm	519 AB	Sympos.
Unlocking the Secrets of Free Text through Natural Language Processing: An Introduction for Pharmacoepidemiologists				
741		10:30 am – 12 pm	524 AB	Sympos.
Elderly				
742		1:30 pm	524 AB	Oral
743		1:45 pm	524 AB	Oral
744		2:00 pm	524 AB	Oral
745		2:15 pm	524 AB	Oral
746		2:30 pm	524 AB	Oral
747		2:45 pm	524 AB	Oral
Methods 4				
748		1:30 pm	519 AB	Oral
749		1:45 pm	519 AB	Oral
750		2:00 pm	519 AB	Oral
751		2:15 pm	519 AB	Oral
752		2:30 pm	519 AB	Oral
753		2:45 pm	519 AB	Oral
Pediatrics: Potpourri				
754		1:30 pm	520 CF	Oral
755		1:45 pm	520 CF	Oral
756		2:00 pm	520 CF	Oral
757		2:15 pm	520 CF	Oral
758		2:30 pm	520 CF	Oral
759		2:45 pm	520 CF	Oral
Self-Controlled Studies				
760		1:30 pm	520 BE	Oral
761		1:45 pm	520 BE	Oral
762		2:00 pm	520 BE	Oral
763		2:15 pm	520 BE	Oral
764		2:30 pm	520 BE	Oral
765		2:45 pm	520 BE	Oral
Sticky Treatments & Sticky Outcome				
766		1:30 pm	520 AD	Oral
767		1:45 pm	520 AD	Oral
768		2:00 pm	520 AD	Oral
769		2:15 pm	520 AD	Oral
770		2:30 pm	520 AD	Oral
771		2:45 pm	520 AD	Oral
Usefulness of Data Sources for CNS Drugs & Diseases				
772		1:30 pm	518 AB	Oral
773		1:45 pm	518 AB	Oral
774		2:00 pm	518 AB	Oral
775		2:15 pm	518 AB	Oral
776		2:30 pm	518 AB	Oral
777		2:45 pm	518 AB	Oral

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Wednesday, August 28 continued				
POSTER SESSION C				
Biologics, Including Vaccines				
778	1	8:00 am – 1:45 pm		Poster
779	2	8:00 am – 1:45 pm		Poster
Burden of Disease/Epidemiology of Illness				
780	3	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
781	4	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
782	5	8:00 am – 1:45 pm		Poster
783	6	8:00 am – 1:45 pm		Poster
784	7	8:00 am – 1:45 pm		Poster
785	8	8:00 am – 1:45 pm		Poster
786	9	8:00 am – 1:45 pm		Poster
787	10	8:00 am – 1:45 pm		Poster
788	11	8:00 am – 1:45 pm		Poster
789	12	8:00 am – 1:45 pm		Poster
790	13	8:00 am – 1:45 pm		Poster
791	14	8:00 am – 1:45 pm		Poster
792	15	8:00 am – 1:45 pm		Poster
793	16	8:00 am – 1:45 pm		Poster
794	17	8:00 am – 1:45 pm		Poster
795	18	8:00 am – 1:45 pm		Poster
796	19	8:00 am – 1:45 pm		Poster
797	20	8:00 am – 1:45 pm		Poster
798	21	8:00 am – 1:45 pm		Poster
799	22	8:00 am – 1:45 pm		Poster
800	23	8:00 am – 1:45 pm		Poster
801	24	8:00 am – 1:45 pm		Poster
802	25	8:00 am – 1:45 pm		Poster
803	26	8:00 am – 1:45 pm		Poster
804	27	8:00 am – 1:45 pm		Poster
805	28	8:00 am – 1:45 pm		Poster
806	29	8:00 am – 1:45 pm		Poster
807	30	8:00 am – 1:45 pm		Poster
808	31	8:00 am – 1:45 pm		Poster
809	32	8:00 am – 1:45 pm		Poster
810	33	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
811	34	8:00 am – 1:45 pm		Poster
812	35	8:00 am – 1:45 pm		Poster
813	36	8:00 am – 1:45 pm		Poster
814	37	8:00 am – 1:45 pm		Poster
815	38	8:00 am – 1:45 pm		Poster
816	39	8:00 am – 1:45 pm		Poster
817	40	8:00 am – 1:45 pm		Poster
818	41	8:00 am – 1:45 pm		Poster
819	42	8:00 am – 1:45 pm		Poster
820	43	8:00 am – 1:45 pm		Poster
Drug Utilization Research/Health Services Research				
822	44	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
823	45	8:00 am – 1:45 pm		Poster
824	46	8:00 am – 1:45 pm		Poster
825	47	8:00 am – 1:45 pm		Poster
826	48	8:00 am – 1:45 pm		Poster
827	49	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
828	50	8:00 am – 1:45 pm		Poster
829	51	8:00 am – 1:45 pm		Poster
830	52	8:00 am – 1:45 pm		Poster
831	53	8:00 am – 1:45 pm		Poster
832	54	8:00 am – 1:45 pm		Poster
833	55	8:00 am – 1:45 pm		Poster
834	56	8:00 am – 1:45 pm		Poster
835	57	8:00 am – 1:45 pm		Poster
836	58	8:00 am – 1:45 pm		Poster
837	59	8:00 am – 1:45 pm		Poster
838	60	8:00 am – 1:45 pm		Poster
840	61	8:00 am – 1:45 pm		Poster
841	62	8:00 am – 1:45 pm		Poster
842	63	8:00 am – 1:45 pm		Poster
843	64	8:00 am – 1:45 pm		Poster
844	65	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
845	66	8:00 am – 1:45 pm		Poster
846	67	8:00 am – 1:45 pm		Poster
847	68	8:00 am – 1:45 pm		Poster
848	69	8:00 am – 1:45 pm		Poster
849	70	8:00 am – 1:45 pm		Poster
850	71	8:00 am – 1:45 pm		Poster
851	72	8:00 am – 1:45 pm		Poster
852	73	8:00 am – 1:45 pm		Poster
853	74	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
854	75	8:00 am – 1:45 pm		Poster
Medical Devices				
855	76	8:00 am – 1:45 pm		Poster
Pharmacoeconomics / Outcomes Research in Pharmacology				
856	77	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
857	78	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
858	79	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
859	80	8:00 am – 1:45 pm		Poster
860	81	8:00 am – 1:45 pm		Poster
861	82	8:00 am – 1:45 pm		Poster
862	83	8:00 am – 1:45 pm		Poster
Asian Pharmacoepidemiology Network (AsPEN) SIG				
864	84	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
Biologics SIG				
866	85	8:00 am – 1:45 pm		Poster
868	86	8:00 am – 1:45 pm		Poster
869	87	8:00 am – 1:45 pm		Poster
871	88	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
872	89	8:00 am – 1:45 pm		Poster
873	90	8:00 am – 1:45 pm		Poster
874	91	8:00 am – 1:45 pm		Poster
876	92	8:00 am – 1:45 pm		Poster
879	93	8:00 am – 1:45 pm		Poster
880	94	8:00 am – 1:45 pm		Poster
882	95	8:00 am – 1:45 pm		Poster
883	96	8:00 am – 1:45 pm		Poster
884	97	8:00 am – 1:45 pm		Poster
885	98	8:00 am – 1:45 pm		Poster
886	99	8:00 am – 1:45 pm		Poster
889	100	8:00 am – 1:45 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX


Abstract #	Poster #	Presentation Time	Room	Format
Wednesday, August 28 continued				
Drug Utilization/Health Services Research SIG				
890	101	8:00 am – 1:45 pm		Poster
891	102	8:00 am – 1:45 pm		Poster
927	103	8:00 am – 1:45 pm		Poster
912	104	8:00 am – 1:45 pm		Poster
893	105	8:00 am – 1:45 pm		Poster
894	106	8:00 am – 1:45 pm		Poster
895	107	8:00 am – 1:45 pm		Poster
1017	108	8:00 am – 1:45 pm		Poster
896	109	8:00 am – 1:45 pm		Poster
897	110	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
898	111	8:00 am – 1:45 pm		Poster
899	112	8:00 am – 1:45 pm		Poster
900	113	8:00 am – 1:45 pm		Poster
901	114	8:00 am – 1:45 pm		Poster
902	115	8:00 am – 1:45 pm		Poster
903	116	8:00 am – 1:45 pm		Poster
904	117	8:00 am – 1:45 pm		Poster
905	118	8:00 am – 1:45 pm		Poster
906	119	8:00 am – 1:45 pm		Poster
907	120	8:00 am – 1:45 pm		Poster
908	121	8:00 am – 1:45 pm		Poster
909	122	8:00 am – 1:45 pm		Poster
910	123	8:00 am – 1:45 pm		Poster
911	124	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
913	125	8:00 am – 1:45 pm		Poster
914	126	8:00 am – 1:45 pm		Poster
915	127	8:00 am – 1:45 pm		Poster
916	128	8:00 am – 1:45 pm		Poster
917	129	8:00 am – 1:45 pm		Poster
918	130	8:00 am – 1:45 pm		Poster
919	131	8:00 am – 1:45 pm		Poster
920	132	8:00 am – 1:45 pm		Poster
921	133	8:00 am – 1:45 pm		Poster
922	134	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
923	135	8:00 am – 1:45 pm		Poster
924	136	8:00 am – 1:45 pm		Poster
925	137	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
926	138	8:00 am – 1:45 pm		Poster
928	139	8:00 am – 1:45 pm		Poster
929	140	8:00 am – 1:45 pm		Poster
930	141	8:00 am – 1:45 pm		Poster
931	142	8:00 am – 1:45 pm		Poster
932	143	8:00 am – 1:45 pm		Poster
933	144	8:00 am – 1:45 pm		Poster
934	145	8:00 am – 1:45 pm		Poster
936	146	8:00 am – 1:45 pm		Poster
937	147	8:00 am – 1:45 pm		Poster
938	148	8:00 am – 1:45 pm		Poster
939	149	8:00 am – 1:45 pm		Poster
940	150	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
941	151	8:00 am – 1:45 pm		Poster
942	152	8:00 am – 1:45 pm		Poster
943	153	8:00 am – 1:45 pm		Poster
944	154	8:00 am – 1:45 pm		Poster
945	155	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
946	156	8:00 am – 1:45 pm		Poster
947	157	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
948	158	8:00 am – 1:45 pm		Poster
949	159	8:00 am – 1:45 pm		Poster
950	160	8:00 am – 1:45 pm		Poster
951	161	8:00 am – 1:45 pm		Poster
952	162	8:00 am – 1:45 pm		Poster
953	163	8:00 am – 1:45 pm		Poster
954	164	8:00 am – 1:45 pm		Poster
956	165	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
957	166	8:00 am – 1:45 pm		Poster
959	167	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
960	168	8:00 am – 1:45 pm		Poster
962	169	8:00 am – 1:45 pm		Poster
963	170	8:00 am – 1:45 pm		Poster
964	171	8:00 am – 1:45 pm		Poster
965	172	8:00 am – 1:45 pm		Poster
966	173	8:00 am – 1:45 pm		Poster
967	174	8:00 am – 1:45 pm		Poster
968	175	8:00 am – 1:45 pm		Poster
969	176	8:00 am – 1:45 pm		Poster
970	177	8:00 am – 1:45 pm		Poster
971	178	8:00 am – 1:45 pm		Poster
972	179	8:00 am – 1:45 pm		Poster
973	180	8:00 am – 1:45 pm		Poster
974	181	8:00 am – 1:45 pm		Poster
975	182	8:00 am – 1:45 pm		Poster
976	183	8:00 am – 1:45 pm		Poster
977	184	8:00 am – 1:45 pm		Poster
978	185	8:00 am – 1:45 pm		Poster
979	186	8:00 am – 1:45 pm		Poster
980	187	8:00 am – 1:45 pm		Poster
981	188	8:00 am – 1:45 pm		Poster
982	189	8:00 am – 1:45 pm		Poster
983	190	8:00 am – 1:45 pm		Poster
984	191	8:00 am – 1:45 pm		Poster
985	192	8:00 am – 1:45 pm		Poster
986	193	8:00 am – 1:45 pm		Poster
987	194	8:00 am – 1:45 pm		Poster
988	195	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
989	196	8:00 am – 1:45 pm		Poster
990	197	8:00 am – 1:45 pm		Poster
991	198	8:00 am – 1:45 pm		Poster
992	199	8:00 am – 1:45 pm		Poster
993	200	8:00 am – 1:45 pm		Poster
994	201	8:00 am – 1:45 pm		Poster
995	202	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
996	203	8:00 am – 1:45 pm		Poster
997	204	8:00 am – 1:45 pm		Poster
998	205	8:00 am – 1:45 pm		Poster
999	206	8:00 am – 1:45 pm		Poster
1000	207	8:00 am – 1:45 pm		Poster
1001	208	8:00 am – 1:45 pm		Poster
1002	209	8:00 am – 1:45 pm		Poster
1003	210	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1004	211	8:00 am – 1:45 pm		Poster
1005	212	8:00 am – 1:45 pm		Poster
1006	213	8:00 am – 1:45 pm		Poster

29th ICPE-Final Program
ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
Wednesday, August 28 continued				
1008	215	8:00 am – 1:45 pm		Poster
1009	216	8:00 am – 1:45 pm		Poster
1010	217	8:00 am – 1:45 pm		Poster
1011	218	8:00 am – 1:45 pm		Poster
1012	219	8:00 am – 1:45 pm		Poster
1013	220	8:00 am – 1:45 pm		Poster
1014	221	8:00 am – 1:45 pm		Poster
1015	222	8:00 am – 1:45 pm		Poster
1016	223	8:00 am – 1:45 pm		Poster
1018	224	8:00 am – 1:45 pm		Poster
1019	225	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1020	226	8:00 am – 1:45 pm		Poster
1021	227	8:00 am – 1:45 pm		Poster
1022	228	8:00 am – 1:45 pm		Poster
1023	229	8:00 am – 1:45 pm		Poster
1024	230	8:00 am – 1:45 pm		Poster
1025	231	8:00 am – 1:45 pm		Poster
1026	232	8:00 am – 1:45 pm		Poster
1027	233	8:00 am – 1:45 pm		Poster
1028	234	8:00 am – 1:45 pm		Poster
1029	235	8:00 am – 1:45 pm		Poster
1030	236	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1031	237	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1032	238	8:00 am – 1:45 pm		Poster
1033	239	8:00 am – 1:45 pm		Poster
1034	240	8:00 am – 1:45 pm		Poster
1035	241	8:00 am – 1:45 pm		Poster
1036	242	8:00 am – 1:45 pm		Poster
1037	243	8:00 am – 1:45 pm		Poster
1038	244	8:00 am – 1:45 pm		Poster
294	245	8:00 am – 1:45 pm		Poster
1040	246	8:00 am – 1:45 pm		Poster
Medical Devices SIG				
1045	247	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
Asian Pharmacoevidence Network (AsPEN) SIG Poster Walk Session				
863	248	8:00 am – 1:45 pm		Poster
865	249	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Medical Devices SIG Poster Walk Session				
1041	250	8:00 am – 1:45 pm		Poster
1042	251	8:00 am – 1:45 pm		Poster
1043	252	8:00 am – 1:45 pm		Poster
1044	253	8:00 am – 1:45 pm		Poster
1046	254	8:00 am – 1:45 pm		Poster
1047	255	8:00 am – 1:45 pm		Poster
Drug Utilization Research/Health Services Research SIG Poster Walk				
839	256	8:00 am – 1:45 pm		Poster
911	257	8:00 am – 1:45 pm		Poster
935	258	8:00 am – 1:45 pm		Poster
955	259	8:00 am – 1:45 pm		Poster
958	260	8:00 am – 1:45 pm		Poster
1039	261	8:00 am – 1:45 pm		Poster
Biologics SIG Poster Walk Session				
867	262	8:00 am – 1:45 pm		Poster
870	263	8:00 am – 1:45 pm		Poster
875	264	8:00 am – 1:45 pm		Poster
877	265	8:00 am – 1:45 pm		Poster
878	266	8:00 am – 1:45 pm		Poster
881	267	8:00 am – 1:45 pm		Poster
887	268	8:00 am – 1:45 pm		Poster
888	269	8:00 am – 1:45 pm		Poster



PDS Pharmacoepidemiology & Drug Safety

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

* Free online access for ISPE members via the society website



Congratulations to The Ronald D. Mann Best Article of 2012 Award Winners

Best paper:

The Risk of Guillain–Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009–2010 Seasonal Influenza Vaccines: Results from Self-Controlled Analyses Jerome I Tokars, Paige Lewis, Frank DeStefano, Matthew Wise, Melissa Viray, Oliver Morgan, Paul Gargiullo and Claudia Vellozzi Vol 21, Issue 5, Pages 546-52

Honorable mention:

Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination Priscilla Valentgas, Anthony A. Amato, Rhonda L. Bohn, K. Arnold Chan, Thomas Cochrane, Donnie P. Funch, Inna Dashevsky, April L. Duddy, Patricia Gladowski, Steven A. Greenberg, Judith M. Kramer, Cheryl McMahill-Walraven, Cynthia Nakasato, Claire M. Spettell, Beth L. Syat, Peter M. Wahl, Alexander M. Walker, Fang Zhang, Jeffrey S. Brown and Richard Platt Vol 21, Issue 12, Pages 1350-58

Honorable Mention:

Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort Maija Purhonen, Hannu Koponen, Jari Tiihonen and Antti Tanskanen Vol 21, Issue 11, Pages 1227-31

Honorable Mention:

New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home Sarah D. Berry, Murray A. Mittleman, Yuqing Zhang, Daniel H. Solomon, Lewis A. Lipsitz, Elizabeth Mostofsky, Dana Goldense and Douglas P. Kiel Vol 21, Issue 5, Pages 560-63

For more information on these top papers and other journal features, please visit

www.pdsjournal.org


Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2013 Volume: 22 • Frequency: Monthly

WILEY

Level 2

- Rental Space
- Rental Space (Optional)
- Ballroom
- Kitchen

- ☑ Cloakroom
- ↕ Escalators
- ? Information
- ♿ Washrooms
- ⬆️ Elevators
- 🚚 Freight elevators
- ☎️ Phones




Level 5 and Mezzanine 6

- Rental Space (Optional)
- Ballroom
- Kitchen
- Project in development - Green roof

- ⬆️ Elevators
- ↕ Escalators
- 🚚 Freight elevators
- ☎️ Phones
- ♿ Washrooms

Level 5



Mezzanine 6

